Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
(cid:3) (cid:3) (cid:3) (cid:3) Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the Fiscal Year Ended December 31, 2014
for The Transition Period From To
Commission file number: 000-36576
MARINUS PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
20-0198082
(I.R.S. Employer
Identification No.)
Three Radnor Corporate Center
100 Matsonford Rd., Suite 304
Radnor, PA 19087
(Address of principal executive offices including zip code)
(484)-801-4670
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common Stock, par value $0.001 per share
Securities registered pursuant to Section 12(g) of the Act: None
Name of each exchange on which registered
The NASDAQ Global Market
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. (cid:3) Yes No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the A c t. (cid:3) Yes No
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act
during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirement for the past 90 days. Yes (cid:3) No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File
required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). Yes (cid:3) No
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained,
to the best of Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any
amendments to this Form 10-K. (cid:3)
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, or a smaller reporting
company. See the definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer (cid:3)
Non-accelerated filer (cid:3)
(Do not check if a smaller reporting company)
Accelerated filer (cid:3)
Smaller reporting company
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). (cid:3) Yes No
The aggregate market value of the Registrant’s Common Stock (the only common equity of the registrant) held by non-affiliates for the last
business day of the Registrant’s most recently completed second fiscal quarter: The aggregate market value of the voting stock held by non-
affiliates of the registrant, as of July 31, 2014, was approximately $51.5 million. Such aggregate market value was computed by reference to the
closing price of the common stock as reported on the NASDAQ Global Market on July 31, 2014. The registrant has elected to use July 31, 2014 as
the calculation date, as on June 30, 2014 (the last business day of the most recently completed second fiscal quarter) the registrant was a privately-
held concern.
The number of shares of the issuer’s Common Stock outstanding as of March 12, 2015 was 14,199,666.
DOCUMENTS INCORPORATED BY REFERENCE
The registrant’s definitive proxy statement to be filed in connection with solicitation of proxies for its 2015 Annual Meeting of Stockholders to be
held within 120 days of the end of its fiscal year, is incorporated by reference into Part III of this Annual Report on Form 10-K.
Table of Contents
TABLE OF CONTENTS
Part I .
Note Regarding Forward-Looking Statements.
Item 1. Business.
Item1A. Risk Factors.
Item1B. Unresolved Staff Comments.
Item 2. Properties.
Item 3. Legal Proceedings.
Item 4. Mine Safety Disclosures.
Part II .
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.
Item 6. Selected Financial Data.
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk.
Item 8. Financial Statements and Supplementary Data.
Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
Item 9A. Controls and Procedures.
Item 9B. Other Information.
Part III.
Item 10. Directors, Executive Officers and Corporate Governance.
Item 11. Executive Compensation.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.
Item 13. Certain Relationships and Related Transactions, and Director Independence.
Item 14. Principal Accountants Fees and Services.
Part IV.
Item 15. Exhibits, Financial Statement Schedules.
Signatures.
Index to Financial Statements.
i
Page
ii
1
27
56
56
56
56
57
57
58
65
65
65
65
66
69
69
69
69
69
69
71
F-1
Table of Contents
Cautionary Note Regarding Forward-Looking Statements.
This Annual Report on Form 10-K contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation
Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words
“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,”
“potential,” “should,” “will,” or “would,” and or the negative of these terms, or other comparable terminology intended to identify statements
about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of
activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we
caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about
which we cannot be certain.
The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:
• our ability to develop and commercialize ganaxolone;
• status, timing and results of preclinical studies and clinical trials;
• the potential benefits of ganaxolone;
• the timing of seeking regulatory approval of ganaxolone;
• our ability to obtain and maintain regulatory approval;
• our estimates of expenses and future revenue and profitability;
• our estimates regarding our capital requirements and our needs for additional financing;
• our plans to develop and market ganaxolone and the timing of our development programs;
• our estimates of the size of the potential markets for ganaxolone;
• our selection and licensing of ganaxolone;
• our ability to attract collaborators with acceptable development, regulatory and commercial expertise;
• the benefits to be derived from corporate collaborations, license agreements, and other collaborative or acquisition efforts, including
those relating to the development and commercialization of ganaxolone;
• sources of revenue, including contributions from corporate collaborations, license agreements, and other collaborative efforts for the
development and commercialization of products;
• our ability to create an effective sales and marketing infrastructure if we elect to market and sell ganaxolone directly;
• the rate and degree of market acceptance of ganaxolone;
• the timing and amount or reimbursement for ganaxolone;
• the success of other competing therapies that may become available;
• the manufacturing capacity for ganaxolone;
• our intellectual property position;
• our ability to maintain and protect our intellectual property rights;
ii
Table of Contents
• our results of operations, financial condition, liquidity, prospects, and growth strategies;
• the industry in which we operate; and
• the trends that may affect the industry or us.
You should refer to Part I, Item 1A “Risk Factors” of this Annual Report on this Form 10-K for a discussion of important factors that may
cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these factors, we
cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. Furthermore, if our forward-
looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking
statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives
and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required by law.
You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed
as exhibits to this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different
from what we expect. We qualify all of our forward-looking statements by these cautionary statements.
iii
Table of Contents
Item 1. Business.
Overview
PART I
We are a clinical stage biopharmaceutical company focused on developing and commercializing innovative neuropsychiatric
therapeutics. Our clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, an endogenous
neurosteriod known for its anticonvulsive and antianxiety activity. By targeting the same spectrum of GABA
ganaxolone delivers its therapeutic benefit through a mechanism that we believe may offer safety and efficacy advantages compared to other
marketed antiepileptic drugs, or AEDs. Ganaxolone was rationally designed to unlock the potential for chronic neurosteroid therapy through
modulation of the GABA
trials and we are conducting the requisite preclinical experiments to ready our intravenous, or IV, dose form for clinical use. We have a dual
strategy of evaluating ganaxolone for treating seizure disorders, and treating targeted orphan diseases for which there are no approved therapies,
the development timelines may be abbreviated, and for which there is a strong mechanistic rationale for ganaxolone to offer therapeutic benefit to
patients with very high unmet needs.
receptor. Our orally administered solid and liquid suspension dose forms are being evaluated in our ongoing clinical
receptors as allopregnanolone,
A
A
Our Pipeline
We are developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including the following:
Our most advanced indication for ganaxolone is as an adjunctive, or add-on, therapy for the treatment of partial, also known as focal,
onset seizures in adults with epilepsy. Phase 3 randomized multinational clinical trial utilizing our oral capsules is underway for this indication.
We plan to release top line data by the first quarter of 2016. We have completed a Phase 2 clinical trial in 147 patients with focal onset seizures
where we demonstrated that patients who added ganaxolone liquid suspension to their medication regimen experienced a statistically significant
reduction in seizures as compared to patients who added placebo.
Based upon both proof-of-concept data for ganaxolone in the treatment of refractory pediatric seizures and a mechanistic rationale for
providing a therapeutic benefit through increased GABAergic signaling, we have initiated an open-label Phase 2 clinical trial evaluating
ganaxolone for treatment of the orphan disease, PCDH19 female pediatric epilepsy. We expect to release initial data from this study during 2015.
1
Table of Contents
We are developing an IV formulation for use in the hospital setting to control acute seizures. We are conducting the requisite preclinical
experiments to ready our IV formulation for clinical use.
In addition to anticonvulsive activity, we believe ganaxolone’s mechanism may improve anxiety and behaviors related to anxiety, such as
irritability or social withdrawal. Ganaxolone is being evaluated in an investigator-sponsored, grant funded, randomized double-blind placebo-
controlled Phase 2 crossover study as potential proof-of-concept in treating behaviors in Fragile X Syndrome, or FXS, which we believe to be an
orphan indication. We plan to complete this study during 2015.
Ganaxolone Mechanism of Action
The effects of allopregnanolone have been studied for over two decades and its role in controlling seizures and improving anxiety, mood
A
type receptors is well documented. Despite these positive characteristics, we believe
and sleep through positive modulation of GABA
allopregnanolone is not suitable for chronic use due to potential undesired hormonal side effects. Ganaxolone was designed to have the same
GABA modulation effects as allopregnanolone without these hormonal side effects. Ganaxolone and allopregnanolone differ from other GABA
agents by interacting with unique binding sites on the GABA
GABA synapse. Ganaxolone’s activation of the extrasynaptic receptor is a unique mechanism that provides stabilizing effects that we believe
differentiates it from other drugs that increase GABA signaling. Preclinical studies provide evidence that the GABA modulatory activity of
ganaxolone is responsible for its anticonvulsive activity in epileptic seizures and its antianxiety effects in FXS and other neuropsychiatric
disorders.
receptor that are located both within, or synaptic, and outside, or extrasynaptic, the
A
Ganaxolone in Epilepsy
Overview and Treatment of Epilepsy
Epilepsy is characterized by seizures that arise from abnormal electrical discharge in the brain, resulting in alterations of consciousness,
involuntary movement, or altered sensations. Seizures in epilepsy may be related to a brain injury or heredity, but often the cause is unknown.
Epileptic seizures are generally described in two major groups, primary generalized seizures and focal onset seizures. Primary generalized seizures
begin with a widespread electrical discharge that involves both sides of the brain at once. Focal onset seizures begin with an electrical discharge in
one limited area of the brain. Generally, a person is diagnosed as having epilepsy when they have had at least two seizures that do not have a self-
limiting cause such as a high fever.
In 2012, Decision Resources reported that approximately five million people were under treatment for epilepsy in the United States,
Europe and Japan. IMS Health reported that global sales of AEDs were approximately $14 billion in 2011. It is estimated that approximately 3.8%
of people will develop epilepsy during their lifetime,
2
Table of Contents
with a higher incidence in men than women. New cases of epilepsy are most common among children, especially during the first year of life. The
rate of new cases gradually declines until about age 10, and then becomes stable. Remission is common for children as they age. After age 55 to
60, the rate of new epilepsy cases starts to increase, as people develop strokes, brain tumors, or Alzheimer’s disease.
Newly diagnosed epilepsy patients are treated with daily administration of an AED. Approximately 60% of patients will achieve an
adequate level of seizure control with a single AED, and the remainder will resort to polypharmacy. Approximately 30 to 35% of all patients do
not reach an acceptable level of seizure control even with polypharmacy, and are considered to be refractory cases. We estimate that the market
opportunity for this refractory patient population, which will be ganaxolone’s initial target segment, will exceed $4 billion in the United States,
Europe and Japan. Despite the widespread availability of generic drugs for the treatment of epilepsy, in many countries, including the United
States, health payors permit these epilepsy patients to switch to costlier medications or polypharmacy in order to gain seizure control or reduce
side effects. Our market research suggests that many physicians attempt to add a medication with a new mechanism of action while also trying to
minimize side effect burden when selecting a substitute or add-on AED. A subset of focal onset seizure patients who cannot gain acceptable
seizure control through pharmacologic treatment options resort to implantable devices or removal of the part of the brain causing the seizures.
Market Opportunity
Epileptic seizures require chronic treatment, often over a lifetime. Available AEDs are efficacious for many patients, but chronic
treatment is complicated by side effects, including cardiovascular risks, liver enzyme induction, kidney stones, behavioral changes, sedation and
adverse effects on cognitive function, drug tolerance, and reproductive risk.
Women have the added complication that several currently available AEDs increase the risk to the fetus, including birth defects, lowered
IQ and low birth weight. Most of these drugs are categorized by the U.S. Food and Drug Administration (FDA) as Pregnancy Category C,
indicating a potential risk to the fetus, and three of these drugs (valproate, carbamazepine, phenytoin) have been classified as Pregnancy
Category D, indicating that use is only justified if there is a serious condition where the need outweighs risk to the fetus based on registry data.
Despite the many available AEDs, approximately 30 to 35% of patients do not attain acceptable seizure control either with single drug or
multiple drug therapy. Furthermore, medications with significant side effects or dosing regimens that undermine compliance make it difficult for
patients to achieve and maintain seizure free status. For these reasons there is a need for new AEDs with novel mechanisms of action and
improved side effect profiles that can maintain seizure control with chronic administration for people with refractory epilepsy. The recent
successful introduction of Vimpat by UCB is an example of market acceptance of a new AED with a novel mechanism. Vimpat was approved in
the United States and European Union in 2008, and achieved global sales of approximately €471 million in 2014. Several other successfully
marketed AEDs experienced similar sales levels with similar duration of time on the market. UCB has stated that it expects Vimpat to achieve
over €1.2 billion in peak sales globally.
Our Solution
We believe ganaxolone to be a first-in-class therapy with potential to provide meaningful treatment advantages for adults with focal onset
seizures who do not achieve adequate seizure control from, have developed tolerance to, or have safety concerns with currently available
medications. We believe ganaxolone, if approved, may provide the following benefits for patients:
• Efficacy for refractory patients with focal onset seizures. Our completed Phase 2 clinical trial in patients with refractory focal
onset seizures demonstrated that patients who added ganaxolone to their medication regimen experienced a statistically significant
reduction in seizures as compared to patients who added placebo.
• Improved safety and tolerability profile. Ganaxolone was engineered to be a synthetic analog of a natural molecule,
allopregnanolone. Completed preclinical safety studies and Phase 1 and 2 clinical trials involving approximately 1,000 subjects show
ganaxolone to be generally safe and well-tolerated, without evidence of toxicity to heart, liver, blood or other body systems and
without many of the side effects common to other AEDs. We believe this safety profile may make ganaxolone a treatment of choice
in antiepileptic polypharmacy regimens.
3
Table of Contents
• Improved reproductive toxicity profile. Based on ganaxolone’s mechanism, and preclinical and clinical findings to date, we believe
ganaxolone will offer a lower risk for reproductive toxicity than many currently available AEDs, which we believe would be an
important safety differentiator for women of childbearing age.
Our market research with physicians indicates neurologists and epilepsy specialists would expect to use ganaxolone in 16 to 29% of their
focal onset seizure patients.
4
Table of Contents
Clinical Trials for Epilepsy in Adults
Controlled Phase 2 Clinical Trial for Adjunctive Treatment of Drug- Resistant Focal Onset Seizures (Study 600)
We successfully completed a double-blind, randomized, placebo-controlled, Phase 2 clinical trial in the United States of ganaxolone as
an adjunctive treatment in patients with refractory focal onset seizures. In this trial, ganaxolone satisfied the primary efficacy endpoint and was
considered to be generally safe and well tolerated. The study enrolled 147 patients who had been diagnosed with epilepsy on average 25 years
prior and 75% of which were taking two or three AEDs to control seizures before they entered the study. Subjects were treated for ten weeks with
placebo or ganaxolone as adjunctive treatment to existing therapy and recorded their seizures daily in a diary. Mean baseline seizure frequency
was 6.5 and 9.2 seizures per seven days in the ganaxolone and placebo groups, respectively. Subjects gradually increased their daily dose up to
1,500 milligrams per day, or mg/day, over the first two weeks, known as titration or the titration period, followed by maintenance dosing at 1,500
mg/day for eight weeks, known as the maintenance period. The primary efficacy endpoint was change from baseline in weekly seizure frequency.
Results of the analysis, using a statistical test (Kruskal-Wallis) that is employed when data have non-normal distribution, are presented in the table
below:
% Seizure Reduction From Baseline
Mean (standard deviation)
Median
Ganaxolone (n=98)
Placebo (n=49)
-17.6% (48.9)
-26.0%
+2.0% (63.2)
-10.2%
Difference
19.6 %
15.7 %
In the intention-to-treat, or ITT, population, which included all study subjects who took at least one dose of study medication, there was a
statistically significant reduction in the percent change in mean weekly seizure frequency in the ganaxolone group, which decreased 17.6% from
baseline at week 10, whereas in the placebo group, mean weekly seizure frequency increased by 2% compared to baseline at week 10, a difference
of 19.6% (p=0.014). The p-value represents the probability that the difference between the two groups is due to chance rather than drug effect, and
when that probability is less than 5%, or p<0.05, the result is considered statistically significant. In the ganaxolone group median seizure
frequency decreased by 26.0%, whereas in the placebo group median seizure frequency decreased by 10.2%, a difference of 15.7%. We believe
this effect size for an adjunctive treatment of a highly refractory patient population is consistent with the Phase 2 results for other AEDs that
ultimately received FDA approval.
Secondary analyses included the analysis of the percentage of subjects with greater than or equal to 50% improvement from baseline, or
responder analysis, mean and percent change in seizure frequency from baseline, number of seizure-free days and seizure-free subjects, change in
seizure frequency by week, and change from baseline in types of seizures. In general, the results of secondary efficacy analyses supported the
primary outcome that subjects treated with ganaxolone showed improved seizure control compared to those treated with placebo. The responder
analysis is considered by the EMA to be the primary analysis of a registration trial. In this study, the percent of responders in the ganaxolone
group compared to the placebo group in the ITT population were 23.5% and 14.6% (p=0.192) for the titration plus maintenance period, and 26.3%
v. 13.0% (p=0.057) for the maintenance period. No gender effect or effect of concomitant medication was observed.
Open Label Extension of Controlled Phase 2 Clinical Trial for Adjunctive Treatment of Drug-Resistant Focal Onset Seizures (Study 601)
Of the treatment-resistant subjects in our Phase 2 clinical trial, 95% of eligible subjects continued in a long-term open-label extension
where the mean duration of treatment was 39 weeks. The objective of the open-label extension study was to evaluate the long-term safety,
tolerability and efficacy of ganaxolone at a target dose of 1,500 mg/day. The primary endpoint was change in seizure frequency at endpoint
compared to baseline of the double-blind study, presented as mean and median change. Secondary assessments were similar to those evaluated in
the blinded portion of the study.
The mean and median percent reductions in weekly seizure frequency were 14.2% and 23.2% from baseline to endpoint, respectively. In
total, 70% of subjects had a reduction in seizure frequency during the study. Importantly, subjects previously randomized to placebo in the double-
blind study (Study 600) that were switched to ganaxolone in the open-label study showed mean and median reduction in seizure frequency
comparable to patients randomized to ganaxolone in the double-blind study.
5
Table of Contents
Secondary analyses included assessment of responders and seizure free status. Twenty-four percent of subjects met responder criteria at
endpoint, defined as a reduction in seizures of 50% or more from baseline, while 43% of those who remained in the study for 52 weeks or more
met 50% responder criteria. Subjects in the study reported a mean increase in number of seizure-free days per week of 17.4%, an increase that we
believe to be meaningful in the context of the severity and persistence of epilepsy in this drug-resistant population.
Phase 2 Clinical Trial of Monotherapy in Drug Resistant Focal Onset Seizures (Study 104)
A controlled clinical trial was also conducted to evaluate ganaxolone as monotherapy for focal onset seizures in a drug-resistant
population. This double-blind, randomized, placebo-controlled, Phase 2 clinical trial enrolled 52 subjects who were withdrawn from their
antiepileptic medications prior to evaluation for surgical treatment of their seizures. The subjects were treated with ganaxolone monotherapy 625
mg three times per day for eight days. The primary efficacy measure was duration of treatment prior to study withdrawal, due to emergence of
seizures, as measured from day 2 of the study.
As depicted in the plot above showing the Kaplan-Meier survival function of subjects remaining in the study, 62% of subjects in the
placebo group left the study due to emergence of seizures by day 8, compared with 39% of ganaxolone subjects (p=0.08). Statistical testing of
completion rates between the two groups found a statistically significant difference between completion rates in the two groups, with 50% of
ganaxolone subjects completing the study compared to 25% of placebo subjects (p=0.04).
Ganaxolone Safety Overview
More than 1,000 subjects have received treatment with ganaxolone ranging in duration from one day to more than two years using doses
from 50 to 2,000 mg/day. A total of 289 healthy subjects received ganaxolone doses of 50 to 2,000 mg/day in Phase 1 studies, for periods of up to
two weeks. In the completed Phase 2 clinical studies, 697 unique subjects have received ganaxolone including 135 pediatric subjects with
epilepsy, 169 adult subjects with epilepsy, and 393 adult subjects with migraine. Ganaxolone was administered in Phase 2 studies to pediatric
subjects at doses up to 54 mg/kg and to adult subjects at doses up to 1,875 mg/day. No drug-related deaths occurred in any of these clinical trials,
and the majority of adverse events were not medically serious and resolved upon discontinuation of therapy. In the ganaxolone safety database
there are no trends of medically important changes in blood chemistry, vital signs, liver function, renal function or cardiovascular parameters in
the adult or pediatric populations.
We have completed preclinical safety pharmacology and toxicology testing, including reproductive toxicology. Animal pharmacokinetic
and in vitro studies show that ganaxolone is primarily metabolized by the CYP3A family of liver enzymes, a common route of drug metabolism.
All in vitro studies have shown ganaxolone has low potential for interaction with other drugs at several multiples of observed human ganaxolone
levels. Furthermore, neither ganaxolone nor its metabolites have a ketone ring at the 3-position, a requirement for hormonal activity. In binding
studies, ganaxolone has no appreciable affinity for estrogen or progesterone receptors. We found no evidence of changes in blood, liver, kidney or
the gastrointestinal systems indicating functional or anatomical adverse effects associated with either single- or multiple-dose treatment with
ganaxolone in preclinical safety pharmacology studies, nor have we seen evidence of any end organ toxicity from human clinical studies. We have
not detected potential for ganaxolone to cause cellular mutations or carcinogenicity in studies to date. We plan to initiate the final two-year
carcinogenicity studies in rats and mice in 2015.
In reproductive toxicology studies, ganaxolone did not cause any malformations of the embryo or fetus in rats or mice and did not
significantly affect the development of offspring. No changes in sperm parameters were found. We believe these findings are important as all
currently marketed AEDs have shown developmental toxicities in animal studies such as fetal death or skeletal abnormalities, generating a rating
of Pregnancy Category C that indicates a finding of developmental toxicities in animal studies. Valproate, carbamazepine, phenytoin and
topiramate have been linked with birth defects in humans, for example, head and facial malformations, and lowered birth weight, at a rate higher
than observed in women who did not take these drugs. This association has resulted in a categorization of Pregnancy Category D for these drugs,
indicating positive evidence of human fetal risk based on scientific data. Based on ganaxolone’s mechanism and preclinical and clinical findings
to date, we intend to seek differentiated labeling including a designation of FDA Pregnancy Category B for ganaxolone, which indicates animal
reproduction studies have failed to demonstrate a risk to the fetus, which we believe would be an important safety differentiator for women of
childbearing age.
6
Table of Contents
Clinical Safety Results in Epilepsy
Ganaxolone was considered to be generally safe and well tolerated in the Phase 2 adjunctive treatment trials in adults with focal onset
seizures. The majority of adverse events associated with ganaxolone treatment were related to known CNS effects of GABA, were not medically
serious and resolved upon discontinuation of therapy. The data did not show any trends of medically important changes in blood chemistry, vital
signs, liver function, renal function or cardiovascular parameters related to ganaxolone treatment.
The most frequent treatment-emergent adverse events, or TEAEs, observed in Study 600 are presented in the table below.
Summary of Most Frequently Reported ( > 5% of Subjects) TEAEs by
System Organ Class and Preferred Term (ITT Population)
Preferred Term
Dizziness
Fatigue
Somnolence
Injury, poisoning and procedural complications
Headache
Coordination abnormal
Convulsion
Nasopharyngitis
Fall
Ganaxolone
(n=98)
%
Placebo
(n=49)
%
16.3
16.3
13.3
17.3
8.2
6.1
5.1
5.1
5.1
8.2
8.2
2.0
22.4
12.2
6.1
8.2
10.2
12.2
The two treatment groups had similar rates of discontinuation due to adverse events (7% ganaxolone, 6% placebo) and similar rates of
serious adverse events, or SAEs (5% ganaxolone, 8% placebo), mostly related to the underlying epilepsy. The majority of TEAEs resolved with
continued treatment or dose reduction. In contrast to some marketed AEDs, the incidence of behavioral TEAEs (reported as depression, insomnia,
affective disorder, confusional state, affect lability, aggression, anxiety) was similar in the ganaxolone and placebo treatment groups.
Ganaxolone continued to be considered generally safe and well tolerated in the long-term open-label extension, Study 601, in which 120
subjects received ganaxolone for a mean duration of 39 weeks. The most common adverse events considered related to ganaxolone treatment were
fatigue (14%), dizziness (9%) and somnolence, also known as sleepiness (7%). Eleven percent of the subjects discontinued due to one or more
adverse events. One SAE out of 17 reported was considered related to ganaxolone treatment, a 59 year old female on 900 mg/day whose liver
enzymes were elevated after 57 days of treatment. The enzyme levels returned to normal with a reduction in dose to 600 mg/day. In this long-term
open-label study of ganaxolone for adjunctive treatment of focal onset seizures, no new safety concerns were identified during extended treatment
with doses up to 1,500 mg/day.
In Study 104, the eight-day monotherapy study of ganaxolone and placebo in presurgical patients, ganaxolone was generally well-
tolerated and the profile of adverse events between the two groups was similar. Dizziness, which was reported in four ganaxolone and three
placebo subjects, was the most frequent adverse event. One SAE was reported in each group; the ganaxolone subject experienced severe agitation
and depression while the placebo subject experienced postictal psychosis. As in the other studies, no clinically meaningful differences between
treatment groups were noted in laboratory, vital sign, electrocardiogram, or physical/neurological exam results.
Ongoing and Planned Clinical Trials in Epilepsy
In October 2013 we initiated an international, randomized, placebo-controlled, Phase 2b clinical trial in adult subjects for adjunctive
treatment of focal onset seizures (Study 603). In Cohort 1, approximately 50 subjects were randomized to receive either placebo or ganaxolone
capsules in a step titration of 1,200 mg/day for four weeks followed by 1,800 mg/day for four weeks. Blood levels of ganaxolone will be assessed
at steady state for each dose level. Subjects from both cohorts enter a one year open label period after the double-blind treatment period.
The study protocol was then amended to meet the requirements for a phase 3 study and Cohort 2 was added to the protocol. In Cohort 2,
an additional 300 subjects are being randomized to receive either placebo or
7
Table of Contents
1,800 mg/day of ganaxolone for 12 weeks. Cohort 2 is intended to meet the Phase 3 design and statistical power requirements and precedents for
the FDA and other regulatory bodies for consideration as one of our adequate and well-controlled studies as part of an FDA or EMA filing
package for registration. The primary endpoint of this trial is change in seizure frequency per month compared to baseline of Cohort 2 subjects
after 14 weeks of treatment, at the end of the blinded phase of the study. We are capturing adverse events and other measures of safety as well as
responder rate, seizure-free status and changes in seizure subtypes. We plan to release top line data in the first quarter of 2016.
We are planning to conduct a second Phase 3, double-blind, randomized fixed-dose study to confirm the efficacy, tolerability and safety
of ganaxolone for adjunctive treatment of focal onset seizures in adults. This study, per European guidelines and United States precedents, will
enroll similar patients as those in our ongoing trial: adult outpatients with drug-resistant focal onset seizures who require add-on therapy in
addition to their current AEDs. The study will contain two or three fixed dose arms of ganaxolone versus placebo for 12 weeks of maintenance
therapy. Change in seizure frequency compared to baseline will be the primary outcome measure. Patients who complete the study would be
eligible to enroll in a one year open-label extension.
Ganaxolone is currently formulated as an oral suspension and as a capsule. Study 600 and 601 were conducted with an oral suspension
formulation and Study 603 is being conducted with a capsule formulation. Pharmacokinetic studies are being planned to establish relative potency
between the capsule and the suspension. Separate pharmacokinetic studies suggest that the capsule is approximately 20% more potent than the
suspension.
Ganaxolone in PCDH19 Female Pediatric Epilepsy - An Orphan Disease
Overview of PCDH19 Female Pediatric Epilepsy
PCDH19 female pediatric epilepsy (PCDH19-FPE) is a rare and serious epileptic syndrome characterized by early-onset cluster seizures,
cognitive and sensory impairment of varying degrees, and psychiatric and behavioral disturbances. The epileptic disorder is an X-linked condition
caused by a missense mutation in the PCDH19 gene, which encodes for a calcium dependent cell-cell adhesion molecule that is expressed in the
central nervous system (hippocampus, cerebral cortex, thalamus, amygdala) and which appears to be related to synaptic transmission and
formation of synaptic connections during brain development. The mean age of onset of this condition is approximately 10 months (range of three-
38 months). There is a genetic test available to determine whether or not a child has the PCDH19 mutation. Although formal epidemiologic data is
not available, results from diagnostic screenings indicate that approximately 10% of girls who have seizure onset before five years of age have
PCDH19 mutations. We estimate the PCDH19 population to be approximately 15,000 to 30,000 patients in the United States. These patients
typically experience multiple types of seizures, including focal and generalized, as well as clusters of seizures that can last from one day to weeks.
Many of these patients will experience developmental delay, intellectual disability and behavioral problems. Seizures often improve in
adolescence, although developmental complications persist. Currently, there are no approved therapies for PCDH19-FPE.
Mechanism of Action
PCDH19 female pediatric epilepsy is caused by a mutation in the PCDH19 gene. This mutation results in impairment of GABAergic
signaling both at the agonist and receptor levels. There is also indirect evidence linking progesterone/allopregnanolone to the onset and offset of
seizures in girls with PCDH19-FPE. It has been hypothesized that disturbances in certain neurosteroid hormones, such as allopregnanolone, may
be implicated in the molecular pathogenesis of PCDH19-FPE. We believe that ganaxolone may be useful in the treatment of PCDH19 female
pediatric epilepsy because it is a synthetic analog of allopregnanolone that can be used to increase GABAergic signaling in these patients. We also
believe that data from our previously conducted studies of pediatric seizure disorders, which demonstrated ganaxolone’s ability to treat multiple
seizure types and showed a safety profile similar to that seen is adults, supports our rationale to pursue this rare disease as PCDH19 female
pediatric patients may experience varying types of seizures.
Ongoing Clinical Trial in Patients with PCDH19 Female Pediatric Epilepsy
Based upon both proof-of-concept data for ganaxolone in the treatment of refractory pediatric seizures and a mechanistic rationale for
providing a therapeutic benefit through increased GABAergic signaling we have initiated an expanded access protocol under our epilepsy
investigational new drug application (IND) for an open label trial. This proof-of-concept Phase 2 trial is designed to enroll approximately 10
female pediatric patients between the ages of 2 and 10 years old, with a confirmed PCDH19 genetic mutation. After establishing baseline seizure
frequency, patients will be treated with
8
Table of Contents
ganaxolone administered as either oral liquid suspension or capsules for up to 26 weeks. The primary endpoint of the study is percent change in
seizure frequency per 28 days relative to baseline. We plan to release initial data from this study during 2015.
Clinical Trial in Refractory Pediatric Epilepsy
We also conducted an open-label clinical trial to evaluate ganaxolone as add-on therapy in children with refractory epilepsy of multiple
seizure types including focal, absence, epileptic spasms, tonic and tonic-clonic. Forty-five subjects aged 1-13 years were treated at doses of up to
12 mg/kg, three times per day. Of the 29 subjects in the study at Week 8, the primary endpoint, twelve (41%) met responder criteria of having
50% or greater improvement from baseline.
Ganaxolone in Fragile X Syndrome, or FXS - An Orphan Disease
Overview and Treatment of FXS
FXS is a genetic condition that causes intellectual disability, behavioral and learning challenges and various physical characteristics. The
impairment can range from learning disabilities to more severe cognitive or intellectual disabilities. According to the Centers for Disease Control
and Prevention, FXS affects 1 in 3,600 to 4,000 males and 1 in 4,000 to 6,000 females of all races and ethnic groups. Approximately 1 in 151
women carry the Fragile X gene and could pass it to their children. Approximately 1 in 468 men carry the Fragile X gene and their daughters will
also be carriers. Patients with FXS exhibit autism-like symptoms including cognitive impairment, anxiety and mood swings, attention deficit and
heightened stimuli. Approximately 7% of women and 18% of men with FXS have seizures. People with FXS are affected throughout their lives.
Currently, there are no known cures or approved therapies for FXS. Special education and symptomatic treatments are employed to lessen the
burden of illness.
Market Opportunity
Approximately one million individuals in the United States have, or are at risk for developing, a Fragile X associated disorder, with
approximately 100,000 people having FXS. Treatment approaches focus primarily on supportive care and medications addressing development
delays, learning disabilities, and social and behavioral problems caused by the disease. Various classes of medications are used to treat behavioral
and mental health conditions associated with FXS. Some patients with FXS benefit from medications that treat attention deficient disorders. Other
patients who experience general anxiety, social anxiety and other chronic conditions may benefit from different types of anti-anxiety medications
and other neuropsychiatric treatments.
Mechanism of Action
FXS arises from a mutation of a gene known as the fmr1 gene in the coding for the Fragile X mental retardation protein. In a mouse
model of this gene mutation, certain brain regions show lower levels of the extrasynaptic GABA
enzymes responsible for GABA function. The result of fewer GABA
seizures. Ganaxolone and other agents that have been shown to improve GABA function have also been shown to improve FXS symptoms in this
mouse model. As FXS symptoms may be diagnosed as early as infancy, it would be beneficial for a drug approved to treat FXS to have a safety
profile acceptable for use in children as well as adults.
receptors in these mice include over-sensitivity to noise, anxiety, and
receptors and reduction of proteins and
A
A
We believe that ganaxolone, with its high-affinity for extrasynaptic GABA
receptors, may increase signaling at existing receptors to
A
normalize GABA function thereby reducing anxiety, hyperactivity and other disabilities associated with this inherited disorder.
Ongoing Clinical Trial (Study 800)
The MIND Institute at the University of California, Davis has been awarded a medical research grant from the DoD to study ganaxolone
for treatment of behaviors in FXS in children and adolescents. The MIND Institute, in collaboration with Marinus, is conducting a randomized,
placebo-controlled, Phase 2 proof-of-concept clinical trial at UC Davis and a site in Belgium. Approximately 60 subjects will be enrolled and
titrated up to a maximum dose of 1,800 mg/day of ganaxolone or placebo over a two-week period followed by four weeks of treatment. At the end
of the first treatment period and following a washout period, subjects are crossed over to the other treatment for a similar two-week titration period
followed by four weeks of treatment.
9
Table of Contents
The primary outcome measure of the study is Clinical Global Impression Rating Scale for Improvement. Secondary outcome measures
include the Aberrant Behaviors Checklist and ratings scales for specific behaviors associated with childhood FXS. We plan to complete this study
during 2015.
Other Potential Future Development Programs for Ganaxolone
We believe that due to its mechanism of action, there is a rationale for ganaxolone therapy to provide a clinical benefit in a broad array of
indications beyond our current trials. Such additional indications may include generalized anxiety disorder, PTSD, addictive disorders, catamenial
epilepsy, perinatal depression, ADHD, and other neurodegenerative disorders. Additionally ganaxolone might be useful in several rare genetic
disorders related to impaired GABA function such as the orphan indications Neimann Pick Disease, Type C, or status epilepticus. We would need
to conduct additional clinical trials in order to obtain labeled indications for any of these programs.
The Injury and Traumatic Stress Consortium, or INTRuST, a group of PTSD treatment centers in the United States, has received
government funding from the US Department of Defense to evaluate new treatments for PTSD. In collaboration with Marinus, INTRuST
conducted a proof-of-concept study of ganaxolone versus placebo in adults with PTSD. The Phase 2 clinical trial was conducted at seven Veterans
Administration centers in the United States. The study enrolled 114 adults with PTSD who were treated for six weeks with ganaxolone at 400-
1200 mg per day or placebo in ascending doses followed by six weeks on open label ganaxolone.
The primary efficacy measure is the Clinician-Administered PTSD Scale, or CAPS, the standard rating assessment in treatment studies
for PTSD, measured at the end of week 6. The CAPS measures levels of repetitive thoughts, startle, vigilance, avoidance and depression that are
the main characteristics of PTSD. Additional efficacy ratings include measures of resilience, sleep, mood and overall global improvement.
Treatment has been completed in this study. While the primary efficacy endpoint was not met in this study, some evidence of efficacy was seen in
patients at the highest dose. Periodic reviews of the safety data from the study showed ganaxolone was safe in this population. While PTSD is
not an indication that is part of our core development strategy, we may continue to work with third parties to fund and conduct future clinical
trials.
Our Strategy
Our goal is to maximize the value of ganaxolone as a first-in-class innovative neuropsychiatric therapy with a portfolio of diversified
indications. The key elements of our strategy to achieve this goal include:
• Executing our registration studies and pursue regulatory approval for ganaxolone for adjunctive treatment of focal onset
seizures and other epilepsy indications. Building on efficacy established in our two completed Phase 2 clinical trials, and a
differentiated safety profile as demonstrated in extensive preclinical studies and trials in more than 1,000 subjects, we are executing
a clinical program to support a registration filing for ganaxolone for adjunctive treatment of focal onset seizures in adults in the
United States, Europe and other major markets. Additionally, if the results from our adjunctive focal onset seizure trials are positive,
we plan to develop ganaxolone in other segments of the epilepsy market including for monotherapy and pediatric epilepsy. As a
result of its efficacy and safety profile, we believe ganaxolone could be a meaningful treatment for epilepsy patients who do not
achieve adequate seizure control from, have developed tolerance to, or have safety concerns with currently available therapies
including concerns around reproductive toxicity.
• Pursuing orphan disease epilepsy indications for ganaxolone . Within epilepsy, there are several smaller patient populations
where a genetic marker associated with the syndrome has been identified that is linked to deficits in GABAergic signaling.
Increasing GABAergic tone with ganaxolone, a positive allosteric modulator of GABA receptors, might provide benefit. These small
populations have the potential for more efficient paths to regulatory approval and commercialization. A proof-of-concept open label
Phase 2 clinical trial is ongoing for ganaxolone in patients with PCDH19-FPE. We may explore development of ganaxolone in other
rare disease epilepsy indications.
• Broadening dose forms to acute care setting . Our present ongoing clinical trials utilize our patented nanoparticulate composition
administered in oral capsule and liquid suspension dose forms. As a complement to these orally administered dose forms, we are
conducting the requisite preclinical experiments to ready our intravenous dose form for clinical use. We plan to evaluate ganaxolone
IV for the acute care setting for in-hospital use and in patient populations that may benefit from both inpatient ganaxolone IV and an
outpatient oral form for chronic administration.
10
Table of Contents
• Expanding non-epilepsy indications for ganaxolone. Due to its mechanism of action, we believe ganaxolone has potential for
therapeutic benefit in a variety of neuropsychiatric disorders in addition to epilepsy. Evidence from preclinical and clinical studies
demonstrates that treatment with an agent similar to naturally occurring allopregnanolone could be of benefit in patients with
anxiety, mood, sleep and developmental disorders. A proof-of-concept clinical trial is ongoing for ganaxolone in patients with FXS.
We may explore development of ganaxolone in other neuropsychiatric disorders and rare disease neurology indications.
• Commercializing ganaxolone in the United States either alone or in collaboration with others. We intend to build sales and
marketing infrastructure to reach high-prescribing neurologists and epilepsy specialists in the United States. We may seek co-
promotion partners for our sales efforts to reach other United States physician groups, such as primary care physicians. We believe a
focused sales and marketing organization could be leveraged to market ganaxolone in other neurology or psychiatry indications if we
are able to obtain regulatory approval for those other indications.
• Establishing collaborations to develop and commercialize ganaxolone in territories outside the United States. We believe that
there is significant market opportunity for ganaxolone in epilepsy and other neurological and psychiatric conditions outside of the
United States. In order to capitalize on this opportunity, we may seek collaborations with pharmaceutical companies that have
greater reach and resources by virtue of their size and experience in markets outside the United States.
Intellectual Property
The proprietary nature of, and protection for our product candidates and discovery programs and know-how are important to our
business. We have sought patent protection in the United States and internationally for ganaxolone and use of ganaxolone nanoparticles in oral
solid and liquid dose formulations. Our policy is to pursue, maintain and defend patent rights whether developed internally or licensed from third
parties and to protect the technology, inventions and improvements that are commercially important to the development of our business.
The basis of our intellectual property was the discovery of a novel composition of nanoparticles and complexing agents that deliver
consistent exposure and improved stability of ganaxolone. This discovery resulted in the issuance of United States and foreign patents, which
cover use of these complexed ganaxolone nanoparticles in oral solid and liquid dose formulations. Our patent portfolio contains seven United
States patents, two pending United States patent applications, and corresponding foreign patents and patent applications directed to solid and
liquid ganaloxone formulations and methods for the making and use thereof. These patents expire in 2026, excluding accounting for possible
patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, or for possible
pediatric exclusivity. Corresponding foreign patents have been granted in Australia, Canada, Eurasia, Japan, Mexico, New Zealand, Singapore and
South Korea. Corresponding foreign patent applications are pending in China, Europe, India, Israel, Japan, Mexico, and South Africa. We have
not licensed any rights to practice these patents in any of these territories. Pursuant to our agreement with Domain Russia Investments Limited, or
DRI, we have assigned patent rights, which rights were subsequently assigned to NovaMedica LLC, whereby we licensed our patents, along with
the rights to develop and commercialize ganaxolone, in Russia and certain other eastern European nations.
Our patent portfolio also contains patents issued in Australia, United States, Europe and New Zealand covering our novel and cost
effective ganaxolone synthesis process, which expire in 2030, excluding accounting for possible patent term extension under the Hatch-Waxman
Act, or for possible pediatric exclusivity. Corresponding foreign patent applications are pending in Brazil, Canada, China, Eurasia, Hong
Kong, Israel, India, Japan, Mexico, New Zealand and South Korea. We continue to prosecute applications in additional geographies.
We filed a provisional application in February 2015 directed to intravenous ganaxolone formulations and methods of using these
formulations to treat refractory epileptic seizures and other disorders. If granted, this patent will expire in 2036, excluding accounting for possible
patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 or the Hatch-Waxman Act.
In addition to patents, we rely upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain
a competitive position. We seek to protect our proprietary information, in part, through confidentiality agreements with our employees,
collaborators, contractors and consultants, and invention assignment agreements with our employees and some of our collaborators. The
confidentiality agreements are
11
Table of Contents
designed to protect our proprietary information and, in the case of agreements or clauses requiring invention assignment, to grant us ownership of
technologies that are developed through a relationship with a third party.
General considerations
As with other biotechnology and pharmaceutical companies, our ability to maintain and solidify a proprietary position for ganaxolone
will depend upon our success in obtaining effective patent claims and enforcing those claims once granted. Our commercial success will depend in
part upon not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us
to alter our development or commercial strategies, obtain licenses, or cease certain activities. The biotechnology and pharmaceutical industries are
characterized by extensive litigation regarding patents and other intellectual property rights.
The term of a patent that covers a FDA-approved drug may be eligible for patent term extension, which provides patent term restoration
as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up
to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under
regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and
only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other foreign jurisdictions to
extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical products receive FDA approval, we expect
to apply for patent term extensions on patents covering those products.
Many pharmaceutical companies, biotechnology companies and academic institutions are competing with us in the field of
neuropsychiatric disorders and filing patent applications potentially relevant to our business. Even when a third-party patent is identified, we may
conclude upon a thorough analysis, that we do not infringe upon the patent or that the patent is invalid. If the third-party patent owner disagrees
with our conclusion and we continue with the business activity in question, we may be subject to patent litigation. Alternatively, we might decide
to initiate litigation in an attempt to have a court declare the third-party patent invalid or non-infringed by our activity. In either scenario, patent
litigation typically is costly and time-consuming, and the outcome can be favorable or unfavorable.
Collaborations
NovaMedica
In connection with our Series C convertible preferred stock financing, in December 2012, we entered into a Technology Transfer
Agreement, or the Transfer Agreement, with DRI, a significant stockholder of our company. Pursuant to the Transfer Agreement, in exchange for
a payment of $100,000, we assigned to DRI certain patents and patents applications in Armenia, Azerbaijan, Belarus, Georgia, Kazakhstan,
Kyrgyzstan, Moldova, Russia, Tajikistan, Turkmenistan, Ukraine and Uzbekistan, or the Covered Territory, and granted to DRI an exclusive,
royalty-free, irrevocable and assignable license under our know-how to develop and commercialize ganaxolone and other products that would
infringe our patent rights or use our know-how, or the Covered Products, in the Covered Territory, in the field of uses for any human or animal
disease or condition excluding the treatment of unpleasant sensory or emotional experience associated with actual or potential tissue damage or
described in terms of such damage, or the Field. Immediately thereafter, we, together with DRI, executed an Assignment and Assumption
Agreement, pursuant to which all of DRI’s rights and obligations under the Transfer Agreement were transferred to NovaMedica, LLC, or
NovaMedica. We agreed to take all action required to register or record the patent transfers to DRI in each country in the Covered Territory and to
ensure the assignment of DRI’s rights under the Transfer Agreement to NovaMedica. NovaMedica is jointly owned by Rusnano Medinvest LLC,
or Rusnano Medinvest, and DRI. RMI Investments, S.á.r.l, a stockholder of ours, is a wholly-owned subsidiary of Rusnano Medinvest.
Under the terms of the Transfer Agreement, NovaMedica, or its permitted transferees or assignees, has the exclusive right within the
Covered Territory to manufacture the Covered Products solely for development and commercialization in the Covered Territory in the Field. Until
the first commercial sale of a Covered Product within the Covered Territory, NovaMedica will have the right to purchase supplies of the Covered
Product from us as are reasonably available to us and as are reasonable and necessary to conduct clinical trials of Covered Product in the Covered
Territory, provided that any such purchase does not reasonably interfere with our having sufficient supplies of Covered Products on hand for use
in development (including the conduct of clinical trials) or commercialization
12
Table of Contents
outside of the Covered Territory. Such purchases will be made on a cost-plus basis. The parties shall enter into the Supply Agreement to supply
ganaxolone and/or Covered Product for development in the Covered Territory within 60 calendar days from NovaMedica’s request, which we
have not yet received.
In accordance with the terms of the Transfer Agreement, on June 25, 2013 we entered into a Clinical Development and Collaboration
Agreement, or the Collaboration Agreement, with NovaMedica, pursuant to which we agreed to assist NovaMedica in the development and
commercialization of Covered Products in the Covered Territory in the Field. The Collaboration Agreement requires the formation of committees
consisting of our representatives and NovaMedica representatives to oversee the general development, day-to-day development work and
commercialization of Covered Products in the Field in the Covered Territory. All decisions of these committees must be made by unanimous vote,
subject to a dispute resolution process. Under the terms of the Collaboration Agreement, the joint committees will determine a development plan
for ganaxolone in clinical trials and a plan for commercialization of ganaxolone. NovaMedica will have sole responsibility for the costs and
expenses of obtaining regulatory approval for Covered Products and for commercializing any approved products in the Covered Territory, and
NovaMedica will have the right to conduct its own clinical studies in the Covered Territory at its sole expense. NovaMedica also has the right to
file applications for approval of Covered Products in the Covered Territory, subject to committee oversight. We have agreed, among other things,
to provide NovaMedica with data and regulatory files necessary for it to obtain necessary approvals in the Covered Territory, information relating
to applications for regulatory approval of Covered Products, certain commercialization information and to assist NovaMedica in conducting any
clinical trials necessary for regulatory approval of Covered Products in the Covered Territory. We also have agreed to provide NovaMedica with
certain development know-how and support, including making our clinical development personnel available to provide scientific and technical
explanations, consultation and support that may be reasonably requested by NovaMedica.
NovaMedica is required to reimburse us for any out-of-pocket expenses incurred by us in providing this assistance, except for expenses
incurred in our participation on the joint committees. Pursuant to the Collaboration Agreement and the Transfer Agreement, we have agreed to use
commercially reasonable efforts to include sites in the Russian Federation in our clinical trial programs for the first indications of the Covered
Products at our sole expense. Under the Transfer Agreement, at least 36 months prior to the first commercial sale of a product candidate in the
Covered Territory, the parties have agreed to negotiate in good faith a supply agreement pursuant to which we or a third party contract
manufacturer authorized by us to manufacture and supply the Covered Products, will supply needed quantities of Covered Product to NovaMedica
solely for commercialization of Covered Products in the Covered Territory, on commercially fair and reasonable terms. Such purchases will be
made on a cost-plus basis. In the event the parties are unable to agree on pricing under the supply agreement, they have agreed to engage an
internationally recognized consulting firm reasonably acceptable to both parties to perform an analysis to determine final pricing under the supply
agreement, which decision will be binding upon the parties. In the event that the parties are unable to reach a reasonably acceptable supply
agreement or we are unable to supply Covered Products to NovaMedica under such supply agreement for a period of at least 60 calendar days
after the specified delivery date and we thereafter fail to cure such failure within 60 days after written notice from NovaMedica, we have agreed to
cooperate with NovaMedica to identify a mutually acceptable alternative source of supply and will provide the necessary consents to allow such
alternative source of supply to provide the needed quantities of the Covered Products to NovaMedica. The terms of the alternative source of
supply would be negotiated directly by NovaMedica with the supplier.
The Collaboration Agreement expires on the earlier of three years following the first commercial sale of a product candidate in the
Covered Territory and terminates upon the termination of the Transfer Agreement. NovaMedica also has the right to terminate the Collaboration
Agreement at any time at its convenience upon 90 days’ prior written notice.
Purdue
In September 2004, we entered into a license agreement with Purdue, which was most recently amended and restated in May 2008 that
granted us exclusive rights to certain know-how and technology relating to ganaxolone, excluding the field of treatment of unpleasant sensory or
emotional experience associated with actual or potential tissue damage, or described in terms of such damage. The agreement contains a right by
us to sublicense subject to prior written approval by Purdue. We are obligated to pay royalties as a percentage in the range of high single digits up
to 10% of net product sales for direct licensed products, such as ganaxolone. The obligation to pay royalties expires, on a country-by-country
basis,
13
Table of Contents
ten years from the first commercial sale of a licensed product in each country. We believe that we will not be obligated to pay royalties under the
agreement because the underlying patents have either expired or are not applicable to ganaxolone. In addition, the agreement also requires that we
pay Purdue a percentage in the mid-single digits of the non-royalty consideration that we receive from a sublicensee and a percentage in the
twenties of milestone payments for indications other than seizure disorders and vascular migraine headaches not associated with mood disorders.
Under the license agreement, we are committed to use commercially reasonable efforts to develop and commercialize at least one licensed
product.
Competition
The pharmaceutical industry is highly competitive and subject to rapid and significant technological change. While we believe that our
development experience and scientific knowledge provide us with competitive advantages, we face competition from both large and small
pharmaceutical and biotechnology companies, specifically with companies that treat neuropsychiatric disorders.
There are a variety of available therapies marketed for neuropsychiatric disorders. In many cases, these products are administered in
combination to enhance efficacy or to reduce side effects. Some of these drugs are branded and subject to patent protection, some are in clinical
development and not yet approved, and others are available on a generic basis. Many of these approved drugs are well established therapies or
products and are widely accepted by physicians, patients and third-party payors. Insurers and other third-party payors may also encourage the use
of generic products. More established companies have a competitive advantage over us due to their greater size, cash flows and institutional
experience. Compared to us, many of our competitors have significantly greater financial, technical and human resources.
Our competitors may also develop drugs that are safer, more effective, more widely used and less costly than ours, and may also be more
successful than us in manufacturing and marketing their products. These appreciable advantages could render ganaxolone obsolete or non-
competitive before we can recover the expenses of ganaxolone’s development and commercialization.
Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated
among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified
scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs.
Competitive Landscape
We primarily compete with pharmaceutical and biotechnology companies that are developing therapies or marketing drugs to treat
indications that we are targeting.
Epileptic Seizures
Currently available AEDs control seizures through a variety of mechanisms, including modulation of voltage-activated sodium channels,
voltage-activated calcium channels, increasing GABA signaling, and interactions with α 2-δ protein or synaptic vesicle protein SV2A. There are
more than 15 approved AEDs available in the United States and worldwide. The top prescribed AEDs include the generic products levetiracetam,
lamotrigine, carbamazepine, oxcarbazepine, valproic acid and topiramate. Decision Resources reports that these AEDs are used to treat a
substantial percentage of epilepsy patients. Recent market entrants include Vimpat (UCB), Potiga (GlaxoSmithKline) and Fycompa (Eisai), and
Aptiom (Sunovion Pharmaceuticals). In addition to ganaxolone there are two new chemical entities in late stage development that we are aware
of, brivaracetam (UCB) and carisbamate (SK Life Science), while Sage Therapeutics is developing SAGE-547, an intravenous formulation of
allopregnanolone for super-refractory status epilepticus.
14
Table of Contents
FXS
There are no drugs approved for the treatment of behavioral and mental health conditions associated with FXS although various classes
of medications are used off-label. Some patients with FXS benefit from medications that treat attention deficient disorders and other patients who
experience general anxiety, social anxiety and other chronic conditions may benefit from different types of anti-anxiety medications.
We are aware of several drugs in development including a number of generic drugs used for other indications such as donepezil,
memantine, sertraline, and minocycline. Companies developing compounds include Alcobra, Sunovion Pharmaceuticals, Afraxis and Neuren
Pharmaceuticals.
PCDH19-FPE
There are no drugs approved for the treatment of PCDH19-FPE. PCDH19-FPE patients are typically prescribed drugs approved for
epileptic seizures, which often times fail to control seizures in this patients population.
Manufacturing
Manufacturing of drugs and product candidates, including ganaxolone, must comply with FDA current good manufacturing practice, or
cGMP, regulations. Ganaxolone is a synthetic small molecule made through a series of organic chemistry steps starting with commercially
available organic chemical raw materials. We conduct manufacturing activities under individual purchase orders with independent contract
manufacturing organizations, or CMOs, to supply our clinical trials. We have an internal quality program and have qualified and signed quality
agreements with our CMOs. We conduct periodic quality audits of their facilities. We believe that our existing suppliers of ganaxolone’s active
pharmaceutical ingredient and finished product will be capable of providing sufficient quantities of each to meet our clinical trial supply needs.
Other CMOs may be used in the future for clinical supplies and, subject to approval, commercial manufacturing.
Ganaxolone Formulations
The therapeutic possibilities of ganaxolone have been understood for some time, however, because ganaxolone is a high-dose water
insoluble compound, developing a formulation that could provide consistent drug exposure and could be manufactured at a commercially feasible
cost had proven challenging. We believe the discovery of our patented nanoparticulate formulation and novel manufacturing process for
ganaxolone address the pharmacokinetic and cost of manufacturing challenges that previously encumbered the clinical and commercial feasibility
of ganaxolone.
Ganaxolone is currently formulated as an oral suspension and as a capsule. We are planning a pharmacokinetic study to establish relative
potency between the oral suspension to the capsule. Additionally, we have developed an intravenous formulation and a prototype for a tablet. We
are presently conducting the requisite preclinical experiments to ready our intravenous dose form for clinical use.
Commercial Operations
If we obtain FDA approval for ganaxolone as an adjunctive treatment for patients with focal onset seizures we intend to build a sales and
marketing infrastructure to reach high prescribing neurologist and epilepsy specialists in the United States. We believe a focused sales and
marketing organization for epilepsy could be leveraged to market ganaxolone in other neurology or psychiatry indications if we are able to obtain
regulatory approval for those other indications. We may seek co-promotion partners for our sales efforts to reach other United States physician
groups, such as primary care physicians. We believe that there is significant market opportunity for ganaxolone in epilepsy and other neurological
and psychiatric conditions outside of the United States. In order to capitalize on this opportunity, we plan to seek collaborations with
pharmaceutical companies that have greater reach and resources by virtue of their size and experience in the field.
Government Regulation
As a clinical stage biopharmaceutical company that operates in the United States, we are subject to extensive regulation by the FDA, and
other federal, state, and local regulatory agencies. The Federal Food, Drug, and Cosmetic Act, or the FDC Act, and its implementing regulations
set forth, among other things, requirements for the research, testing, development, manufacture, quality control, safety, effectiveness, approval,
packaging, labeling, storage, record keeping, reporting, distribution, import, export, advertising and promotion of our products. Although the
discussion below focuses on regulation in the United States, we anticipate seeking approval for, and marketing of, our products in other countries.
Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the United States,
although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way
through the EMA,
15
Table of Contents
but country-specific regulation remains essential in many respects. The process of obtaining regulatory marketing approvals and the subsequent
compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial
resources and may not be successful.
United States Government Regulation
The FDA is the main regulatory body that controls pharmaceuticals in the United States, and its regulatory authority is based in the FDC
Act. Pharmaceutical products are also subject to other federal, state and local statutes. A failure to comply explicitly with any requirements during
the product development, approval, or post-approval periods, may lead to administrative or judicial sanctions. These sanctions could include the
imposition by the FDA or an institutional review board, or IRB, of a hold on clinical trials, refusal to approve pending marketing applications or
supplements, withdrawal of approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
injunctions, fines, civil penalties or criminal prosecution.
The steps required before a new drug may be marketed in the United States generally include:
• completion of non-clinical, or preclinical, studies, animal studies and formulation studies in compliance with the FDA’s good
laboratory practice, or GLP, regulations;
• submission to the FDA of an IND to support human clinical testing;
• approval by an IRB at each clinical site before each trial may be initiated;
• performance of adequate and well-controlled clinical trials in accordance with federal regulations, including requirements for good
clinical practices, or GCPs, to establish the safety and efficacy of the investigational product candidate for each targeted indication;
• submission of a new drug application, or NDA, to the FDA;
• satisfactory completion of an FDA Advisory Committee review, if applicable;
• satisfactory completion of an FDA inspection of clinical trial sites to ensure compliance with GCPs;
• satisfactory completion of an FDA inspection of the manufacturing facilities at which the investigational product candidate is
produced to assess compliance with cGMP, and to assure that the facilities, methods and controls are adequate; and
• FDA review and approval of the NDA.
Clinical Trials
An IND is a request for authorization from the FDA to administer an investigational product candidate to humans. This authorization is
required before interstate shipping and administration of any new drug product to humans that is not the subject of an approved NDA. A 30-day
waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has neither
commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin. The FDA may submit
questions after the 30 day period and after the trial was allowed to begin. Clinical trials involve the administration of the investigational product
candidate to subjects under the supervision of qualified investigators following GCPs, requirements meant to protect the rights and health of
subjects and to define the roles of clinical trial sponsors, administrators and monitors. Clinical trials are conducted under protocols that detail the
subject inclusion and exclusion criteria, the dosing regimen, the parameters to be used in monitoring safety, and the efficacy criteria to be
evaluated. Each protocol involving testing on United States subjects and subsequent protocol amendments must be submitted to the FDA as part
of the IND. The informed written consent of each participating subject is required. The clinical investigation of an investigational product
candidate is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The
three phases of an investigation are as follows:
• Phase 1. Phase 1 includes the initial introduction of an investigational product candidate into humans. Phase 1 studies may be
conducted in subjects with the target disease or condition or healthy volunteers. These studies are designed to evaluate the safety,
metabolism, pharmacokinetic properties, or PKs, and
16
Table of Contents
pharmacologic actions of the investigational product candidate in humans, the side effects associated with increasing doses, and if
possible, to gain early evidence on effectiveness. During Phase 1 studies, sufficient information about the investigational product
candidate’s PKs and pharmacological effects may be obtained to permit the design of Phase 2 studies. The total number of
participants included in Phase 1 studies varies, but is generally in the range of 20 to 80.
• Phase 2. Phase 2 includes the controlled clinical trials conducted to evaluate the effectiveness of the investigational product
candidate for a particular indication(s) in subjects with the disease or condition under study, to determine dosage tolerance and
optimal dosage, and to identify possible adverse side effects and safety risks associated with the product candidate. Phase 2 studies
are typically well-controlled, closely monitored, and conducted in a limited subject population, usually involving no more than
several hundred participants.
• Phase 3. Phase 3 studies are controlled clinical trials conducted in an expanded subject population at geographically dispersed
clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the investigational product candidate
has been obtained, and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk
relationship of the product candidate, and to provide an adequate basis for drug approval. Phase 3 studies usually involve several
hundred to several thousand participants. In most cases, the FDA requires two adequate and well controlled Phase 3 studies to
demonstrate the efficacy of the drug. A single Phase 3 study with other confirmatory evidence may be sufficient in rare instances
where the study is a large multicenter trial demonstrating internal consistency and a statistically very persuasive finding of a
clinically meaningful effect on mortality, irreversible morbidity or prevention of a disease with a potentially serious outcome and
confirmation of the result in a second trial would be practically or ethically impossible.
The decision to terminate development of an investigational product candidate may be made by either a health authority body, such as the
FDA or IRB/ethics committees, or by a company for various reasons. The FDA may order the temporary, or permanent, discontinuation of a
clinical trial, which is referred to as a clinical hold, at any time, or impose other sanctions, if it believes that the clinical trial either is not being
conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. In some cases, clinical trials are
overseen by an independent group of qualified experts organized by the trial sponsor, or the clinical monitoring board or data safety monitoring
board. This group provides authorization for whether or not a trial may move forward at designated check points. These decisions are based on the
limited access to data from the ongoing trial. The suspension or termination of development can occur during any phase of clinical trials if it is
determined that the participants or subjects are being exposed to an unacceptable health risk. In addition, there are requirements for the
registration of ongoing clinical trials of product candidates on public registries and the disclosure of certain information pertaining to the trials as
well as clinical trial results after completion.
A sponsor may be able to request a special protocol assessment, or SPA, the purpose of which is to reach agreement with the FDA on the
Phase 3 study protocol design and analysis that will form the primary basis of an efficacy claim. A sponsor meeting the regulatory criteria may
make a specific request for an SPA and provide information regarding the design and size of the proposed clinical trial. An SPA request must be
made before the proposed trial begins, and all open issues must be resolved before the trial begins. If a written agreement is reached, it will be
documented and made part of the record. The agreement will be binding on the FDA and may not be changed by the sponsor or the FDA after the
trial begins except with the written agreement of the sponsor and the FDA or if the FDA determines that a substantial scientific issue essential to
determining the safety or efficacy of the product candidate was identified after the testing began. An SPA is not binding if new circumstances
arise, and there is no guarantee that a study will ultimately be adequate to support an approval even if the study is subject to an SPA.
Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational
product candidate information is submitted to the FDA in the form of an NDA to request market approval for the product in specified indications.
New Drug Applications
In order to obtain approval to market a drug in the United States, a marketing application must be submitted to the FDA that provides
data establishing the safety and effectiveness of the product candidate for the proposed indication. The application includes all relevant data
available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with
detailed information relating to
17
Table of Contents
the product’s chemistry, manufacturing, controls and proposed labeling, among other things. Data can come from company-sponsored clinical
trials intended to test the safety and effectiveness of a product, or from a number of alternative sources, including studies initiated by investigators.
To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the
investigational product candidate to the satisfaction of the FDA.
In most cases, the NDA must be accompanied by a substantial user fee; there may be some instances in which the user fee is waived. The
FDA will initially review the NDA for completeness before it accepts the NDA for filing. The FDA has 60 days from its receipt of an NDA to
determine whether the application will be accepted for filing based on the agency’s threshold determination that it is sufficiently complete to
permit substantive review. After the NDA submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain
performance goals in the review of NDAs. Most such applications for standard review product candidates are reviewed within ten to twelve
months. The FDA can extend this review by three months to consider certain late-submitted information or information intended to clarify
information already provided in the submission. The FDA reviews the NDA to determine, among other things, whether the proposed product is
safe and effective for its intended use, and whether the product is being manufactured in accordance with cGMP. The FDA may refer applications
for novel product candidates which present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes
clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what
conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when
making decisions.
Before approving an NDA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the
product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure
consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or
more clinical sites to assure compliance with GCP. After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval
letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial
additional testing or information in order for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the
FDA’s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions
in two or six months depending on the type of information included. Notwithstanding the submission of any requested additional information, the
FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.
An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. As a
condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to help ensure that the benefits of the drug
outweigh the potential risks. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe
use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under
certain circumstances, special monitoring, and the use of patient registries. The requirement for a REMS can materially affect the potential market
and profitability of the drug. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug’s
safety or efficacy. Once granted, product approvals may be withdrawn if compliance with regulatory requirements is not maintained or problems
are identified following initial marketing.
18
Table of Contents
Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing
processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA
supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures
and actions in reviewing NDA supplements as it does in reviewing NDAs.
Advertising and Promotion
The FDA and other federal regulatory agencies closely regulate the marketing and promotion of drugs through, among other things,
standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and
educational activities, and promotional activities involving the Internet. A product cannot be commercially promoted before it is approved. After
approval, product promotion can include only those claims relating to safety and effectiveness that are consistent with the labeling approved by
the FDA. Healthcare providers are permitted to prescribe drugs for “off-label” uses—that is, uses not approved by the FDA and therefore not
described in the drug’s labeling—because the FDA does not regulate the practice of medicine. However, FDA regulations impose stringent
restrictions on manufacturers’ communications regarding off-label uses. Broadly speaking, a manufacturer may not promote a drug for off-label
use, but may engage in non-promotional, balanced communication regarding off- label use under specified conditions. Failure to comply with
applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and enforcement action by the FDA, the
United States Department of Justice, or DOJ, or the Office of the Inspector General of the United States Department of Health and Human
Services, or HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial
impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug
products.
Post-Approval Regulations
After regulatory approval of a drug is obtained, a company is required to comply with a number of post-approval requirements. For
example, as a condition of approval of an NDA, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to
further assess and monitor the product’s safety and effectiveness after commercialization. In addition, as a holder of an approved NDA, a
company would be required to report adverse reactions and production problems to the FDA, to provide updated safety and efficacy information,
and to comply with requirements concerning advertising and promotional labeling for any of its products. Also, quality control and manufacturing
procedures must continue to conform to cGMP after approval to assure and preserve the long term stability of the drug product. The FDA
periodically inspects manufacturing facilities to assess compliance with cGMP, which imposes extensive procedural and substantive record
keeping requirements. In addition, changes to the manufacturing process are strictly regulated, and, depending on the significance of the change,
may require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from
cGMP and impose documentation requirements upon a company and any third-party manufacturers that a company may decide to use.
Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance
with cGMP and other aspects of regulatory compliance.
We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of ganaxolone. Future
FDA and state inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt
production or distribution, or require substantial resources to correct. In addition, discovery of previously unknown problems with a product or the
failure to comply with applicable requirements may result in restrictions on a product, manufacturer or holder of an approved NDA, including
withdrawal or recall of the product from the market or other voluntary, FDA-initiated or judicial action that could delay or prohibit further
marketing.
Newly discovered or developed safety or effectiveness data may require changes to a product’s approved labeling, including the addition
of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government
requirements, including those resulting from new legislation, may be established, or the FDA’s policies may change, which could delay or prevent
regulatory approval of our products under development.
19
Table of Contents
The Hatch-Waxman Amendments to the FDC Act
Orange Book Listing
In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the
applicant’s product or a method of using the product. Upon approval of a drug, each of the patents listed in the application for the drug is then
published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed
in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an abbreviated new drug application, or
ANDA, or 505(b)(2) application. An ANDA provides for marketing of a drug product that has the same active ingredients, generally in the same
strengths and dosage form, as the listed drug and has been shown through PK testing to be bioequivalent to the listed drug. Other than the
requirement for bioequivalence testing, ANDA applicants are generally not required to conduct, or submit results of, preclinical studies or clinical
tests to prove the safety or effectiveness of their drug product. 505(b)(2) applications provide for marketing of a drug product that may have the
same active ingredients as the listed drug and contains full safety and effectiveness data as an NDA, but at least some of this information comes
from studies not conducted by or for the applicant. Drugs approved in this way are commonly referred to as “generic equivalents” to the listed
drug, and can often be substituted by pharmacists under prescriptions written for the original listed drug.
The ANDA or 505(b)(2) applicant is required to certify to the FDA concerning any patents listed for the approved product in the FDA’s
Orange Book. Specifically, the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired;
(iii) the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed patent is
invalid or will not be infringed by the new product. The ANDA or 505(b)(2) applicant may also elect to submit a statement certifying that its
proposed ANDA label does not contain (or carves out) any language regarding a patented method of use rather than certify to such listed method
of use patent. If the applicant does not challenge the listed patents by filing a certification that the listed patent is invalid or will not be infringed
by the new product, the ANDA or 505(b)(2) application will not be approved until all the listed patents claiming the referenced product have
expired.
A certification that the new product will not infringe the already approved product’s listed patents, or that such patents are invalid, is
called a Paragraph IV certification. If the ANDA or 505(b)(2) applicant has provided a Paragraph IV certification to the FDA, the applicant must
also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA or 505(b)(2) application has been accepted for
filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV
certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the
FDA from approving the ANDA or 505(b)(2) application until the earliest of 30 months, expiration of the patent, settlement of the lawsuit, and a
decision in the infringement case that is favorable to the ANDA or 505(b)(2) applicant.
The ANDA or 505(b)(2) application also will not be approved until any applicable non-patent exclusivity listed in the Orange Book for
the referenced product has expired.
Marketing Exclusivity
Upon NDA approval of a new chemical entity, which is a drug that contains no active moiety that has been approved by the FDA in any
other NDA, that drug receives five years of marketing exclusivity during which the FDA cannot approve any ANDA seeking approval of a
generic version of that drug. Certain changes to a drug, such as the addition of a new indication to the package insert, are associated with a three-
year period of exclusivity during which the FDA cannot approve an ANDA for a generic drug that includes the change.
An ANDA may be submitted one year before marketing exclusivity expires if a Paragraph IV certification is filed. In this case, the
30 months stay, if applicable, runs from the end of the five years marketing exclusivity period. If there is no listed patent in the Orange Book,
there may not be a Paragraph IV certification, and, thus, no ANDA may be filed before the expiration of the exclusivity period.
Patent Term Extension
After NDA approval, owners of relevant drug patents may apply for up to a five year patent extension. The allowable patent term
extension is calculated as half of the drug’s testing phase—the time between an effective IND and NDA submission—and all of the review
phase—the time between NDA submission and approval up to a
20
Table of Contents
maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total
patent term after the extension may not exceed 14 years.
Many other countries also provide for patent term extensions or similar extensions of patent protection for pharmaceutical products. For
example, in Japan, it may be possible to extend the patent term for up to five years and in Europe, it may be possible to obtain a supplementary
patent certificate that would effectively extend patent protection for up to five years.
The Foreign Corrupt Practices Act
The Foreign Corrupt Practices Act, or FCPA, prohibits any United States individual or business from paying, offering, or authorizing
payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing
any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates
companies whose securities are listed in the United States to comply with accounting provisions requiring such companies to maintain books and
records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an
adequate system of internal accounting controls for international operations.
European and Other International Government Regulation
In addition to regulations in the United States, we will be subject to a variety of regulations in other jurisdictions governing, among other
things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we must
obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the
product in those countries. Some countries outside of the United States have a similar process that requires the submission of a request for a
clinical trial authorization, or CTA, much like the IND prior to the commencement of human clinical trials. In Europe, for example, a request for a
CTA must be submitted to each country’s national health authority and an independent ethics committee, much like the FDA and IRB,
respectively. Once the CTA request is approved in accordance with a country’s requirements, clinical trial development may proceed.
To obtain regulatory approval to commercialize a new drug under European Union regulatory systems, we must submit a marketing
authorization application, or MAA. The MAA is similar to the NDA, with the exception of, among other things, country-specific document
requirements.
For other countries outside of the European Union, such as countries in Eastern Europe, Russia, Latin America or Asia, the requirements
governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. Internationally, clinical trials
are generally required to be conducted in accordance with GCP, applicable regulatory requirements of each jurisdiction and the medical ethics
principles that have their origin in the Declaration of Helsinki.
Compliance
During all phases of development (pre- and post-marketing), failure to comply with applicable regulatory requirements may result in
administrative or judicial sanctions. These sanctions could include the FDA’s imposition of a clinical hold on trials, refusal to approve pending
applications, withdrawal of an approval, warning letters, product recalls, product seizures, total or partial suspension of production or distribution,
product detention or refusal to permit the import or export of products, injunctions, fines, civil penalties or criminal prosecution. Any agency or
judicial enforcement action could have a material adverse effect on us.
Other Special Regulatory Procedures
Orphan Drug Designation
The FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000
individuals in the United States, or, if the disease or condition affects more than 200,000 individuals in the United States, there is no reasonable
expectation that the cost of developing and making the drug would be recovered from sales in the United States. In the European Union, the
EMA’s Committee for Orphan Medicinal Products grants Orphan Drug Designation to promote the development of products that are intended for
the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions affecting not more
21
Table of Contents
than five in 10,000 persons in the European Union community. Additionally, designation is granted for products intended for the diagnosis,
prevention or treatment of a life- threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely
that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug.
In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards
clinical trial costs, tax credits for certain research and user fee waivers under certain circumstances. In addition, if a product receives the first FDA
approval for the indication for which it has orphan designation, the product is entitled to seven years of market exclusivity, which means the FDA
may not approve any other application for the same drug for the same indication for a period of seven years, except in limited circumstances, such
as a showing of clinical superiority over the product with orphan exclusivity. Orphan drug exclusivity does not prevent the FDA from approving a
different drug for the same disease or condition, or the same drug for a different disease or condition.
In the European Union, Orphan Drug Designation also entitles a party to financial incentives such as reduction of fees or fee waivers and
ten years of market exclusivity is granted following drug approval. This period may be reduced to six years if the Orphan Drug Designation
criteria are no longer met, including where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity.
Orphan drug designation must be requested before submission of an application for marketing approval. Orphan drug designation does
not convey any advantage in, or shorten the duration of the regulatory review and approval process.
Priority Review (United States) and Accelerated Review (European Union)
Based on results of the Phase 3 study(ies) submitted in an NDA, upon the request of an applicant, a priority review designation may be
granted to a product by the FDA, which sets the target date for FDA action on the application at six months from FDA filing. Priority review is
given where preliminary estimates indicate that a product, if approved, has the potential to provide a safe and effective therapy where no
satisfactory alternative therapy exists, or a significant improvement compared to marketed products is possible. If criteria are not met for priority
review, the standard FDA review period is ten months from FDA filing. Priority review designation does not change the scientific/medical
standard for approval or the quality of evidence necessary to support approval.
Under the Centralized Procedure in the European Union, the maximum timeframe for the evaluation of a MAA is 210 days (excluding
“clock stops,” when additional written or oral information is to be provided by the applicant in response to questions asked by the Committee for
Medicinal Products for Human Use, or CHMP). Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal
product is expected to be of a major public health interest, defined by three cumulative criteria: the seriousness of the disease (e.g., heavy
disabling or life-threatening diseases) to be treated; the absence or insufficiency of an appropriate alternative therapeutic approach; and
anticipation of high therapeutic benefit. In this circumstance, EMA ensures that the opinion of the CHMP is given within 150 days.
Healthcare Reform
In March 2010, President Obama signed one of the most significant healthcare reform measures in decades. The Patient Protection and
Affordable Care Act and the Health Care and Education Reconciliation Act of 2010, or Affordable Care Act, substantially changes the way
healthcare will be financed by both governmental and private insurers, and significantly impacts the pharmaceutical industry. The Affordable Care
Act will impact existing government healthcare programs and will result in the development of new programs. For example, the Affordable Care
Act provides for Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback
program.
Among the Affordable Care Act’s provisions of importance to the pharmaceutical industry are the following:
• an annual, nondeductible fee on any covered entity engaged in manufacturing or importing certain branded prescription drugs and
biological products, apportioned among such entities in accordance with their respective market share in certain government
healthcare programs;
22
Table of Contents
• an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to
January 1, 2010, to 23.0% and 13.0% of the average manufacturer price, or AMP, for most branded and generic drugs, respectively;
• expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government
investigative powers, and enhanced penalties for noncompliance;
• a new partial prescription drug benefit for Medicare recipients, or Medicare Part D, coverage gap discount program, in which
manufacturers must agree to offer 50.0% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible
beneficiaries during their coverage gap period, as a condition for the manufacturers’ outpatient drugs to be covered under Medicare
Part D;
• extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid
managed care organizations;
• expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to
additional individuals beginning in 2014 and by adding new mandatory eligibility categories for individuals with income at or below
133.0% of the Federal Poverty Level, thereby potentially increasing manufacturers’ Medicaid rebate liability;
• expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
• new requirements to report annually specified financial arrangements with physicians and teaching hospitals, as defined in the
Affordable Care Act and its implementing regulations, including reporting any “payments or transfers of value” made or distributed
to physicians and teaching hospitals,and reporting any ownership and investment interests held by physicians and their immediate
family members and applicable group purchasing organizations during the preceding calendar year, with data collection to be
required beginning August 1, 2013 and reporting to the Centers for Medicare and Medicaid Services, or CMS, to be required by
March 31, 2014 and by the 90th day of each subsequent calendar year;
• a new requirement to annually report drug samples that manufacturers and distributors provide to physicians;
• a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical
effectiveness research, along with funding for such research; and
• a mandatory nondeductible payment for employers with 50 or more full-time employees (or equivalents) who fail to provide certain
minimum health insurance coverage for such employees and their dependents, beginning in 2015 (pursuant to relief enacted by the
Treasury Department).
The Affordable Care Act also establishes an Independent Payment Advisory Board, or IPAB, to reduce the per capita rate of growth in
Medicare spending. Beginning in 2014, IPAB is mandated to propose changes in Medicare payments if it determines that the rate of growth of
Medicare expenditures exceeds target growth rates. The IPAB has broad discretion to propose policies to reduce expenditures, which may have a
negative impact on payment rates for pharmaceutical products. A proposal made by the IPAB is required to be implemented by CMS unless
Congress adopts a proposal with savings greater than those proposed by the IPAB. IPAB proposals may impact payments for physician and free-
standing services beginning in 2015 and for hospital services beginning in 2020.
In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011,
President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit
Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction
of an amount greater than $1.2 trillion for the years 2013 through 2021, triggering the legislation’s automatic reductions to several government
programs. These reductions include aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, starting in
2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced
Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover
overpayments to providers
23
Table of Contents
from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding, which could have a
material adverse effect on our customers and accordingly, our financial operations.
We anticipate that the Affordable Care Act will result in additional downward pressure on coverage and the price that we receive for any
approved product, and could seriously harm our business. Any reduction in reimbursement from Medicare and other government programs may
result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may
prevent us from being able to generate revenue, attain profitability, or commercialize our products. In addition, it is possible that there will be
further legislation or regulation that could harm our business, financial condition and results of operations.
Coverage and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we obtain regulatory approval.
In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will
depend in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative
authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide
coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug
product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the
FDA-approved drugs for a particular indication. Third-party payors are increasingly challenging the price and examining the medical necessity
and cost- effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required
to obtain FDA approvals. Ganaxolone may not be considered medically necessary or cost-effective. A payor’s decision to provide coverage for a
drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to
enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.
In 2003, the United States Congress enacted legislation providing Medicare Part D, which became effective at the beginning of 2006.
Government payment for some of the costs of prescription drugs may increase demand for any products for which we receive marketing approval.
However, to obtain payments under this program, we would be required to sell products to Medicare recipients through prescription drug plans
operating pursuant to this legislation. These plans will likely negotiate discounted prices for our products. Federal, state and local governments in
the United States continue to consider legislation to limit the growth of healthcare costs, including the cost of prescription drugs. Future legislation
could limit payments for pharmaceuticals such as the product candidates that we are developing.
Different pricing and reimbursement schemes exist in other countries. In the European Union, governments influence the price of
pharmaceutical products through their pricing and reimbursement rules and control of national healthcare systems that fund a large part of the cost
of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a
reimbursement price has been agreed upon. To obtain reimbursement or pricing approval, some of these countries may require the completion of
clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow
companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure on healthcare costs in general,
particularly prescription drugs, has become more intense. As a result, increasingly high barriers are being erected to the entry of new products.
The European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance
systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for
the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal
product on the market. We may face competition for ganaxolone from lower-priced products in foreign countries that have placed price controls
on pharmaceutical products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing
within a country.
The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-
party payors fail to provide adequate coverage and reimbursement. In addition, an increasing emphasis on managed care in the United States has
increased and will continue to increase the pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement rates may change
at any time.
24
Table of Contents
Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less
favorable coverage policies and reimbursement rates may be implemented in the future.
Other Healthcare Laws and Compliance Requirements
The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving
remuneration to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service
reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to
arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other. Although
there are a number of statutory exemptions and regulatory safe harbors protecting some business arrangements from prosecution, the exemptions
and safe harbors are drawn narrowly and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be
subject to scrutiny if they do not qualify for an exemption or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor
protection from federal Anti-Kickback Statute liability. The reach of the Anti-Kickback Statute was broadened by the Affordable Care Act, which,
among other things, amends the intent requirement of the federal Anti-Kickback Statute. Pursuant to the statutory amendment, a person or entity
no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the
Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below) or the civil monetary
penalties statute, which imposes penalties against any person who is determined to have presented or caused to be presented a claim to a federal
health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent.
The federal False Claims Act prohibits any person from knowingly presenting, or causing to be presented, a false claim for payment to
the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent
claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes “any
request or demand” for money or property presented to the United States government. Recently, several pharmaceutical and other healthcare
companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would
bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the companies’
marketing of the product for unapproved, and thus non-reimbursable, uses. The Health Insurance Portability and Accountability Act of 1996, or
HIPAA, created new federal criminal statutes that prohibit knowingly and willfully executing a scheme to defraud any healthcare benefit program,
including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially
false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Also, many states
have similar fraud and abuse statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in
several states, apply regardless of the payor.
In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct
our business. HIPAA, as amended by The Health Information Technology for Economic and Clinical Health Act, or HITECH, and its
implementing regulations, imposes requirements relating to the privacy, security and transmission of individually identifiable health information.
Among other things, HITECH makes HIPAA’s privacy and security standards directly applicable to “business associates”—independent
contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a
covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and
possibly other persons, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce
the federal HIPAA laws and seek attorney’s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy
and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the
same effect, thus complicating compliance efforts.
In the United States our activities are potentially subject to additional regulation by various federal, state and local authorities in addition
to the FDA, including CMS, other divisions of HHS (for example, the Office of Inspector General), the DOJ and individual United States
Attorney offices within the DOJ, and state and local governments. If a drug product is reimbursed by Medicare or Medicaid, pricing and rebate
programs must comply with, as applicable, The Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or Medicare
Modernization Act, as well as the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990,
25
Table of Contents
or the OBRA, and the Veterans Health Care Act of 1992, or the VHCA, each as amended. Among other things, the OBRA requires drug
manufacturers to pay rebates on prescription drugs to state Medicaid programs and empowers states to negotiate rebates on pharmaceutical prices,
which may result in prices for our future products that will likely be lower than the prices we might otherwise obtain. If products are made
available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply.
Under the VHCA, drug companies are required to offer some drugs at a reduced price to a number of federal agencies including the United States
Department of Veterans Affairs and the DoD, the Public Health Service and some private Public Health Service designated entities in order to
participate in other federal funding programs including Medicaid. Recent legislative changes require that discounted prices be offered for
specified DoD purchases for its TRICARE program via a rebate system. Participation under the VHCA requires submission of pricing data and
calculation of discounts and rebates pursuant to complex statutory formulas, as well as the entry into government procurement contracts governed
by the Federal Acquisition Regulation.
Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our
business activities could be subject to challenge under one or more of such laws. If our operations are found to be in violation of any of the federal
and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and
significant civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government programs, injunctions, recall or
seizure of products, total or partial suspension of production, denial or withdrawal of pre-marketing product approvals, private “qui tam” actions
brought by individual whistleblowers in the name of the government or refusal to allow us to enter into supply contracts, including government
contracts, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our
results of operations. To the extent that any of our products are sold in a foreign country, we may be subject to similar foreign laws and
regulations, which may include, for instance, applicable post- marketing requirements, including safety surveillance, anti-fraud and abuse laws,
and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.
In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale
distributors of pharmaceutical products in a state, including, in some states, manufacturers and distributors who ship products into the state even if
such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and
distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt
new technology capable of tracking and tracing product as it moves through the distribution chain. In addition, in November 2013, the Drug
Quality and Security Act became law and establishes requirements to facilitate the tracing of prescription drug products through the
pharmaceutical supply distribution chain. This law includes a number of new requirements that will be implemented over time and will require us
to devote additional resources to satisfy these requirements. Several states have enacted legislation requiring pharmaceutical companies to, among
other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing,
pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit pharmacies and other healthcare entities
from providing specified physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit other specified
sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.
Research and Development
Conducting research and development is central to our business model. We have invested and expect to continue to invest significant
time and capital in our research and development operations. Our research and development expenses were $8.7 million and $4.2 million in 2014
and 2013, respectively.
Employees
As of December 31, 2014, we had nine full-time employees. In addition to our full-time employees, we contract with third-parties for the
conduct of certain clinical development, manufacturing, accounting and administrative activities. We anticipate increasing our head count. We
have no collective bargaining agreements with our employees and none are represented by labor unions.
26
Table of Contents
Corporate Information
We were incorporated in Delaware in August 2003. Our principal executive offices are located at 3 Radnor Corporate Center, 100
Matsonford Rd, Suite 304, Radnor, Pennsylvania 19087 and our telephone number is (484) 801-4670. Our website address is
www.marinuspharma.com . The inclusion of our website address is, in each case, intended to be an inactive textual reference only and not an
active hyperlink to our website. The information contained in, or that can be accessed through, our website is not part of this Annual Report on
Form 10-K.
Item 1A. Risk Factors.
Risks Related to Our Financial Position and Capital Needs
We have a limited operating history, have incurred significant losses since our inception and anticipate that we will continue to incur losses in
the future.
We commenced operations in 2003, and we have only a limited operating history upon which you can evaluate our business and
prospects. Our operations to date have been limited to conducting product development activities for ganaxolone and performing research and
development with respect to our clinical and preclinical programs. In addition, as a clinical stage biopharmaceutical company, we have not yet
demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly
evolving fields, particularly in the biopharmaceutical area. Nor have we demonstrated an ability to obtain regulatory approval for or to
commercialize any of our product candidates. Consequently, any predictions about our future performance may not be as accurate as they would
be if we had a history of successfully developing and commercializing biopharmaceutical products.
We have incurred significant operating losses since our inception, including net losses of $10.8 million for the year ended December 31,
2014. As of December 31, 2014, we had an accumulated deficit of $72.3 million. Our prior losses, combined with expected future losses, have had
and will continue to have an adverse effect on our stockholders’ equity and working capital. Our losses have resulted principally from costs
incurred in our research and development activities. We anticipate that our operating losses will substantially increase over the next several years
as we execute our plan to expand our research, development and commercialization activities, including the clinical development and planned
commercialization of our product candidate, ganaxolone, and incur the additional costs of operating as a public company. In addition, if we obtain
regulatory approval of ganaxolone, we may incur significant sales and marketing expenses. Because of the numerous risks and uncertainties
associated with developing biopharmaceutical products, we are unable to predict the extent of any future losses or whether or when we will
become profitable, if ever.
We have not generated any revenue to date from product sales. We may never achieve or sustain profitability, which could depress the market
price of our common stock, and could cause you to lose all or a part of your investment.
To date, we have no products approved for commercial sale and have not generated any revenue from sales of any of our product
candidates, and we do not know when, or if, we will generate revenues in the future. Our ability to generate revenue from product sales and
achieve profitability will depend upon our ability to successfully gain regulatory approval and commercialize ganaxolone or other product
candidates that we may develop, in-license or acquire in the future. Even if we are able to successfully achieve regulatory approval for
ganaxolone, we do not know when we will generate revenue from product sales, if at all. Our ability to generate revenue from product sales from
ganaxolone or any other future product candidates also depends on a number of additional factors, including our ability to:
• successfully complete development activities, including enrollment of study participants and completion of the necessary clinical
trials;
• complete and submit new drug applications, or NDAs, to the United States Food and Drug Administration, or FDA, and obtain
regulatory approval for indications for which there is a commercial market;
• complete and submit applications to, and obtain regulatory approval from, foreign regulatory authorities;
• make or have made commercial quantities of our products at acceptable cost levels;
27
Table of Contents
• develop a commercial organization capable of manufacturing, selling, marketing and distributing any products we intend to sell
ourselves in the markets in which we choose to commercialize on our own;
• find suitable partners to help us market, sell and distribute our approved products in other markets; and
• obtain adequate pricing, coverage and reimbursement from third parties, including government and private payors.
In addition, because of the numerous risks and uncertainties associated with product development, including that ganaxolone may not
advance through development or achieve the endpoints of applicable clinical trials, we are unable to predict the timing or amount of increased
expenses, or if or when we will be able to achieve or maintain profitability. Even if we are able to complete the development and regulatory
process for ganaxolone, we anticipate incurring significant costs associated with commercializing ganaxolone.
Even if we are able to generate revenue from the sale of ganaxolone or any future commercial products, we may not become profitable
and will need to obtain additional funding to continue operations. If we fail to become profitable or are unable to sustain profitability on a
continuing basis, and we are not successful in obtaining additional funding, then we may be unable to continue our operations at planned levels,
which would depress the market price of our common stock.
We will require additional capital to fund our operations and if we fail to obtain necessary financing, we may be unable to complete the
development and commercialization of ganaxolone.
Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to
advance the clinical development of ganaxolone and launch and commercialize ganaxolone, if we receive regulatory approval. We will require
additional capital for the further development and potential commercialization of ganaxolone and may also need to raise additional funds sooner to
pursue a more accelerated development of ganaxolone. If we are unable to raise capital when needed or on attractive terms, we could be forced to
delay, reduce or eliminate our research and development programs or any future commercialization efforts.
We believe that our cash and cash equivalents as of December 31, 2014, will enable us to fund our operating expenses and capital
expenditure requirements into the second half of 2016. We have based this estimate on assumptions that may prove to be wrong, and we could
deploy our available capital resources sooner than we currently expect. Our future funding requirements, both near and long-term, will depend on
many factors, including, but not limited to the:
• initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for
ganaxolone or any other future product candidates;
• clinical development plans we establish for ganaxolone and any other future product candidates;
• obligation to make royalty and non-royalty sublicense receipt payments to third-party licensors, if any, under our licensing
agreements;
• number and characteristics of product candidates that we discover or in-license and develop;
• outcome, timing and cost of regulatory review by the FDA and comparable foreign regulatory authorities, including the potential for
the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;
• costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property
rights;
• effects of competing technological and market developments;
• costs and timing of the implementation of commercial-scale manufacturing activities; and
• costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive
regulatory approval.
28
Table of Contents
If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to
become profitable will be compromised.
Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to ganaxolone or
any other future product candidates.
Until we can generate substantial revenue from product sales, if ever, we expect to seek additional capital through a combination of
private and public equity offerings, debt financings, strategic collaborations and alliances and licensing arrangements. To the extent that we raise
additional capital through the sale of equity or convertible debt securities, the ownership interests of stockholders will be diluted, and the terms
may include liquidation or other preferences that adversely affect the rights of stockholders. Debt financing, if available, may involve agreements
that include liens or other restrictive covenants limiting our ability to take important actions, such as incurring additional debt, making capital
expenditures or declaring dividends. If we raise additional funds through strategic collaborations and alliances or licensing arrangements with
third parties, we may have to relinquish valuable rights to ganaxolone or any other future product candidates in particular countries, or grant
licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when needed, we may be
required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market
ganaxolone or any other future product candidates that we would otherwise prefer to develop and market ourselves.
We intend to expend our limited resources to pursue our sole clinical stage product candidate, ganaxolone, for seizure disorders and may fail
to capitalize on other indications, technologies or product candidates that may be more profitable or for which there may be a greater
likelihood of success.
Because we have limited financial and managerial resources, we are focusing on research programs relating to ganaxolone for focal onset
seizures, which concentrates the risk of product failure in the event ganaxolone proves to be ineffective or inadequate for clinical development or
commercialization in this indication. As a result, we may forego or delay pursuit of opportunities for other indications or with other technologies
or product candidates that later could prove to have greater commercial potential. We may be unable to capitalize on viable commercial products
or profitable market opportunities as a result of our resource allocation decisions. Our spending on proprietary research and development
programs relating to ganaxolone may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or
target market for ganaxolone, we may relinquish valuable rights to ganaxolone through collaboration, licensing or other royalty arrangements in
cases in which it would have been more advantageous for us to retain sole development and commercialization rights to ganaxolone.
Risks Related to Our Business and Development of Our Product
Our future success is dependent on the successful clinical development, regulatory approval and commercialization of ganaxolone, which is
currently undergoing two clinical trials and will require significant capital resources and years of additional clinical development effort.
We do not have any products that have gained regulatory approval. Currently, our only clinical stage product candidate is ganaxolone. As
a result, our business is dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if
approved, successfully commercialize ganaxolone in a timely manner. We cannot commercialize ganaxolone in the United States without first
obtaining regulatory approval from the FDA; similarly, we cannot commercialize ganaxolone outside of the United States without obtaining
regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of ganaxolone
for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two
adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that ganaxolone is
safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. We have expanded
our ongoing Phase 2b clinical trial so that it may serve as one of our adequate and well-controlled clinical trials for ganaxolone in epilepsy;
however, we cannot be certain that the FDA will accept the trial as such. Even if ganaxolone were to successfully obtain approval from the FDA
and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age
groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we
are unable to obtain regulatory approval for ganaxolone in one or more jurisdictions, or any approval contains significant limitations, we may not
be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other product candidate that we may in-
license,
29
Table of Contents
develop or acquire in the future. Furthermore, even if we obtain regulatory approval for ganaxolone, we will still need to develop a commercial
organization, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If
we are unable to successfully commercialize ganaxolone, we may not be able to earn sufficient revenue to continue our business.
Because the results of preclinical studies or earlier clinical trials are not necessarily predictive of future results, ganaxolone may not have
favorable results in later preclinical studies or clinical trials or receive regulatory approval.
Success in preclinical studies and early clinical trials does not ensure that later trials will generate adequate data to demonstrate the
efficacy and safety of ganaxolone. A number of companies in the pharmaceutical and biotechnology industries, including those with greater
resources and experience, have suffered significant setbacks in preclinical studies and clinical trials, even after seeing promising results in earlier
studies and trials. Despite the results reported in earlier clinical trials for ganaxolone, we do not know whether the clinical trials we may conduct
will demonstrate adequate efficacy and safety to result in regulatory approval to market ganaxolone in any particular jurisdiction. If later stage
clinical trials do not produce favorable results, our ability to achieve regulatory approval for ganaxolone may be adversely impacted.
The therapeutic efficacy and safety of ganaxolone are unproven, and we may not be able to successfully develop and commercialize
ganaxolone in the future.
Ganaxolone is a novel compound and its potential benefit as a therapeutic for focal onset seizures, PCDH19 female pediatric epilepsy, or
PCDH19, and Fragile X Syndrome, or FXS, is unproven. Our ability to generate revenue from ganaxolone, which we do not expect will occur for
at least the next several years, if ever, will depend heavily on our successful development and commercialization after regulatory approval, which
is subject to many potential risks and may not occur. Ganaxolone may interact with human biological systems in unforeseen, ineffective or
harmful ways. If ganaxolone is associated with undesirable side effects or has characteristics that are unexpected, we may need to abandon its
development or limit development to certain uses or subpopulations in which the undesirable side effects or other characteristics are less
prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in early stage testing for
treating the target indications for ganaxolone have later been found to cause side effects that prevented further development of the compound. As
a result of these and other risks described herein that are inherent in the development of novel therapeutic agents, we may never successfully
develop, enter into or maintain third-party licensing or collaboration transactions with respect to, or successfully commercialize, ganaxolone, in
which case we will not achieve profitability and the value of our stock may decline.
Clinical development of product candidates involves a lengthy and expensive process with an uncertain outcome.
Clinical testing is expensive, can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process.
We may experience delays in our ongoing or future clinical trials and we do not know whether planned clinical trials will begin or enroll
subjects on time, need to be redesigned or be completed on schedule, if at all. There can be no assurance that the FDA or other foreign regulatory
authorities will not put clinical trials of ganaxolone on clinical hold now or in the future. Clinical trials may be delayed, suspended or prematurely
terminated for a variety of reasons, such as:
• delay or failure in reaching agreement with the FDA or a comparable foreign regulatory authority on a trial design that we are able
to execute;
• delay or failure in obtaining authorization to commence a trial or inability to comply with conditions imposed by a regulatory
authority regarding the scope or design of a clinical trial;
• delay or failure in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical
trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial
sites;
• delay or failure in obtaining institutional review board, or IRB, approval or the approval of other reviewing entities, including
comparable foreign regulatory authorities, to conduct a clinical trial at each site;
30
Table of Contents
• withdrawal of clinical trial sites from our clinical trials as a result of changing standards of care or the ineligibility of a site to
participate in our clinical trials;
• delay or failure in recruiting and enrolling suitable study subjects to participate in a trial;
• delay or failure in study subjects completing a trial or returning for post-treatment follow-up;
• clinical sites and investigators deviating from a trial protocol, failing to conduct the trial in accordance with regulatory requirements,
or dropping out of a trial;
• inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial
programs, including some that may be for competing product candidates with the same indication;
• failure of our third-party clinical trial managers to satisfy their contractual duties or meet expected deadlines;
• delay or failure in adding new clinical trial sites;
• ambiguous or negative interim results or results that are inconsistent with earlier results;
• feedback from the FDA, the IRB, data safety monitoring boards, or a comparable foreign regulatory authority, or results from earlier
stage or concurrent preclinical studies and clinical trials, that might require modification to the protocol for the trial;
• decision by the FDA, the IRB, a comparable foreign regulatory authority, or us, or recommendation by a data safety monitoring
board or comparable foreign regulatory authority, to suspend or terminate clinical trials at any time for safety issues or for any other
reason;
• unacceptable risk-benefit profile, unforeseen safety issues or adverse side effects or adverse events;
• failure of a product candidate to demonstrate any benefit;
• difficulties in manufacturing or obtaining from third parties sufficient quantities of a product candidate for use in clinical trials;
• lack of adequate funding to continue the clinical trial, including the incurrence of unforeseen costs due to enrollment delays,
requirements to conduct additional clinical trials or increased expenses associated with the services of our CROs and other third
parties;
• political developments that affect our ability to develop and obtain approval for ganaxolone, or license rights to develop and obtain
approval for ganaxolone, in a foreign country; or
• changes in governmental regulations or administrative actions.
Study subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of
the subject population, the proximity of subjects to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, ability to obtain
and maintain subject consents, risk that enrolled subjects will drop out before completion, competing clinical trials and clinicians’ and subjects’
perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new drugs
that may be approved or product candidates that may be studied in competing clinical trials for the indications we are investigating. We rely on
CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and while we have agreements governing their
committed activities, we have limited influence over their actual performance.
If we experience delays in the completion of any clinical trial of ganaxolone, the commercial prospects of ganaxolone may be harmed,
and our ability to generate product revenue from ganaxolone, if approved, will be delayed. In addition, any delays in completing our clinical trials
will increase our costs, slow down our development and approval process for ganaxolone and jeopardize our ability to commence product sales
and generate revenues. In
31
Table of Contents
addition, many of the factors that could cause a delay in the commencement or completion of clinical trials may also ultimately lead to the denial
of regulatory approval of ganaxolone.
Ganaxolone may cause undesirable side effects or have other properties that could delay or prevent its regulatory approval, limit the
commercial profile of an approved label, or result in significant negative consequences following any marketing approval.
Undesirable side effects caused by ganaxolone could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could
result in a restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authority. Although
ganaxolone has generally been well tolerated by subjects in our earlier-stage clinical trials, in some cases there were side effects, and some of the
side effects were severe. Specifically, in our most recently completed clinical trial, where ganaxolone was administered as an adjunctive to
standard therapy in adult subjects with focal onset seizures, the most frequent side effects (those reported in greater than 5% of ganaxolone
subjects) were dizziness, fatigue and somnolence (or drowsiness). More side effects of the Central Nervous System, or CNS, were categorized as
severe as compared to side effects of other body systems, though no specific CNS side effect was reported as severe by more than one subject.
If these side effects are reported in future clinical trials, or if other safety or toxicity issues are reported in our future clinical trials, we
may not receive approval to market ganaxolone, which could prevent us from ever generating revenue or achieving profitability. Furthermore,
although we are currently developing ganaxolone for three indications, negative safety findings in any one indication could force us to delay or
discontinue development in other indications. Results of our clinical trials could reveal an unacceptably high severity and prevalence of side
effects. In such an event, our clinical trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could
order us to cease further development, or deny approval, of ganaxolone for any or all targeted indications. Drug-related side effects could affect
study subject recruitment or the ability of enrolled subjects to complete our future clinical trials and may result in potential product liability
claims.
Additionally, if ganaxolone receives marketing approval, and we or others later identify undesirable side effects caused by ganaxolone, a
number of potentially significant negative consequences could result, including:
• we may be forced to suspend marketing of ganaxolone;
• regulatory authorities may withdraw their approvals of ganaxolone;
• regulatory authorities may require additional warnings on the label that could diminish the usage or otherwise limit the commercial
success of ganaxolone;
• we may be required to conduct post-marketing studies;
• we could be sued and held liable for harm caused to subjects or patients; and
• our reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of ganaxolone, if approved.
Even if ganaxolone receives regulatory approval, we may still face future development and regulatory difficulties.
Even if we obtain regulatory approval for ganaxolone, it would be subject to ongoing requirements by the FDA and comparable foreign
regulatory authorities governing the manufacture, quality control, further development, labeling, packaging, storage, distribution, safety
surveillance, import, export, advertising, promotion, recordkeeping and reporting of safety and other post-market information. The safety profile
of ganaxolone will continue to be closely monitored by the FDA and comparable foreign regulatory authorities after approval. If new safety
information becomes available after approval of ganaxolone, the FDA or comparable foreign regulatory authorities may require labeling changes
or establishment of a Risk Evaluation and Mitigation Strategy, or REMS, or similar strategy, impose significant restrictions on ganaxolone’s
indicated uses or marketing, or impose ongoing requirements for potentially costly post-approval studies or post-market surveillance. For
example, the label ultimately approved for ganaxolone, if it achieves marketing approval, may include restrictions on use.
32
Table of Contents
In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and
other regulatory authorities for compliance with current good manufacturing practices, or cGMP, and other regulations. If we or a regulatory
authority discover previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with
the facility where the product is manufactured, a regulatory authority may impose restrictions on that product, the manufacturing facility or us,
including requiring recall or withdrawal of the product from the market or suspension of manufacturing. If we, ganaxolone or the manufacturing
facilities for ganaxolone fail to comply with applicable regulatory requirements, a regulatory authority may:
• issue warning letters or untitled letters;
• mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners;
• require us to enter into a consent decree, which can include imposition of various fines, reimbursements for inspection costs,
required due dates for specific actions and penalties for noncompliance;
• seek an injunction or impose civil or criminal penalties or monetary fines;
• suspend or withdraw regulatory approval;
• suspend any ongoing clinical trials;
• refuse to approve pending applications or supplements to applications filed by us;
• suspend or impose restrictions on operations, including costly new manufacturing requirements; or
• seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall.
The occurrence of any event or penalty described above may inhibit or preclude our ability to commercialize ganaxolone and generate
revenue.
The FDA’s and other regulatory authorities’ policies may change, and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of ganaxolone. We cannot predict the likelihood, nature or extent of government regulation that may
arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing
requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing
approval that we may have obtained, and we may not achieve or sustain profitability, which would adversely affect our business, prospects,
financial condition and results of operations.
Advertising and promotion of any product candidate that obtains approval in the United States will be heavily scrutinized by, among
others, the FDA, the Department of Justice, or the DOJ, the Office of Inspector General of the Department of Health and Human Services, or
HHS, state attorneys general, members of Congress and the public. Violations, including promotion of our products for unapproved or off-label
uses, are subject to enforcement letters, inquiries and investigations, and civil and criminal sanctions by the FDA or other government agencies.
Additionally, advertising and promotion of any product candidate that obtains approval outside of the United States will be heavily scrutinized by
comparable foreign regulatory authorities.
In the United States, engaging in impermissible promotion of ganaxolone for off-label uses can also subject us to false claims litigation
under federal and state statutes, and other litigation and/or investigation, which can lead to civil and criminal penalties and fines and agreements
that materially restrict the manner in which we promote or distribute our drug products. These false claims statutes include the federal False
Claims Act, which allows any individual to bring a lawsuit against a pharmaceutical company on behalf of the federal government alleging
submission of false or fraudulent claims, or causing to present such false or fraudulent claims, for payment by a federal program such as Medicare
or Medicaid. If the government prevails in the lawsuit, the individual will share in any fines or settlement funds. Since 2004, these False Claims
Act lawsuits against pharmaceutical companies have increased significantly in volume and breadth, leading to several substantial civil and
criminal settlements based on certain sales practices promoting off-label drug uses. This increasing focus and scrutiny has increased the risk that a
33
Table of Contents
pharmaceutical company will have to defend a false claim action, pay settlement fines or restitution, agree to comply with burdensome reporting
and compliance obligations, and be excluded from the Medicare, Medicaid and other federal and state healthcare programs. If we do not lawfully
promote our approved products, we may become subject to such litigation and/or investigation and, if we are not successful in defending against
such actions, those actions could compromise our ability to become profitable.
Failure to obtain regulatory approval in international jurisdictions would prevent ganaxolone from being marketed in these jurisdictions.
In order to market and sell our products in the European Union and many other jurisdictions, we must obtain separate marketing
approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve
additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory
approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many
countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in
that country. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA
does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United
States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for
marketing approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of
ganaxolone by regulatory authorities in the European Union or another country or jurisdiction, the commercial prospects of ganaxolone may be
significantly diminished and our business prospects could decline.
We may not be able to obtain orphan drug exclusivity for ganaxolone or any other product candidates for which we seek it, which could limit
the potential profitability of ganaxolone or such other product candidates.
Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient
populations as orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a
rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals in the United States. Generally, if a
product with an orphan drug designation subsequently receives the first marketing approval for an indication for which it receives the designation,
then the product is entitled to a period of marketing exclusivity that precludes the applicable regulatory authority from approving another
marketing application for the same drug for the same indication for the exclusivity period except in limited situations. For purposes of small
molecule drugs, the FDA defines “same drug” as a drug that contains the same active moiety and is intended for the same use as the drug in
question. A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which
it received orphan designation.
We expect that we may in the future pursue orphan drug designations for ganaxolone for one or more indications, including behaviors in
FXS and the treatment of PCDH19 female pediatric epilepsy, as well as certain of our future product candidates. However, obtaining an orphan
drug designation can be difficult and we may not be successful in doing so for ganaxolone or any of our future product candidates. Even if we
were to obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product from the competition of
different drugs for the same condition, which could be approved during the exclusivity period. Additionally, after an orphan drug is approved, the
FDA could subsequently approve another application for the same drug for the same indication if the FDA concludes that the later drug is shown
to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusive marketing rights in the United States also may be
lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient
quantity of the drug to meet the needs of patients with the rare disease or condition. The failure to obtain an orphan drug designation for any
product candidates we may develop, the inability to maintain that designation for the duration of the applicable period, or the inability to obtain or
maintain orphan drug exclusivity could reduce our ability to make sufficient sales of the applicable product candidate to balance our expenses
incurred to develop it, which would have a negative impact on our operational results and financial condition.
34
Table of Contents
Our business and operations would suffer in the event of computer system failures.
Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which
we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, fire, terrorism, war and telecommunication and
electrical failures. In addition, our systems safeguard important confidential personal data regarding subjects enrolled in our clinical trials. If a
disruption event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs.
For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval
efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of
or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the
further development of ganaxolone could be delayed.
Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.
Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes,
typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we
are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition
and increase our costs and expenses. We rely on third-party manufacturers to produce ganaxolone. Our ability to obtain clinical supplies of
ganaxolone could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.
The ultimate impact on us, our significant suppliers and our general infrastructure of being in certain geographical areas is unknown, but our
operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.
Risks Related to the Commercialization of Our Product
Our commercial success depends upon attaining significant market acceptance of ganaxolone, if approved, among physicians, patients,
government and private payors and others in the medical community.
Even if ganaxolone receives regulatory approval, it may not gain market acceptance among physicians, patients, government and private
payors, or others in the medical community. Market acceptance of ganaxolone, if we receive approval, depends on a number of factors, including
the:
• efficacy and safety of ganaxolone, or ganaxolone administered with other drugs, each as demonstrated in clinical trials and post-
marketing experience;
• clinical indications for which ganaxolone is approved;
• acceptance by physicians and patients of ganaxolone as a safe and effective treatment;
• potential and perceived advantages of ganaxolone over alternative treatments;
• safety of ganaxolone seen in a broader patient group, including its use outside the approved indications should physicians choose to
prescribe for such uses;
• prevalence and severity of any side effects;
• product labeling or product insert requirements of the FDA or other regulatory authorities;
• timing of market introduction of ganaxolone as well as competitive products;
• cost of treatment in relation to alternative treatments;
• availability of coverage and adequate reimbursement and pricing by government and private payors;
• relative convenience and ease of administration; and
• effectiveness of our sales and marketing efforts.
35
Table of Contents
If ganaxolone is approved but fails to achieve market acceptance among physicians, patients, government or private payors or others in
the medical community, or the products or product candidates that are being administered with ganaxolone are restricted, withdrawn or recalled,
or fail to be approved, as the case may be, we may not be able to generate significant revenues, which would compromise our ability to become
profitable.
If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell ganaxolone, we
may be unable to generate any revenue.
We do not currently have an organization for the sale, marketing and distribution of pharmaceutical products and the cost of establishing
and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the
FDA and comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make
arrangements with third parties to perform these services. If we are unable to establish adequate sales, marketing and distribution capabilities,
whether independently or with third parties, we may not be able to generate product revenue and may not become profitable. We will be
competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial
organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these
more established companies. To the extent we rely on third parties to commercialize ganaxolone, if approved, we may have little or no control
over the marketing and sales efforts of such third parties, and our revenues from product sales may be lower than if we had commercialized
ganaxolone ourselves.
A variety of risks associated with marketing ganaxolone internationally could materially adversely affect our business.
We plan to seek regulatory approval for ganaxolone outside of the United States, and, accordingly, we expect that we will be subject to
additional risks related to operating in foreign countries if we obtain the necessary approvals, including:
• differing regulatory requirements in foreign countries;
• the potential for so-called parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts
to import goods from a foreign market (with low or lower prices) rather than buying them locally;
• unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
• economic weakness, including inflation, or political instability in particular foreign economies and markets;
• compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
• foreign taxes, including withholding of payroll taxes;
• foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations
incident to doing business in another country;
• difficulties staffing and managing foreign operations;
• workforce uncertainty in countries where labor unrest is more common than in the United States;
• challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and
protect intellectual property rights to the same extent as the United States;
• production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
• business interruptions resulting from geo-political actions, including war and terrorism.
36
Table of Contents
These and other risks associated with our international operations may materially adversely affect our ability to attain or maintain
profitable operations.
Even if we are able to commercialize ganaxolone, it may not receive coverage and adequate reimbursement from third-party payors, which
could harm our business.
Our ability to commercialize ganaxolone successfully will depend, in part, on the extent to which coverage and adequate reimbursement
for ganaxolone and related treatments will be available from government health administration authorities, private health insurers and other
organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, determine
which medications they will cover and establish reimbursement levels. A primary trend in the United States healthcare industry and elsewhere is
cost containment. Government authorities and third- party payors have attempted to control costs by limiting coverage and the amount of
reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined
discounts from list prices and are challenging the prices charged for drugs. Third-party payors may also seek additional clinical evidence, beyond
the data required to obtain marketing approval, demonstrating clinical benefits and value in specific patient populations before covering
ganaxolone for those patients. We cannot be sure that coverage and adequate reimbursement will be available for ganaxolone and, if
reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of,
ganaxolone, if we obtain marketing approval. If reimbursement is not available or is available only at limited levels, we may not be able to
successfully commercialize ganaxolone even if we obtain marketing approval.
There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited
than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and
reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development,
manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and
may only be temporary. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based
on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs
may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of
laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors
often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to obtain coverage
and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have a
material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.
We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully
than we do.
The development and commercialization of new drug products is highly competitive. We face competition with respect to ganaxolone
and will face competition with respect to any other product candidates that we may seek to develop or commercialize in the future, from major
pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. There are a number of large
pharmaceutical and biotechnology companies that currently market and sell products or are pursuing the development of products for the
treatment of the disease indications for which we are developing ganaxolone. Some of these competitive products and therapies are based on
scientific approaches that are the same as, or similar to, our approach, and others are based on entirely different approaches. For example, there are
neuroreceptor that we are targeting
several companies developing product candidates that target the same gamma-aminobutyric acid, or GABA
or that are testing product candidates in the same indications that we are testing. Potential competitors also include academic institutions,
government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative
arrangements for research, development, manufacturing and commercialization.
A,
Ganaxolone is presently being developed primarily as a neuropsychiatric therapeutic. There are a variety of available marketed therapies
available for these patients. Some of these other drugs are branded and subject to patent protection, some are in clinical development and not yet
approved, and others are available on a generic basis.
Specifically, there are more than 15 approved antiepileptic drugs, or AEDs, available in the United States and worldwide, including the
generic products levetiracetam, lamotrigine, carbamazepine, oxcarbazepine, valproic
37
Table of Contents
acid and topiramate. Recent market entrants include branded products developed by UCB, GlaxoSmithKline, Eisai, and Sunovion
Pharmaceuticals. Additionally, there are several drugs in development for the treatment of behavioral and mental health conditions associated with
FXS, including compounds being developed by Roche, Sunovion Pharmaceuticals, Afraxis, Alcobra and Neuren Pharmaceuticals.
Many of the approved drugs are well established therapies or products and are widely accepted by physicians, patients and third-party
payors. Insurers and other third-party payors may also encourage the use of generic products. These factors may make it difficult for us to achieve
market acceptance at desired levels or in a timely manner to ensure viability of our business.
More established companies may have a competitive advantage over us due to their greater size, cash flows and institutional experience.
Compared to us, many of our competitors may have significantly greater financial, technical and human resources.
As a result of these factors, our competitors may obtain regulatory approval of their products before we are able to, which may limit our
ability to develop or commercialize ganaxolone. Our competitors may also develop drugs that are safer, more effective, more widely used and
cheaper than ours, and may also be more successful than us in manufacturing and marketing their products. These appreciable advantages could
render ganaxolone obsolete or non-competitive before we can recover the expenses of ganaxolone’s development and commercialization.
Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated
among a smaller number of our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified
scientific, management and commercial personnel, establishing clinical trial sites and subject registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs.
Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of ganaxolone or other
product candidates that we may develop.
We face an inherent risk of product liability exposure related to the testing of ganaxolone by us or our investigators in human clinical
trials and will face an even greater risk if ganaxolone receives regulatory approval and we commercially sell ganaxolone after obtaining such
regulatory approval. Product liability claims may be brought against us by study subjects enrolled in our clinical trials, patients, healthcare
providers or others using, administering or selling ganaxolone. If we cannot successfully defend ourselves against claims that ganaxolone caused
injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in, for example:
• decreased demand for ganaxolone;
• termination of clinical trial sites or entire trial programs;
• injury to our reputation and significant negative media attention;
• withdrawal of clinical trial subjects;
• significant costs to defend the related litigation;
• substantial monetary awards to clinical trial subjects or patients;
• loss of revenue;
• diversion of management and scientific resources from our business operations;
• the inability to commercialize ganaxolone; and
• increased scrutiny and potential investigation by, among others, the FDA, the DOJ, the Office of Inspector General of the HHS,
state attorneys general, members of Congress and the public.
38
Table of Contents
We currently have $10.0 million in product liability insurance coverage in the aggregate, which may not be adequate to cover all
liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable
cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our product liability insurance coverage to include the
sale of commercial products if we obtain marketing approval for ganaxolone, but we may be unable to obtain commercially reasonable product
liability insurance for ganaxolone, if approved for marketing. Large judgments have been awarded in class action lawsuits based on drugs that had
unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our
insurance coverage, could decrease our cash and adversely affect our business.
Risks Related to Our Dependence on Third Parties
We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their
contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize ganaxolone.
We rely on third-party CROs to monitor and manage data for our ongoing preclinical and clinical programs. We rely on these parties for
execution of our preclinical studies and clinical trials, and we control only some aspects of their activities. Nevertheless, we are responsible for
ensuring that each of our preclinical studies and clinical trials are conducted in accordance with the applicable protocol and legal, regulatory and
scientific requirements and standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We also rely on third
parties to assist in conducting our preclinical studies in accordance with Good Laboratory Practices, or GLP, and the Animal Welfare Act
requirements. We and our CROs are required to comply with federal regulations and Good Clinical Practices, or GCP, which are international
requirements meant to protect the rights and health of subjects that are enforced by the FDA, the Competent Authorities of the Member States of
the European Economic Area and comparable foreign regulatory authorities for ganaxolone and any future product candidates in clinical
development. Regulatory authorities enforce GCP through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any
of our CROs fail to comply with applicable GCP, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or
comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We
cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials
comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Failure to
comply with these regulations may require us to repeat preclinical studies and clinical trials, which would delay the regulatory approval process.
Our CROs are not our employees, and except for remedies available to us under our agreements with such CROs, we cannot control
whether or not they devote sufficient time and resources to our ongoing clinical, nonclinical and preclinical programs. If CROs do not successfully
carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the data they obtain is compromised due
to the failure to adhere to our protocols, regulatory requirements or for other reasons, our preclinical studies and clinical trials may be extended,
delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize ganaxolone. As a result, our results
of operations and the commercial prospects for ganaxolone would be harmed, our costs could increase and our ability to generate revenue could
be delayed.
Because we have relied on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves
risk that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the
use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this
information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to
identify and monitor our third-party providers. To the extent we are unable to identify and successfully manage the performance of third-party
service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can
be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse
impact on our business, financial condition and prospects.
If we lose our relationships with CROs, our drug development efforts could be delayed.
We rely on third-party vendors and CROs for preclinical studies and clinical trials related to our drug development efforts. Switching or
adding additional CROs would involve additional cost and requires management time and focus. Our CROs generally have the right to terminate
their agreements with us in the event of an uncured
39
Table of Contents
material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us, or research projects pursuant to
such agreements, if, in the reasonable opinion of the relevant CRO, the safety of the subjects participating in our clinical trials warrants such
termination. These agreements or research projects may also be terminated if we make a general assignment for the benefit of our creditors or if
we are liquidated. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause
delays in our development programs. In addition, there is a natural transition period when a new CRO commences work and the new CRO may
not provide the same type or level of services as the original provider. If any of our relationships with our third-party CROs terminate, we may not
be able to enter into arrangements with alternative CROs or to do so on commercially reasonable terms.
Our experience manufacturing ganaxolone is limited to the needs of our preclinical studies and clinical trials. We have no experience
manufacturing ganaxolone on a commercial scale and have no manufacturing facility. We are dependent on third-party manufacturers for
the manufacture of ganaxolone as well as on third parties for our supply chain, and if we experience problems with any such third parties, the
manufacturing of ganaxolone could be delayed.
We do not own or operate facilities for the manufacture of ganaxolone. We currently have no plans to build our own clinical or
commercial scale manufacturing capabilities. We currently rely on contract manufacturing organizations, or CMOs, for the chemical manufacture
of active pharmaceutical ingredients for ganaxolone and another CMO for the production of the ganaxolone nanoparticulate formulation into
capsules. To meet our projected needs for preclinical and clinical supplies to support our activities through regulatory approval and commercial
manufacturing, the CMOs with whom we currently work will need to increase the scale of production. We may need to identify additional CMOs
for continued production of supply for ganaxolone. Although alternative third-party suppliers with the necessary manufacturing and regulatory
expertise and facilities exist, it could be expensive and take a significant amount of time to arrange for alternative suppliers. If we are unable to
arrange for alternative third-party manufacturing sources on commercially reasonable terms, in a timely manner or at all, we may not be able to
complete development of ganaxolone, or market or distribute ganaxolone.
Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured ganaxolone ourselves, including
reliance on the third party for regulatory compliance and quality assurance, the possibility of breach of the manufacturing agreement by the third
party because of factors beyond our control, including a failure to synthesize and manufacture ganaxolone or any products we may eventually
commercialize in accordance with our specifications, and the possibility of termination or nonrenewal of the agreement by the third party, based
on its own business priorities, at a time that is costly or damaging to us. In addition, the FDA and other regulatory authorities would require that
ganaxolone and any products that we may eventually commercialize be manufactured according to cGMP and similar foreign standards. Any
failure by our third-party manufacturers to comply with cGMP or failure to scale up manufacturing processes, including any failure to deliver
sufficient quantities of ganaxolone in a timely manner, could lead to a delay in, or failure to obtain, regulatory approval of ganaxolone. In
addition, such failure could be the basis for the FDA to issue a warning letter, withdraw approvals for ganaxolone previously granted to us, or take
other regulatory or legal action, including recall or seizure of outside supplies of ganaxolone, total or partial suspension of production, suspension
of ongoing clinical trials, refusal to approve pending applications or supplemental applications, detention of product, refusal to permit the import
or export of products, injunction, or imposing civil and criminal penalties.
Any significant disruption in our supplier relationships could harm our business. Any significant delay in the supply of ganaxolone or its
key materials for an ongoing preclinical study or clinical trial could considerably delay completion of our preclinical study or clinical trial, product
testing and potential regulatory approval of ganaxolone. If our manufacturers or we are unable to purchase these key materials after regulatory
approval has been obtained for ganaxolone, the commercial launch of ganaxolone would be delayed or there would be a shortage in supply, which
would impair our ability to generate revenues from the sale of ganaxolone.
We may elect to enter into licensing or collaboration agreements to partner ganaxolone in territories currently retained by us. Our dependence
on such relationships may adversely affect our business.
Because we have limited resources, we may seek to enter into collaboration agreements with other pharmaceutical or biotechnology
companies. Any failure by our partners to perform their obligations or any decision by our partners to terminate these agreements could negatively
impact our ability to successfully develop, obtain regulatory approvals for and commercialize ganaxolone. In the event we grant exclusive rights
to such partners, we would be precluded from potential commercialization of ganaxolone within the territories in which we have a partner. In
addition, any termination of our collaboration agreements will terminate the funding we may receive
40
Table of Contents
under the relevant collaboration agreement and may impair our ability to fund further development efforts and our progress in our development
programs.
Our commercialization strategy for ganaxolone may depend on our ability to enter into agreements with collaborators to obtain assistance
and funding for the development and potential commercialization of ganaxolone in the territories in which we seek to partner. Despite our efforts,
we may be unable to secure additional collaborative licensing or other arrangements that are necessary for us to further develop and
commercialize ganaxolone. Supporting diligence activities conducted by potential collaborators and negotiating the financial and other terms of a
collaboration agreement are long and complex processes with uncertain results. Even if we are successful in entering into one or more
collaboration agreements, collaborations may involve greater uncertainty for us, as we have less control over certain aspects of our collaborative
programs than we do over our proprietary development and commercialization programs. We may determine that continuing a collaboration under
the terms provided is not in our best interest, and we may terminate the collaboration. Our potential future collaborators could delay or terminate
their agreements, and as a result ganaxolone may never be successfully commercialized.
Further, our potential future collaborators may develop alternative products or pursue alternative technologies either on their own or in
collaboration with others, including our competitors, and the priorities or focus of our collaborators may shift such that ganaxolone receives less
attention or resources than we would like, or they may be terminated altogether. Any such actions by our potential future collaborators may
adversely affect our business prospects and ability to earn revenue. In addition, we could have disputes with our potential future collaborators,
such as the interpretation of terms in our agreements. Any such disagreements could lead to delays in the development or commercialization of
ganaxolone or could result in time-consuming and expensive litigation or arbitration, which may not be resolved in our favor.
Government funding for certain of our programs adds uncertainty to our research efforts with respect to those programs and may impose
requirements that increase the costs of commercialization and production of product candidates developed under those government-funded
programs.
Our preclinical studies and clinical trials to evaluate ganaxolone in FXS patients have been conducted with the MIND Institute at the
University of California, Davis which receives funding from the United States Department of Defense, or the DoD, for such studies and trials. In
addition, our preclinical studies and clinical trials to evaluate ganaxolone in patients suffering from posttraumatic stress disorder, or PTSD, have
been primarily conducted by the United States Department of Veterans Affairs, which also receives funding from the DoD. Programs funded by
the United States government and its agencies, including the DoD, include provisions that reflect the government’s substantial rights and
remedies, many of which are not typically found in commercial contracts, including powers of the government to:
• terminate agreements, in whole or in part, for any reason or no reason;
• reduce or modify the government’s obligations under such agreements without the consent of the other party;
• claim rights, including intellectual property rights, in products and data developed under such agreements;
• audit contract-related costs and fees, including allocated indirect costs;
• suspend the contractor from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;
• impose United States manufacturing requirements for products that embody inventions conceived or first reduced to practice under
such agreements;
• suspend or debar the contractor from doing future business with the government; and
• control and potentially prohibit the export of products.
We may not have the right to prohibit the United States government from using or allowing others to use certain technologies developed
by us, and we may not be able to prohibit third party companies, including our competitors, from using those technologies in providing products
and services to the United States government. The
41
Table of Contents
United States government generally obtains the right to royalty-free use of technologies that are developed under United States government
contracts.
In addition, government contracts normally contain additional requirements that may increase our costs of doing business, reduce our
profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:
• specialized accounting systems unique to government contracts;
• mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have
been spent;
• public disclosures of certain contract information, which may enable competitors to gain insights into our research program; and
• mandatory socioeconomic compliance requirements, including labor standards, non-discrimination and affirmative action programs
and environmental compliance requirements.
If we fail to maintain compliance with these requirements, we may be subject to potential contract liability and to termination of our
contracts.
Changes in government budgets and agendas may result in a decreased and de-prioritized emphasis on supporting the development of
ganaxolone in patients suffering from certain FXS-associated behavioral symptoms. Although we intend to fund a portion of our development
programs for ganaxolone in patients with FXS, any reduction or delay in DoD funding to our collaborators may force us to suspend or terminate
these programs or seek alternative funding, which may not be available on non-dilutive terms, terms favorable to us or at all.
If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be
liable for damages.
Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and
biological materials by our third-party manufacturers. Our manufacturers are subject to federal, state and local laws and regulations in the United
States governing the use, manufacture, storage, handling and disposal of medical, radioactive and hazardous materials. Although we believe that
our manufacturers’ procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot
completely eliminate the risk of contamination or injury resulting from medical, radioactive or hazardous materials. As a result of any such
contamination or injury we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our
business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our
resources. We do not have any insurance for liabilities arising from medical radioactive or hazardous materials. Compliance with applicable
environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and
production efforts, which could harm our business, prospects, financial condition or results of operations.
Risks Related to Regulatory Compliance
Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may
increase the difficulty and cost for us to obtain marketing approval of and commercialize ganaxolone and affect the prices we may obtain.
The regulations that govern, among other things, marketing approvals, coverage, pricing and reimbursement for new drug products vary
widely from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory
changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of ganaxolone, restrict or regulate
post-approval activities and affect our ability to successfully sell ganaxolone, if we obtain marketing approval.
In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or Medicare Modernization Act,
changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the
elderly and introduced a new reimbursement methodology based on average sales prices for physician administered drugs. In recent years,
Congress has
42
Table of Contents
considered further reductions in Medicare reimbursement for drugs administered by physicians. The Centers for Medicare and Medicaid Services,
the agency that runs the Medicare program, also has the authority to revise reimbursement rates and to implement coverage restrictions for some
drugs. Cost reduction initiatives and changes in coverage implemented through legislation or regulation could decrease utilization of and
reimbursement for any approved products, which in turn would affect the price we can receive for those products. While the Medicare
Modernization Act and Medicare regulations apply only to drug benefits for Medicare beneficiaries, private payors often follow Medicare
coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from
federal legislation or regulation may result in a similar reduction in payments from private payors.
In March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education
Affordability Reconciliation Act of 2010, or the Affordable Care Act, a sweeping law intended to broaden access to health insurance, reduce or
constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and
health insurance industries, impose new taxes and fees on pharmaceutical and medical device manufacturers and impose additional health policy
reforms. The Affordable Care Act expanded manufacturers’ rebate liability to include covered drugs dispensed to individuals who are enrolled in
Medicaid managed care organizations, increased the minimum rebate due for innovator drugs from 15.1% of average manufacturer price, or AMP,
to 23.1% of AMP and capped the total rebate amount for innovator drugs at 100.0% of AMP. The Affordable Care Act and subsequent legislation
also changed the definition of AMP. Furthermore, the Affordable Care Act imposes a significant annual, nondeductible fee on companies that
manufacture or import certain branded prescription drug products. Substantial new provisions affecting compliance have also been enacted, which
may affect our business practices with healthcare practitioners, and a significant number of provisions are not yet, or have only recently become,
effective. Although it is too early to determine the effect of the Affordable Care Act, it appears likely to continue the pressure on pharmaceutical
pricing, especially under the Medicare program, and may also increase our regulatory burdens and operating costs.
In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. More recently, in
August 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, creates the Joint Select Committee on
Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit
reduction of an amount greater than $1.2 trillion for the years 2013 through 2021, triggering the legislation’s automatic reduction to several
government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, starting in
2013. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced
Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover
overpayments to providers from three to five years. If we ever obtain regulatory approval and commercialization of ganaxolone, these new laws
may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and
accordingly, our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict
sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether
FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of ganaxolone may
be.
In the United States, the European Union and other potentially significant markets for ganaxolone, government authorities and third-party
payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and
therapies, which has resulted in lower average selling prices. Furthermore, the increased emphasis on managed healthcare in the United States and
on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement
and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of
managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform,
pharmaceutical reimbursement policies and pricing in general.
Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins
after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to
continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for ganaxolone in a
particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods,
which could negatively impact the revenue we are able to generate from the sale of the product in that particular country.
43
Table of Contents
Adverse pricing limitations may hinder our ability to recoup our investment in ganaxolone even if ganaxolone obtains marketing approval.
Laws and regulations governing international operations may preclude us from developing, manufacturing and selling product candidates
outside of the United States and require us to develop and implement costly compliance programs.
As we seek to expand our operations outside of the United States, we must comply with numerous laws and regulations in each
jurisdiction in which we plan to operate. The creation and implementation of international business practices compliance programs is costly and
such programs are difficult to enforce, particularly where reliance on third parties is required.
The Foreign Corrupt Practices Act, or FCPA, prohibits any United States individual or business from paying, offering, authorizing
payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing
any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates
companies whose securities are listed in the United States to comply with certain accounting provisions requiring such companies to maintain
books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and
maintain an adequate system of internal accounting controls for international operations. The anti-bribery provisions of the FCPA are enforced
primarily by the DOJ. The SEC is involved with enforcement of the books and records provisions of the FCPA.
Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition,
the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and
doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other
work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.
Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with
certain foreign nationals, of information classified for national security purposes, as well as certain products and technical data relating to those
products. Our expanding presence outside of the United States will require us to dedicate additional resources to comply with these laws, and
these laws may preclude us from developing, manufacturing, or selling ganaxolone outside of the United States, which could limit our growth
potential and increase our development costs.
The failure to comply with laws governing international business practices may result in substantial penalties, including suspension or
debarment from government contracting. Violation of the FCPA can result in significant civil and criminal penalties. Indictment alone under the
FCPA can lead to suspension of the right to do business with the United States government until the pending claims are resolved. Conviction of a
violation of the FCPA can result in long-term disqualification as a government contractor. The termination of a government contract or
relationship as a result of our failure to satisfy any of our obligations under laws governing international business practices would have a negative
impact on our operations and harm our reputation and ability to procure government contracts. The SEC also may suspend or bar issuers from
trading securities on United States exchanges for violations of the FCPA’s accounting provisions.
Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare
laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished
profits and future earnings.
Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product
candidates for which we obtain marketing approval. Our future arrangements with third-party payors and customers may expose us to broadly
applicable fraud and abuse and other healthcare laws and regulations that may affect the business or financial arrangements and relationships
through which we would market, sell and distribute our products. Even though we do not and will not control referrals of healthcare services or
bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and
patients’ rights are and will be applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations that may
affect our operations (including our marketing, promotion, educational programs, pricing, and relationships with healthcare providers or other
entities, among other things) and expose us to areas of risk including the following:
44
Table of Contents
• the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving
or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an
individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal
healthcare program such as Medicare and Medicaid;
• federal civil and criminal false claims laws and civil monetary penalty laws impose criminal and civil penalties, including through
civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the
federal government, including the Medicare and Medicaid programs, claims for payment that are false or fraudulent or making a
false statement to avoid, decrease or conceal an obligation to pay money to the federal government;
• the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for
executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and
willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the
delivery of or payment for healthcare benefits, items or services;
• HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, also imposes
obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of
individually identifiable health information;
• the Affordable Care Act requires manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under
Medicare, Medicaid, or Children’s Health Insurance Program, to report annually to HHS information related to payments and other
transfers of value to physicians and teaching hospitals, and ownership and investment interests held by physicians and their
immediate family members and applicable group purchasing organizations; and
• analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing
arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including
private insurers; some state laws require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary
compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug
manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or
marketing expenditures; and state and foreign laws govern the privacy and security of health information in specified circumstances,
many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance
efforts.
Efforts to ensure that our business arrangements with third parties are compliant with applicable healthcare laws and regulations will
involve the expenditure of appropriate, and possibly significant, resources. Nonetheless, it is possible that governmental authorities will conclude
that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may
apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion from
government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any physicians
or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be
subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.
Risks Related to Our Intellectual Property
If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology and product
candidates, our competitive position could be harmed.
Our commercial success will depend in large part on our ability to obtain and maintain patent and other intellectual property protection in
the United States and other countries with respect to our proprietary technology and products. We rely on trade secret, patent, copyright and
trademark laws, and confidentiality, licensing and other agreements with employees and third parties, all of which offer only limited protection.
We seek to protect our
45
Table of Contents
proprietary position by filing and prosecuting patent applications in the United States and abroad related to our novel technologies and products
that are important to our business.
The patent positions of biotechnology and pharmaceutical companies generally are highly uncertain, involve complex legal and factual
questions and have in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial
value of our patents, including those patent rights licensed to us by third parties, are highly uncertain. The steps we or our licensors have taken to
protect our proprietary rights may not be adequate to preclude misappropriation of our proprietary information or infringement of our intellectual
property rights, both inside and outside the United States. Further, the examination process may require us or our licensors to narrow the claims
for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. The rights
already granted under any of our currently issued patents or those licensed to us and those that may be granted under future issued patents may not
provide us with the proprietary protection or competitive advantages we are seeking. If we or our licensors are unable to obtain and maintain
patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficient, our competitors could develop
and commercialize technology and products similar or superior to ours, and our ability to successfully commercialize our technology and products
may be adversely affected. It is also possible that we or our licensors will fail to identify patentable aspects of inventions made in the course of our
development and commercialization activities before it is too late to obtain patent protection on them.
With respect to patent rights, we do not know whether any of our granted or issued patents will effectively prevent others from
commercializing competitive technologies and products. Publications of discoveries in the scientific literature often lag behind the actual
discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing or in some
cases not at all, until they are issued as a patent. Therefore we cannot be certain that we or our licensors were the first to make the inventions
claimed in our owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of
such inventions.
Our pending applications cannot be enforced against third parties practicing the technology claimed in such applications unless and until
a patent issues from such applications. Because the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability,
issued patents that we own or have licensed from third parties may be challenged in the courts or patent offices in the United States and abroad.
Such challenges may result in the loss of patent protection, the narrowing of claims in such patents or the invalidity or unenforceability of such
patents, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the
duration of the patent protection for our technology and products. Protecting against the unauthorized use of our or our licensors’ patented
technology, trademarks and other intellectual property rights is expensive, difficult and may in some cases not be possible. In some cases, it may
be difficult or impossible to detect third-party infringement or misappropriation of our intellectual property rights, even in relation to issued patent
claims, and proving any such infringement may be even more difficult.
Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be
uncertain and could harm our business.
Our commercial success depends upon our ability to develop, manufacture, market and sell ganaxolone, and to use our related proprietary
technologies. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with
respect to ganaxolone, including interference or derivation proceedings before the United States Patent and Trademark Office, or USPTO. Third
parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. If we are found to infringe
a third party’s intellectual property rights, we could be required to obtain a license from such third party to continue commercializing ganaxolone.
However, we may not be able to obtain any required license on commercially reasonable terms or at all. Under certain circumstances, we could be
forced, including by court order, to cease commercializing ganaxolone. In addition, in any such proceeding or litigation, we could be found liable
for monetary damages. A finding of infringement could prevent us from commercializing ganaxolone or force us to cease some of our business
operations, which could materially harm our business. Any claims by third parties that we have misappropriated their confidential information or
trade secrets could have a similar negative impact on our business.
While ganaxolone is in preclinical studies and clinical trials, we believe that the use of ganaxolone in these preclinical studies and clinical
trials falls within the scope of the exemptions provided by 35 U.S.C. Section 271(e) in the United States, which exempts from patent infringement
liability activities reasonably related to the
46
Table of Contents
development and submission of information to the FDA. As ganaxolone progresses toward commercialization, the possibility of a patent
infringement claim against us increases. While ganaxolone itself is off patent, we attempt to ensure that our solid and liquid nanoparticulate
formulation of ganaxolone and the methods we employ to manufacture ganaxolone do not infringe other parties’ patents and other proprietary
rights. There can be no assurance they do not, however, and competitors or other parties may assert that we infringe their proprietary rights in any
event.
If we breach our license agreement with Purdue Neuroscience Company, it could have a material adverse effect on our commercialization
efforts for ganaxolone or such other compounds in the United States.
In September 2004, we entered into a license agreement with Purdue Neuroscience Company, or Purdue, which was most recently
amended and restated in May 2008, granting us exclusive rights to certain know-how and technology relating thereto, excluding the field of
treatment of unpleasant sensory or emotional experience associated with actual or potential tissue damage, or described in terms of such damage.
If we materially breach or fail to perform any provision under this license agreement (including failure to make payments to Purdue when due for
royalties and other sub-license revenue, failure to cure a breach for failure to use commercially reasonable efforts to develop and commercialize at
least one licensed product, and commencement of bankruptcy or insolvency proceedings against us) Purdue has the right to terminate our license,
and upon the effective date of such termination, we must cease all activities licensed all rights, data, information, know-how, and material licensed
or transferred to us under this license agreement will revert to Purdue and all rights, data, information, know-how, material, records and
registrations developed or made by us that relate in whole or in part to the activities contemplated by our amended and restated license agreement
with Purdue will be transferred to Purdue. To the extent such a breach relates to ganaxolone, we would expect to exercise all rights and remedies
available to us, including attempting to cure any breach by us, and otherwise seek to preserve our rights, but we may not be able to do so in a
timely manner, at an acceptable cost to us or at all. Any uncured, material breach under the license agreement could result in our loss of rights to
practice our patent rights and could have a material adverse effect on our commercialization efforts for ganaxolone.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on ganaxolone and any future product candidates throughout the world would be prohibitively
expensive, and our or our licensors’ intellectual property rights in some countries outside the United States can be less extensive than those in the
United States. In addition, the laws and practices of some foreign countries do not protect intellectual property rights to the same extent as federal
and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries
outside the United States, or from selling or importing products made using our inventions into or within the United States or other jurisdictions.
Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products, and may
export otherwise infringing products to territories where we have patent protection, but where enforcement is not as strong as that in the United
States. These products may compete with our products in jurisdictions where we do not have any issued patents and our patent claims or other
intellectual property rights may not be effective or sufficient to prevent them from competing with us in these jurisdictions.
Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign
jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other
intellectual property protection, particularly those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of
our or our licensor’s patents or marketing of competing products in violation of our proprietary rights generally in those countries. Proceedings to
enforce our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our
business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could
provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if
any, may not be commercially meaningful.
The laws of certain foreign countries may not protect our rights to the same extent as the laws of the United States, and these foreign laws
may also be subject to change. For example, novel formulations and manufacturing processes may not be patentable in certain jurisdictions, and
the requirements for patentability may differ in certain countries, particularly developing countries. Furthermore, generic drug manufacturers or
other competitors may challenge the scope, validity or enforceability of our patents, requiring us to engage in complex, lengthy and costly
litigation or other proceedings. Generic drug manufacturers may develop, seek approval for, and launch generic
47
Table of Contents
versions of our products. Many countries, including European Union countries, India, Japan and China, have compulsory licensing laws under
which a patent owner may be compelled under certain circumstances to grant licenses to third parties. In those countries, we may have limited
remedies if patents are infringed or if we are compelled to grant a license to a third party, which could materially diminish the value of our patents.
This could limit our potential revenue opportunities. Accordingly, our efforts to enforce intellectual property rights around the world may be
inadequate to obtain a significant commercial advantage from our intellectual property.
Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.
Given the amount of time required for the development, testing and regulatory review of new product candidates, such as ganaxolone,
patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent
terms in the United States and, if available, in other countries where we are prosecuting patents. In the United States, the Drug Price Competition
and Patent Term Restoration Act of 1984 permits a patent term extension of up to five years beyond the normal expiration of the patent, which is
limited to the approved indication (or any additional indications approved during the period of extension). However, the applicable authorities,
including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our
assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than
we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our
clinical and preclinical data and launch their product earlier than might otherwise be the case.
Changes in patent laws, including recent patent reform legislation, could increase the uncertainties and costs surrounding the prosecution of
our patent applications and the enforcement or defense of our issued patents.
As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents.
Obtaining and enforcing patents in the pharmaceutical industry involve technological and legal complexity, and obtaining and enforcing
pharmaceutical patents is costly, time-consuming, and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws
in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. For example, the
United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain
circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to
obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on
decisions by Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that
would weaken our ability to obtain new patents or to enforce existing patents and patents we may obtain in the future. Recent patent reform
legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our
issued patents.
In September 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes
a number of significant changes to United States patent law. These include provisions that affect the way patent applications will be prosecuted
and may also affect patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a “first to file”
system in which the first inventor to file a patent application will be entitled to the patent. Third parties are allowed to submit prior art before the
issuance of a patent by the USPTO and may become involved in opposition, derivation, reexamination, inter-parties review or interference
proceedings challenging our patent rights or the patent rights of our licensors. An adverse determination in any such submission, proceeding or
litigation could reduce the scope of, or invalidate patent rights, which could adversely affect our competitive position.
The USPTO is currently developing regulations and procedures to govern administration of the Leahy-Smith Act, and many of the
substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, did not become effective until
March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the
Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the
enforcement or defense of our issued patents.
48
Table of Contents
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submissions, fee payment and
other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance
with these requirements.
Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the
lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be
cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-
compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to
official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we or our
licensors fail to maintain the patents and patent applications covering our product candidates, our competitive position would be adversely
affected.
We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and
unsuccessful and have a material adverse effect on the success of our business.
Competitors may infringe our patents or misappropriate or otherwise violate our intellectual property rights. To counter infringement or
unauthorized use, litigation may be necessary in the future to enforce or defend our intellectual property rights, to protect our trade secrets or to
determine the validity and scope of our own intellectual property rights or the proprietary rights of others. Also, third parties may initiate legal
proceedings against us to challenge the validity or scope of intellectual property rights we own or control. These proceedings can be expensive
and time consuming. Many of our current and potential competitors have the ability to dedicate substantially greater resources to defend their
intellectual property rights than we can. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or
misappropriating our intellectual property. Litigation could result in substantial costs and diversion of management resources, which could harm
our business and financial results. In addition, in an infringement proceeding, a court may decide that a patent owned or controlled by us is invalid
or unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the
technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held
unenforceable or interpreted narrowly. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.
There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts
or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our common stock.
We may be subject to claims by third parties asserting that we have misappropriated their intellectual property, or claiming ownership of what
we regard as our own intellectual property.
Some of our employees were previously employed at universities or at other biotechnology or pharmaceutical companies, including our
competitors or potential competitors. Some of these employees, including each member of our senior management, executed proprietary rights,
non-disclosure and non-competition agreements, or similar agreements, in connection with such previous employment. Although we try to ensure
that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or
these employees have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such third party.
Litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we
may lose valuable intellectual property rights or personnel or sustain damages. Such intellectual property rights could be awarded to a third party,
and we could be required to obtain a license from such third party to commercialize our technology or products. Such a license may not be
available on commercially reasonable terms or at all. Even if we are successful in defending against such claims, litigation could result in
substantial costs and be a distraction to management.
Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have
limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are
illustrative:
49
Table of Contents
• others may be able to make compounds or ganaxolone formulations that are similar to our ganaxolone formulations but that are not
covered by the claims of the patents that we own or control;
• we or any strategic partners might not have been the first to make the inventions covered by the issued patents or pending patent
applications that we own or control;
• we might not have been the first to file patent applications covering certain of our inventions;
• others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our
intellectual property rights;
• it is possible that our pending patent applications will not lead to issued patents;
• issued patents that we own or control may not provide us with any competitive advantages, or may be held invalid or unenforceable
as a result of legal challenges;
• our competitors might conduct research and development activities in the United States and other countries that provide a safe
harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have
patent rights and then use the information learned from such activities to develop competitive products for sale in our major
commercial markets;
• we may not develop additional proprietary technologies that are patentable; and
• the patents of others may have an adverse effect on our business.
Risks Related to Employee Matters, Managing Growth and Becoming a Public Company
Our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel.
We are highly dependent upon Christopher M. Cashman, our Chief Executive Officer, Edward F. Smith, our Chief Financial Officer,
Albena I. Patroneva, M.D., our Chief Medical Officer and Gail M. Farfel, Ph.D., our Chief Clinical Development and Regulatory Officer. The
employment agreements we have with the persons named above do not prevent such persons from terminating their employment with us at any
time. We do not maintain “key person” insurance for any of our executives or other employees. The loss of the services of any of these persons
could impede the achievement of our research, development and commercialization objectives.
We will need to grow the size of our organization, and we may experience difficulties in managing this growth.
As of December 31, 2014, we had nine full-time employees. As our development and commercialization plans and strategies develop, or
as a result of any future acquisitions, we will need additional managerial, operational, sales, marketing, financial and other resources. In addition,
it may become more cost effective to bring in house certain resources currently outsourced to consultants and other third-parties. Our
management, personnel and systems currently in place may not be adequate to support our future growth. Future growth would impose significant
added responsibilities on members of management, including:
• managing our clinical trials effectively;
• identifying, recruiting, maintaining, motivating and integrating additional employees;
• managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees,
contractors and other third parties;
• improving our managerial, development, operational and finance systems; and
• expanding our facilities.
As our operations expand, we will need to manage additional relationships with various strategic partners, suppliers and other third
parties. Our future financial performance and our ability to commercialize ganaxolone, if
50
Table of Contents
approved, and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to
manage our development efforts and clinical trials effectively and hire, train and integrate additional management, administrative and sales and
marketing personnel. Our failure to accomplish any of these tasks could prevent us from successfully growing our company.
If we are unable to attract and retain highly qualified employees, and other personnel, advisors and consultants with scientific, technical and
managerial expertise, we may not be able to grow effectively.
Our future growth and success depend on our ability to recruit, retain, manage and motivate our employees, consultants and other third-
parties. The loss of any member of our senior management team or the inability to hire or retain experienced management personnel could
compromise our ability to execute our business plan and harm our operating results.
Because of the specialized scientific and managerial nature of our business, we rely heavily on our ability to attract and retain qualified
scientific, technical and managerial personnel, advisors and consultants. The competition for qualified personnel in the pharmaceutical field is
significant and, as a result, we may be unable to continue to attract and retain qualified personnel necessary for the development of our business.
We may acquire other assets or businesses, or form collaborations or make investments in other companies or technologies that could harm
our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.
As part of our business strategy, we may pursue acquisitions of assets, including preclinical, clinical or commercial stage products or
product candidates, or businesses, or strategic alliances and collaborations, to expand our existing technologies and operations. We may not
identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of
any such transaction, any of which could have a detrimental effect on our financial condition, results of operations and cash flows. We have no
experience with acquiring other companies, products or product candidates, and limited experience with forming strategic alliances and
collaborations. We may not be able to find suitable acquisition candidates, and if we make any acquisitions, we may not be able to integrate these
acquisitions successfully into our existing business and we may incur additional debt or assume unknown or contingent liabilities in connection
therewith. Integration of an acquired company or assets may also disrupt ongoing operations, require the hiring of additional personnel and the
implementation of additional internal systems and infrastructure, especially the acquisition of commercial assets, and require management
resources that would otherwise focus on developing our existing business. We may not be able to find suitable strategic alliance or collaboration
partners or identify other investment opportunities, and we may experience losses related to any such investments.
To finance any acquisitions or collaborations, we may choose to issue debt or equity securities as consideration. Any such issuance of
shares would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other
assets or companies or fund a transaction using our stock as consideration. Alternatively, it may be necessary for us to raise additional funds for
acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all.
Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements,
which could cause significant liability for us and harm our reputation.
We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or
similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory
authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and
regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or
data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct for our
directors, officers and employees, or the Code of Conduct, but it is not always possible to identify and deter employee misconduct, and the
precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting
us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any
such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a
significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.
51
Table of Contents
Risks Related to Ownership of Our Common Stock
We do not know whether an active, liquid and orderly trading market will develop for our common stock and as a result it may be difficult for
you to sell your shares of our common stock.
Although we are listed on The NASDAQ Global Market, an active trading market for our shares may never develop or be sustained. The
market value of our common stock may decrease. The lack of an active market may impair your ability to sell your shares at the time you wish to
sell them or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Further, an
inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into
collaborations or acquire companies or products by using our shares of common stock as consideration.
The market price of our stock may be volatile, and you could lose all or part of your investment.
The trading price of our common stock is likely to be highly volatile and could be subject to wide fluctuations in response to various
factors, some of which are beyond our control. In addition to the factors discussed in this “Risk Factors” section, these factors include:
• the success of competitive products or technologies;
• regulatory actions with respect to our products or our competitors’ products;
• actual or anticipated changes in our growth rate relative to our competitors;
• announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital
commitments;
• results of clinical trials of ganaxolone or product candidates of our competitors;
• regulatory or legal developments in the United States and other countries;
• developments or disputes concerning patent applications, issued patents or other proprietary rights;
• the recruitment or departure of key personnel;
• the level of expenses related to our clinical development programs;
• the results of our efforts to in-license or acquire additional product candidates or products;
• actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts;
• variations in our financial results or those of companies that are perceived to be similar to us;
• fluctuations in the valuation of companies perceived by investors to be comparable to us;
• share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
• announcement or expectation of additional financing efforts;
• sales of our common stock by us, our insiders or our other stockholders;
• changes in the structure of healthcare payment systems;
• market conditions in the pharmaceutical and biotechnology sectors;
• general economic, industry and market conditions; and
• other events or factors, many of which are beyond our control.
52
Table of Contents
In addition, the stock market in general, The NASDAQ Global Market and pharmaceutical and biotechnology companies in particular,
have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these
companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating
performance. The realization of any of these risks or any of a broad range of other risks, including those described in these “Risk Factors,” could
have a dramatic and material adverse impact on the market price of our common stock.
We may be subject to securities litigation, which is expensive and could divert our management’s attention.
The market price of our common stock may be volatile, and in the past companies that have experienced volatility in the market price of
their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities litigation
against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our
business.
Insiders have substantial influence over us and could delay or prevent a change in corporate control.
We estimate that our executive officers, directors, and holders of 5% or more of our capital stock collectively beneficially own
approximately 82% of our voting stock. This concentration of ownership could harm the market price of our common stock by:
• delaying, deferring or preventing a change in control of our company;
• impeding a merger, consolidation, takeover or other business combination involving our company; or
• discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of our company.
The interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they
may act in a manner that advances their best interests and not necessarily those of other stockholders, including seeking a premium value for their
common stock, and might negatively affect the prevailing market price for our common stock.
We are an “emerging growth company” and we intend to take advantage of reduced disclosure and governance requirements applicable to
emerging growth companies, which could result in our common stock being less attractive to investors.
We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. For as long as we
continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to
other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements
of Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation
in our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive
compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company
for up to five years following the year in which we completed our initial public offering, although circumstances could cause us to lose that status
earlier, including if the market value of our common stock held by non-affiliates exceeds $700.0 million as of any June 30 before that time or if
we have total annual gross revenue of $1.0 billion or more during any fiscal year before that time, in which cases we would no longer be an
emerging growth company as of the following December 31. If we issue more than $1.0 billion in non-convertible debt during any three-year
period before that time, we would cease to be an emerging growth company immediately. Even after we no longer qualify as an emerging growth
company, we may still qualify as a “smaller reporting company” which would allow us to take advantage of many of the same exemptions from
disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if
investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.
Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those
standards apply to private companies. We have irrevocably elected not to avail
53
Table of Contents
ourselves of this exemption from new or revised accounting standards and, therefore, will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies. As a result, changes in rules of United States generally accepted
accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could
significantly affect our financial position and results of operations.
We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to
new compliance initiatives.
Now that we are a public company, we are incurring significant legal, accounting and other expenses that we did not incur as a private
company, and these expenses may increase even more after we are no longer an “emerging growth company.” We are subject to the reporting
requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Protection Act, as well as rules adopted, and
to be adopted, by the SEC and NASDAQ Stock Market. Our management and other personnel need to devote a substantial amount of time to these
compliance initiatives. Moreover, we expect these rules and regulations to substantially increase our legal and financial compliance costs and to
make some activities more time-consuming and costly. We estimate that we will incur approximately $1.0 million to $2.0 million in incremental
costs per year associated with being a publicly traded company, although it is possible that our actual incremental costs will be higher than we
currently estimate. The increased costs will increase our net loss. For example, we expect these rules and regulations to make it more difficult and
more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain sufficient
coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of
these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board
committees or as executive officers.
Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your
sole source of gain.
We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to
finance the growth and development of our business. In addition, our ability to pay cash dividends is prohibited by our credit facility with Square
1 Bank, entered into in April 2014 and amended in December 2014, and the terms of any future debt agreements may also preclude us from
paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.
Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall.
If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lock-up
and other legal restrictions on resale lapse, the trading price of our common stock could decline. As of December 31, 2014, we had outstanding a
total of 14,007,754 shares of common stock. In addition, shares of common stock that are either subject to outstanding options or reserved for
future issuance under our employee benefit plans will become eligible for sale in the public market to the extent permitted by the provisions of
various vesting schedules, the lock-up agreements and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock
are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline.
Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could
result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.
We expect that significant additional capital will be needed in the future to continue our planned operations. To raise capital, we may sell
substantial amounts of common stock or securities convertible into or exchangeable for common stock. These future issuances of equity or equity-
linked securities, together with the exercise of stock options, warrants outstanding or granted in the future and any additional shares issued in
connection with acquisitions, if any, may result in material dilution to our investors. Such sales may also result in material dilution to our
stockholders, and new investors could gain rights, preferences and privileges senior to those of holders of our common stock.
Pursuant to our equity incentive plans, our compensation committee is authorized to grant equity-based incentive awards to our directors,
executive officers and other employees and service providers. The number of
54
Table of Contents
shares of our common stock available for future grant under our 2005 Stock Option and Incentive Plan, as amended, and our 2014 Equity
Incentive Plan was zero as of December 31, 2014. In accordance with our 2014 Equity Incentive Plan, on January 1, 2015, 560,310 shares of
common stock became available for future grant under the plan. Future equity incentive grants and issuances of common stock under our equity
incentive plans may have an adverse effect on the market price of our common stock.
We have broad discretion in the use of our cash reserves and may not use them effectively.
Our management has broad discretion over the management of our operations and cash resources and could deploy our resources in ways
that do not improve our business, including our ganaxolone clinical development programs, or enhance the value of our common stock. The
failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our
business, cause the market price of our common stock to decline and delay the development of ganaxolone.
Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by
others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our
current management.
Provisions in our amended and restated certificate of incorporation and amended and restated bylaws, as well as provisions of Delaware
law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our
stockholders, or remove our current management. These include provisions that:
• permit our board of directors to issue up to 25,000,000 shares of preferred stock, with any rights, preferences and privileges as it
may designate;
• provide that all vacancies on our board of directors, including as a result of newly created directorships, may, except as otherwise
required by law, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum;
• establish a classified board of directors such that only one of three classes of directors is elected each year;
• provide that directors can only be removed for cause;
• require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders
and not be taken by written consent;
• provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as
directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and
content of a stockholder’s notice;
• not provide for cumulative voting rights, thereby allowing the holders of a majority of the shares of common stock entitled to vote
in any election of directors to elect all of the directors standing for election; and
• provide that special meetings of our stockholders may be called only by the chairperson of the board of directors, the chief executive
officer or the board of directors.
These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it
more difficult for stockholders to replace members of our board of directors, who are responsible for appointing the members of our management.
Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which
may discourage, delay or prevent someone from acquiring us or merging with us whether or not it is desired by or beneficial to our stockholders.
Under Delaware law, a corporation may not, in general, engage in a business combination with any holder of 15.0% or more of its capital stock
unless the holder has held the stock for three years or, among other things, the board of directors has approved the transaction. Any provision of
our amended and restated certificate of incorporation or amended and restated bylaws or Delaware law that has the effect of delaying or deterring
a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also
affect the price that some investors are willing to pay for our common stock.
55
Table of Contents
Item 1B. Unresolved Staff Comments.
None.
Item 2. Properties.
Our principal offices occupy approximately 4,000 square feet of leased office space in Radnor, Pennsylvania pursuant to a lease
agreement that expires in 2020. We believe that our current facilities are suitable and adequate to meet our current needs. We may add new
facilities or expand existing facilities as we add employees, and we believe that suitable additional or substitute space will be available as needed
to accommodate any such expansion of our operations.
Item 3. Legal Proceedings.
From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a
party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have
a material adverse effect on our business, operating results or financial condition.
Item 4. Mine Safety Disclosures.
Not applicable.
56
Table of Contents
PART II
Item 5. Market for Common Equity , Related Stockholder Matters and Issuer Purchases of Equity Securities .
Market Information
Our common stock has been listed on the NASDAQ Global Market under the symbol “MRNS” since July 31, 2014. Prior to that time, there
was no public market for our stock. The following table sets forth for the indicated periods the high and low intra-day sales prices per share for
our common stock on the NASDAQ Global Market.
Third Quarter (from July 31, 2014)
Fourth Quarter
Holders of Record
Year Ended December 31, 2014
Low
High
$
$
10.58 $
11.18 $
5.49
4.00
As of March 12, 2015 there were approximately 100 holders of record of shares of our common stock.
Dividend Policy
We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future
earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our
common stock for the foreseeable future. Additionally, our ability to pay cash dividends is prohibited by our credit facility with Square 1 Bank.
Recent Sales of Unregistered Securities
None.
Use of Proceeds
Our initial public offering of common stock was effected pursuant to a registration statement on Form S-1 (File No 333-195895) that was
declared effective by the SEC on July 31, 2014, pursuant to which we registered the offering and sale of 6,468,750 shares of common stock,
$0.001 par value per share (including 843,750 shares available to the underwriters’ for exercise of an option to purchase additional shares, of
which 133,000 was exercised in September 2014) at a public offering price of $8.00 per share for an aggregate public offering price of $46.1
million. Stifel, Nicolaus & Company, Incorporated and JMP Securities LLC acted as joint book-running managers for the initial public offering.
Oppenheimer & Co. acted as lead manager and Janney Montgomery Scott acted as co-manager for the initial public offering.
As a result of the initial public offering, we received net proceeds of approximately $41.2 million during the third quarter of 2014 from the
sale of 5,758,000 shares of common stock, after deducting underwriting discounts, commissions and estimated offering expenses borne by us.
None of such payments were direct or indirect payments to any of (i) our directors or officers or their associates, (ii) persons owning 10 percent or
more of our common stock, or (iii) our affiliates.
There has been no material change in the planned use of proceeds from our initial public offering from that described in the final prospectus
related to the offering, which we filed with the SEC on August 1, 2014. As of December 31, 2014, we have used approximately $2.5 million of
the funds received from our initial public offering (IPO) for clinical trials and payments to research and development consultants
Item 6. Selected Financial Data
Not applicable for smaller reporting company.
57
Table of Contents
Item 7. Management’s Discussion and Analysis of Finan cial Condition and Results of Operations.
You should read the following discussion and analysis of our financial condition and results of operations together with our financial
statements and the related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion
and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our
business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read “Cautionary Note
Regarding Forward-Looking Statements” and Item 1A. Risk Factors of this Annual Report on Form 10-K for a discussion of important factors
that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the
following discussion and analysis .
Overview
A
We are a clinical stage biopharmaceutical company focused on developing and commercializing innovative neuropsychiatric
therapeutics. Our clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, an endogenous
neurosteroid produced in the central nervous system and known for its anticonvulsive and antianxiety activity. By targeting the same spectrum of
GABA
receptors as endogenous allopregnanolone, ganaxolone delivers its therapeutic benefit through a natural mechanism that we believe may
offer safety and efficacy advantages compared to other marketed antiepileptic medications. Ganaxolone was rationally designed to unlock the
receptor. We have a dual strategy of evaluating ganaxolone for
potential for chronic neurosteriod therapy through modulation of the GABA
treating seizure disorders, and treating targeted orphan diseases for which there are no approved therapies, the development timelines may be
abbreviated, and for which there is a strong mechanistic rationale for ganaxolone to offer therapeutic benefit to patients with very high unmet
needs. Our orally administered solid and liquid suspension dose forms are being evaluated in our ongoing clinical trials and we are conducting the
requisite preclinical experiments to ready our intravenous, or IV, dose form for clinical use.
A
Our lead indication for ganaxolone is as an adjunctive, or add-on, therapy for the treatment of partial, also known as focal, onset seizures
in adults with epilepsy. We have completed a Phase 2 clinical trial in 147 patients with focal onset seizures demonstrating that patients who added
ganaxolone to their medication regimen experienced a statistically significant reduction in seizures as compared to patients who added placebo.
We are currently enrolling patients in a multinational, randomized, placebo-controlled, Phase 3 clinical trial to evaluate ganaxolone as adjunctive
treatment of partial-onset seizures in in adult subjects. We believe ganaxolone also has potential in a broad range of neuropsychiatric disorders,
including orphan indications. We have generated proof-of-concept data for ganaxolone in the treatment of refractory pediatric seizures and as
monotherapy for adult refractory focal onset seizures. We currently have a Phase 2 proof-of-concept clinical study on-going with ganaxolone for
the treatment of PCDH19 female pediatric epilepsy and a Phase 2 proof-of-concept investigator sponsored clinical trial evaluating ganaxolone as a
treatment for behaviors in Fragile X Syndrome. Both PCDH19 female pediatric epilepsy and Fragile X Syndrome are potential orphan disorders
that have been related to mutations affecting neurosteroid signaling at extrasynaptic GABA
receptors.
A
Our operations to date have consisted primarily of organizing and staffing our company, developing ganaxolone, including conducting
preclinical testing and clinical trials, and raising capital. We have funded our operations primarily through sales of equity and debt securities.
From inception through December 31, 2014, we have received net proceeds of $110.4 million from the issuance of preferred stock, common stock
and convertible notes payable. At December 31, 2014, we had cash and cash equivalents of $49.7 million. In connection with our initial public
offering, which closed during the third quarter of 2014, we received net proceeds of $41.2 million from the sale of 5,758,000 shares of our
common stock. We have no products currently available for sale and substantially all of our revenue to date has been derived from research
grants. We have incurred operating losses since inception, have not generated any product sales revenue and have not achieved profitable
operations. We incurred net losses of $10.8 million for the year ended December 31, 2014. Our accumulated deficit as of December 31, 2014 was
$72.3 million, and we expect to continue to incur substantial losses in future periods. We anticipate that our operating expenses will increase
substantially as we continue to advance our clinical-stage product candidate, ganaxolone.
We anticipate that our expenses will increase substantially as we:
• increase the targeted enrollment and add enrollment sites and geographies for our ongoing Phase 3 clinical trial for adjunctive treatment
of ganaxolone in adult patients with refractory partial onset epileptic seizures;
• conduct clinical proof-of-concept clinical trials in targeted pediatric rare disease indications, including
58
Table of Contents
PCDH19 and FXS;
• continue the research, development and scale-up manufacturing capabilities to commercialize products and dose forms for which we
may obtain regulatory approval;
• maintain, expand and protect our global intellectual property portfolio;
• hire additional clinical, manufacturing, and scientific personnel; and
• add operational, financial and management information systems and personnel, including personnel to support our drug development
and potential future commercialization efforts.
In addition, we have incurred and will continue to incur significant expenses as a result of becoming a public company, which subjects us to
the reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Sarbanes-Oxley Act of 2002 and the
rules and regulations of The NASDAQ Global Market. Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we will be
required to furnish a report by our management on our internal control over financial reporting. Commencing with our fiscal year ending
December 31, 2015, we must perform system and process evaluation and testing of our internal control over financial reporting to allow
management to report on the effectiveness of our internal control over financial reporting in our Form 10-K filing for that year, as required by
Section 404.
We believe that our cash and cash equivalents as of December 31, 2014 will enable us to fund our operating expenses and capital
expenditure requirements into the second half of 2016. However, we will need to secure additional funding in the future, from one or more equity
or debt financings, collaborations, or other sources, in order to carry out all of our planned research and development activities with respect to
ganaxolone.
Financial Overview
Research and Development Expenses
Our research and development expenses consist primarily of costs incurred for the development of ganaxolone, which include:
• employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;
• expenses incurred under agreements with Clinical Research Organizations, or CROs, and investigative sites that conduct our clinical
trials and preclinical studies;
• the cost of acquiring, developing and manufacturing clinical trial materials;
• facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities,
insurance and other supplies; and
• costs associated with preclinical activities and regulatory operations.
We expense research and development costs when we incur them. We record costs for some development activities, such as clinical
trials, based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations or
information our vendors provide to us.
We will incur substantial costs beyond our present and planned clinical trials in order to file an NDA and Supplemental New Drug
Applications, or sNDAs, for ganaxolone in patients with focal onset seizures, PCDH19, FXS and other target indications, and in each case, the
nature, design, size and cost of further studies and trials will depend in large part on the outcome of preceding studies and trials and discussions
with regulators. It is difficult to determine with certainty the costs and duration of our current or future clinical trials and preclinical studies, or if,
when or to what extent we will generate revenue from the commercialization and sale of ganaxolone if we obtain regulatory approval. We may
never succeed in achieving regulatory approval for ganaxolone. The duration, costs and timing of clinical trials and development of ganaxolone
will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial
enrollment rate and significant and changing government regulation.
59
Table of Contents
In addition, the probability of success for ganaxolone will depend on numerous factors, including competition, manufacturing capability
and commercial viability. See “Risk Factors.” Our commercial success depends upon attaining significant market acceptance of ganaxolone, if
approved, among physicians, patients, healthcare payors and the medical community. We will determine which programs to pursue and how much
to fund each program in response to the scientific and clinical success of ganaxolone, as well as an assessment of ganaxolone’s commercial
potential.
General and Administrative Expenses
General and administrative expenses consist principally of salaries and related costs for executive and other administrative personnel and
consultants, including stock-based compensation and travel expenses. Other general and administrative expenses include professional fees for
legal, patent review, consulting and accounting services. General and administrative expenses are expensed when incurred.
We expect that our general and administrative expenses will increase in the future as a result of new management and employee hiring
and our scaling operations commensurate with supporting more advanced clinical trials and public company infrastructure. These increases will
likely include increased costs for insurance, hiring of additional personnel, outside consultants, investor relations, legal counsel and accountants,
among other expenses.
Change in Fair Value of Warrant Liability
Our warrants to purchase our preferred stock were classified as warrant liability and recorded at fair value. This warrant liability was
subject to re-measurement at each balance sheet date and we recognized any change in fair value in our statements of operations as a change in
fair value of the derivative liability. These warrants expired upon our initial public offering and, as a result, the fair value of the warrants was
reduced to zero as of December 31, 2014.
Interest Income
Interest income consists principally of interest income earned on cash and cash equivalent balances.
Interest Expense
Interest expense is primarily attributable to interest expense associated with our previously outstanding convertible notes and our credit
facility entered into in April 2014, and amended in December 2014.
Cumulative Preferred Stock Dividends
Cumulative preferred stock dividends represented dividends payable upon a liquidation or deemed liquidation in connection with our
Series B and C convertible preferred stock. We are no longer recording preferred stock dividends effective upon the closing of our initial public
offering, which occurred during the third quarter of 2014.
Results of Operations
Research and Development Expenses
Research and development expenses increased $4.5 million, to $8.7 million, for the year ended December 31, 2014, compared to the
same period of 2013. The increase resulted primarily from an increase in clinical costs related to our ongoing clinical trial of ganaxolone in
patients with focal onset seizures that commenced at the end of 2013. Substantially all research and development expenses relate to our clinical
trial in focal onset epileptic seizures.
General and Administrative Expenses
General and administrative expenses increased $2.0 million, to $3.2 million, for the year ended December 31, 2014, compared to the
same period of 2013. The increase in general and administrative expenses was primarily due to the hiring of new management and the upward
scaling of our operations in connection with both our new public company status and ongoing clinical trial of ganaxolone in patients with focal
onset seizures that commenced during 2013.
60
Table of Contents
Change in Fair Value of Warrant Liability
We recorded changes in the fair value of our warrant liability which resulted in a gain of $1.2 million and $0.2 million for the years
ended December 31, 2014 and 2013, respectively. We reduced the value of the liability to zero in connection with the closing of our initial public
offering in the third quarter of 2014 as the warrants expired unexercised.
Cumulative Preferred Stock Dividends
Cumulative preferred stock dividends decreased $1.3 million, to $2.5 million, for the year ended December 31, 2014, compared to the
same period of 2013. Upon conversion of all outstanding convertible preferred stock in connection with our initial public offering, all cumulative
preferred stock dividends were canceled.
Liquidity and Capital Resources
Since inception, we have incurred net losses and negative cash flows from our operations. We incurred net losses of $10.8 million and
$5.3 million for the years ended December 31, 2014 and 2013, respectively. Our cash used in operating activities was $8.6 million for the year
ended December 31, 2014 compared to $6.6 million for the same period a year ago. Historically, we have financed our operations principally
through the sale of common stock, preferred stock and convertible debt. From inception through December 31, 2014, we have received net
proceeds of $110.4 million from the issuance of preferred stock, common stock and convertible notes payable. At December 31, 2014, we had
cash and cash equivalents of $49.7 million.
During the third quarter of 2014, we completed our initial public offering. In connection with the initial public offering, we sold a total
of 5,758,000 shares of common stock and received aggregate net proceeds, after underwriting discounts and commissions and other estimated
offering expenses, of approximately $41.2 million, and all of our outstanding shares of convertible preferred stock converted into shares of
common stock.
Square 1 Credit Facility
In April 2014, we borrowed $2.0 million in connection with a term loan pursuant to a Loan and Security Agreement (LSA) we entered
into with Square 1 Bank (Square 1). Pursuant to the terms of the LSA, we made monthly interest-only payments for outstanding borrowings at an
interest rate equal to the greater of (a) prime plus 2.25% or (b) 5.5% until the LSA was amended in December 2014.
In December 2014, we entered into a First Amendment to Loan and Security Agreement (Amended LSA) with Square 1. The Amended
LSA increased the total term loan availability from $2.0 million to $12.0 million, available in four tranches (in thousands):
Tranche
A
B
C
D
Term
Loan
Available
Term
Loan
Borrowed
$
$
2,000 $
5,000
2,500
2,500
12,000
$
2,000
5,000
—
—
7,000
Borrowed Date
April 2014
December 2014
*
*
* Our ability to borrow under the remaining tranches of $2.5 million each depends upon meeting certain clinical trial milestones. The
availability end dates of Tranches C and D are September 1, 2015 and March 31, 2016, respectively.
As of December 31, 2014, our outstanding term loan balance of $7.0 million was classified as long-term debt on our balance sheet. In
connection with the execution of both the LSA and Amended LSA, we paid debt costs to the financial institution of $25 thousand, which are being
amortized into interest expense over the remaining term of the loans. Interest expense related to the loans was $117 thousand for the year ended
December 31, 2014. As of December 31, 2014, we had accrued interest of $39 thousand. There are no financial covenants associated with these
term loans. As of December 31, 2014, we were in compliance with all non-financial covenants.
61
Table of Contents
Cash Flows
Operating Activities. Cash used in operating activities increased to $8.6 million for the year ended December 31, 2014 compared to
$6.6 million for the same period a year ago. The increase was driven primarily by an increase in our net loss of $5.6 million and an increase in our
noncash gain on our warrant liability of $1.0 million. This was partially offset by net decreases in operating assets and increases in operating
liabilities of $4.3 million, and increases in stock-based compensation expense of $0.5 million. The net decreases in operating assets and increases
in operating liabilities for the year ended December 31, 2014 compared to the same period a year ago are primarily due to $1.7 million in prepaid
clinical trial expenses from 2013 being expensed throughout 2014, as well as additional accrued clinical trial expenses of $0.7 million as of
December 31, 2014.
Investing Activities. Cash used in investing activities for the purchase of property and equipment was less than $0.1 million for the years
ended December 31, 2014 and 2013.
Financing Activities. Cash provided by financing activities increased to $48.3 million for the year ended December 31, 2014 compared
to $8.0 million for the same period a year ago. The increase is primarily attributable to $41.2 million of net proceeds received in 2014 from the
closing of our initial public offering and $7.0 million received in 2014 related to our credit facility with Square 1 Bank, offset by $7.5 million
received in 2013 related to the issuance of Series C Preferred Stock.
Funding Requirements
We have not achieved profitability since our inception, and we expect to continue to incur net losses for the foreseeable future. We
expect our cash expenditures to increase in the near term as we fund our planned clinical trials for ganaxolone. We will incur significant legal,
accounting and other expenses associated with being a public company that we were not required to incur as a private company. In addition,
Section 404, as well as rules adopted by the SEC and The NASDAQ Stock Market, require public companies to implement specified corporate
governance practices that were previously inapplicable to us as a private company. We expect these rules and regulations will increase our legal
and financial compliance costs and will make some activities more time-consuming and costly.
We believe that our cash and cash equivalents as of December 31, 2014, will enable us to fund our operating expenses and capital
expenditure requirements into the second half of 2016. However, we will need to raise substantial additional financing in the future to fund our
operations. In order to meet these additional cash requirements, we may seek to sell additional equity or convertible debt securities that may result
in dilution to our stockholders. If we raise additional funds through the issuance of convertible debt securities, these securities could have rights
senior to those of our common stock and could contain covenants that restrict our operations. There can be no assurance that we will be able to
obtain additional equity or debt financing on terms acceptable to us, if at all. Our failure to obtain sufficient funds on acceptable terms when
needed could have a negative impact on our business, results of operations, and financial condition. Our future capital requirements will depend
on many factors, including:
• the results of our preclinical studies and clinical trials;
• the development, formulation and commercialization activities related to ganaxolone;
• the scope, progress, results and costs of researching and developing ganaxolone or any other future product candidates, and
conducting preclinical studies and clinical trials;
• the timing of, and the costs involved in, obtaining regulatory approvals for ganaxolone or any other future product candidates;
• the cost of commercialization activities if ganaxolone or any other future product candidates are approved for sale, including
marketing, sales and distribution costs;
• the cost of manufacturing ganaxolone or any other future product candidates in preclinical studies, clinical trials and, if approved, in
commercial sale;
• our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of such
agreements;
62
Table of Contents
• any product liability, infringement or other lawsuits related to our products;
• the expenses needed to attract and retain skilled personnel;
• the costs associated with being a public company;
• the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including litigation costs
and the outcome of such litigation; and
• the timing, receipt and amount of sales of, or royalties on, future approved products, if any.
Please see “Risk Factors” for additional risks associated with our substantial capital requirements.
Significant Contractual Obligations and Commitments
The following summarizes our significant contractual obligations as of December 31, 2014 (in thousands):
Contractual Obligations
Operating lease obligations(1)
Square 1 credit facility(2)
Total
$
$
Total
Less than
1 year
1 - 3 years
3 - 5 years
More than
5 years
Payment due by period
681 $
7,943
8,624
$
100 $
462
562
$
397 $
7,481 $
$
7,878
184 $
— $
$
184
—
—
—
(1) Represents commitments for future minimum lease payments.
(2) Represents principal and interest payment obligations that will become due in connection with the outstanding loan facility.
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.
Discussion of Critical Accounting Policies and Significant Judgments and Estimates
We base this management’s discussion and analysis of our financial condition and results of operations on our financial statements,
which we have prepared in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of our
financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses and
the disclosure of contingent assets and liabilities in our financial statements. We evaluate our estimates and judgments, including those related to
warrant liabilities, stock-based compensation and accrued clinical trial expenses on an ongoing basis. We base our estimates on historical
experience, known trends and events and various other factors that we believe to be reasonable under the circumstances, the results of which form
the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results
may differ from these estimates under different assumptions or conditions. You should consider your evaluation of our financial condition and
results of operations with these policies, judgments and estimates in mind.
While we describe our significant accounting policies in the notes to our financial statements appearing elsewhere in this Annual Report
on Form 10-K, we believe the following accounting policies are the most critical to the judgments and estimates we use in the preparation of our
financial statements.
Stock-Based Compensation
We recognize compensation expense related to the fair value of stock-based awards in our statements of operations. For stock options we
issued to employees, consultants, and members of our board of directors for their services on our board of directors, we estimate the grant-date fair
value of options using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model requires management to make
assumptions with respect to the expected term of the option, the expected volatility of the common stock consistent with the expected
63
Table of Contents
life of the option, risk-free interest rates, and the value of the common stock. For awards subject to time-based vesting, we recognize stock-based
compensation expense, net of estimated forfeitures, on a straight-line basis over the requisite service period, which is generally the vesting term of
the award. For awards subject to performance-based vesting conditions, we recognize stock-based compensation expense when it is probable that
the performance condition will be achieved. We are required to estimate forfeitures at the time of grant and to revise the estimates, if necessary, in
subsequent periods if actual forfeitures differ from those estimates. We record stock-based awards issued to non-employees at their fair values,
and periodically revalue them as the equity instruments vest and are recognized as expense over the related service period of the award.
Clinical Trial Expense Accruals
As part of the process of preparing our financial statements, we are required to estimate our accrued expenses. Our clinical trial accrual
process seeks to account for expenses resulting from our obligations under contracts with vendors, consultants and CROs and clinical site
agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from
contract to contract and may result in payment flows that do not match the periods over which materials or services are provided to us under such
contracts. Our objective is to reflect the appropriate clinical trial expenses in our financial statements by matching the appropriate expenses with
the period in which services and efforts are expended. We account for these expenses according to the progress of the trial as measured by subject
progression and the timing of various aspects of the trial.
We determine accrual estimates through financial models that take into account discussion with applicable personnel and outside service
providers as to the progress or state of completion of trials. During the course of a clinical trial, we adjust our clinical expense recognition if actual
results differ from our estimates. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on
the facts and circumstances known to us at that time. Our clinical trial accrual and prepaid assets are dependent, in part, upon the receipt of timely
and accurate reporting from CROs and other third-party vendors. Although we do not expect our estimates to differ materially from amounts we
actually incur, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may
vary and may result in us reporting amounts that are too high or too low for any particular period.
JOBS Act
Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period
provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth
company” can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We
have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to
the same new or revised accounting standards as other public companies that are not emerging growth companies.
Recent Accounting Pronouncements
In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-10, Elimination
of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation ,
which eliminates all incremental financial reporting requirements for development stage entities by removing Accounting Standards Codification
(ASC) Topic 915, Development Stage Entities , from the FASB Accounting Standards Codification. ASC Topic 915 is removed effective for
annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of
the June 30, 2014 interim financial statements.
In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going
Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new
standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of
the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the
entity’s ability to continue as a going concern. The ASU applies to all entities and is effective for annual periods ending after December 15, 2016,
and interim periods thereafter, with early adoption permitted. The company is currently evaluating the impact the adoption of this ASU will have
on its financial statements.
64
Table of Contents
Item 7A. Quantitative and Qualitative Discl osures About Market Risk.
We are exposed to market risks in the ordinary course of our business. These market risks are principally limited to interest rate
fluctuations.
We had cash and cash equivalents of $49.7 million at December 31, 2014, consisting primarily of funds in cash and money market
accounts. The primary objective of our investment activities is to preserve principal and liquidity while maximizing income without significantly
increasing risk. We do not enter into investments for trading or speculative purposes. Due to the short-term nature of our investment portfolio, we
do not believe an immediate 1.0% increase in interest rates would have a material effect on the fair market value of our portfolio, and accordingly
we do not expect a sudden change in market interest rates to affect materially our operating results or cash flows.
Our long-term debt carries a variable interest rate indexed to the prime rate, with a fixed minimum rate of 6.5%. The prime rate in the
U.S. has remained at 3.25% since December of 2008. While we cannot predict when, if at all, this rate will be increased, we believe the stability
of the prime rate over the past six years sufficiently mitigates interest rate risk related to our debt. We do not believe an immediate 1.0% increase
in the prime rate would have a material effect on the future cash flows related to our debt, and accordingly we do not expect a sudden change in
the prime rate to affect materially our operating results or cash flows.
Item 8. Financial Statements an d Supplementary Data.
Our financial statements, accompanying notes and Report of Independent Registered Public Accounting Firm are included in this Annual
Report on Form 10-K beginning on page F-1, which are incorporated in this Item 8 by reference.
Item 9. Changes in and Disagreements with Accoun tants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures .
Evaluation of Disclosure Controls and Procedures.
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our
disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period
covered by this Annual Report on Form 10-K. Management recognizes that any controls and procedures, no matter how well designed and
operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the
cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer
have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that the
information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed,
summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports we
file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and principal
financial and accounting officer, to allow timely decisions regarding required disclosures.
Management’s Report on Internal Control Over Financial Reporting
This annual report does not include a report of management’s assessment regarding internal control over financial reporting or an attestation
report of the Company’s registered public accounting firm due to a transition period established by rules of the SEC for newly public companies.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15
(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended
65
Table of Contents
December 31, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Item 9B. Other Informati on.
On March 11, 2015, we entered into amended and restated employment agreements with Christopher M. Cashman and Edward F. Smith
and an employment agreement with Albena Patroneva, each of which is described in this Item 9B.
Christopher M. Cashman
On March 11, 2015, we entered into an amended and restated employment agreement with Christopher M. Cashman, our Chairman,
President and Chief Executive Officer. The principal terms of Mr. Cashman’s employment agreement are as follows:
• base salary of $470,000 per year;
• annual performance bonus in an amount up to 50.0% of base salary based on the achievement of certain performance goals
established by our Board or the compensation committee; and
• stock options and awards as described below under the heading “Outstanding Equity Awards at Fiscal Year-End.”
Upon a termination of Mr. Cashman’s employment by us without cause or a resignation by Mr. Cashman for good reason, Mr. Cashman
is eligible to receive a continuation of his base salary for twelve months, with an accelerated payment of any balance upon a change in control
as defined in the agreement, subject to his execution and delivery of a general release of claims. If such termination occurs within three
months before or within twelve months after a change in control the severance payable increase to an amount equal to his base salary for a
period of twenty-four months plus his prorated target bonus payable in a lump sum. Upon such termination, Mr. Cashman is also eligible to
receive payment or reimbursement of the his medical insurance premiums at the same level as was in effect on the termination date for a
period of twelve months, which period increases to twenty-four months if the termination of employment occurs three-months before or
twelve months after a change in control.
Termination for “cause” under Mr. Cashman’s employment agreement generally means termination of Mr. Cashman by us for: (i) his
misuse of alcoholic beverages, controlled substances or other narcotics, which misuse has had or is reasonably likely to have a material
adverse effect on our business or financial affairs or our reputation; (ii) failure to cooperate with us in any investigation or formal proceeding;
(iii) the commission of, or a plea of guilty or nolo contendere with respect to, or conviction for, a felony (or any lesser included offense or
crime in exchange for withdrawal of a felony indictment or charged crime that might result in a penalty of incarceration), a crime involving
moral turpitude or any other offense that results in or could result in any prison sentence; (iv) adjudication as an incompetent; (v) a breach of
any material term of the employment agreement; (vi) violation in any material respect of any of our rules, regulations or policies; (vii) gross
insubordination; (viii) engaging in any conduct, action or behavior that, in the reasonable opinion of our Board, has had a material adverse
effect on our reputation; (ix) any continued or repeated absence; or (x) misappropriation of any funds or property.
Termination for “good reason” under Mr. Cashman’s employment agreement generally means termination by Mr. Cashman for (i) a
reassignment to a location outside the greater Philadelphia area; (ii) any material failure by us to comply with any material term of the
employment agreement; (iii) the demotion of Mr. Cashman to a lesser position or a substantial diminution of Mr. Cashman’s authority, duties
or responsibilities or (iv) a material diminution of his base salary and benefits, except under certain limited circumstances.
66
Table of Contents
Mr. Cashman is entitled to participate in all of our group welfare plans, subject to the terms and conditions applicable to such plans as
approved from time to time by our Board. Mr. Cashman’s employment agreement contains customary non-solicitation and non-competition
covenants, which covenants remain in effect for one year following any cessation of employment with respect to Mr. Cashman. Further,
Mr. Cashman has executed a Mutual Non-Disclosure Agreement.
Edward F. Smith
On March 11, 2015, we entered into an amended and restated employment agreement with Edward F. Smith, our Vice President, Chief
Financial Officer, Treasurer and Secretary. The principal terms of Mr. Smith’s employment agreement are as follows:
• base salary of $350,000 per year;
• annual performance bonus in an amount up to 35.0% of base salary based on the achievement of certain performance goals
established by our Board or the compensation committee; and
• stock options and awards as described below under the heading “Outstanding Equity Awards at Fiscal Year-End.”
Upon a termination of Mr. Smith’s employment by us without cause or a resignation by Mr. Smith for good reason, Mr. Smith is eligible
to receive a continuation of his base salary for nine months, with an accelerated payment of any balance upon a change in control as defined
in the agreement, subject to his execution and delivery of a general release of claims. If such termination occurs within three months before
or within twelve months after a change in control the severance payable increase to an amount equal to his base salary for a period of eighteen
months payable in a lump sum. Upon such termination, Mr. Smith is also eligible to receive payment or reimbursement of the his medical
insurance premiums at the same level as was in effect on the termination date for a period of nine months, which period increases to eighteen
months if the termination of employment occurs three-months before or twelve months after a change in control.
Termination for “cause” under Mr. Smith’s employment agreement generally means termination of Mr. Smith by us for: (i) his misuse of
alcoholic beverages, controlled substances or other narcotics, which misuse has had or is reasonably likely to have a material adverse effect
on our business or financial affairs or our reputation; (ii) failure to cooperate with us in any investigation or formal proceeding; (iii) the
commission of, or a plea of guilty or nolo contendere with respect to, or conviction for, a felony (or any lesser included offense or crime in
exchange for withdrawal of a felony indictment or charged crime that might result in a penalty of incarceration), a crime involving moral
turpitude or any other offense that results in or could result in any prison sentence; (iv) adjudication as an incompetent; (v) a breach of any
material term of the employment agreement; (vi) violation in any material respect of any of our rules, regulations or policies; (vii) gross
insubordination; (viii) engaging in any conduct, action or behavior that, in the reasonable opinion of our Board, has had a material adverse
effect on our reputation; (ix) any continued or repeated absence; or (x) misappropriation of any funds or property.
Termination for “good reason” under Mr. Smith’s employment agreement generally means termination by Mr. Smith for (i) a
reassignment to a location outside the greater Philadelphia area; (ii) any material failure by us to comply with any material term of the
employment agreement; (iii) the demotion of Mr. Smith to a lesser position or a substantial diminution of Mr. Smith’s authority, duties or
responsibilities or (iv) a material diminution of his base salary and benefits, except under certain limited circumstances.
Mr. Smith is entitled to participate in all of our group welfare plans, subject to the terms and conditions applicable to such plans as
approved from time to time by our Board. Mr. Smith’s employment agreement contains customary non-solicitation and non-competition
covenants, which covenants remain in effect for six months following any cessation of employment with respect to Mr. Smith. Further,
Mr. Smith has executed a Confidentiality Agreement which expires five years after the last disclosure of confidential information by the
Company.
67
Table of Contents
Albena Patroneva, M.D.
On March 11, 2015, we entered into an employment agreement with Albena Patroneva, our Chief Medical Officer. The principal terms of
Dr. Patroneva’s employment agreement are as follows:
• base salary of $335,000 per year;
• annual performance bonus in an amount up to 35.0% of base salary based on the achievement of certain performance goals
established by our Board or the compensation committee; and
• stock options and awards as described below under the heading “Outstanding Equity Awards at Fiscal Year-End.”
Upon a termination of Dr. Patroneva’s employment by us without cause or a resignation by Dr. Patroneva for good reason, Dr. Patroneva
is eligible to receive a continuation of her base salary for nine months, with an accelerated payment of any balance upon a change in control
as defined in the agreement, subject to her execution and delivery of a general release of claims. If such termination occurs within three
months before or within twelve months after a change in control the severance payable increase to an amount equal to her base salary for a
period of eighteen months payable in a lump sum. Upon such termination, Dr. Patroneva is also eligible to receive payment or reimbursement
of the her medical insurance premiums at the same level as was in effect on the termination date for a period of nine months, which period
increases to eighteen months if the termination of employment occurs three months before or twelve months after a change in control.
Termination for “cause” under Dr. Patroneva ‘s employment agreement generally means termination of Dr. Patroneva by us for: (i) her
misuse of alcoholic beverages, controlled substances or other narcotics, which misuse has had or is reasonably likely to have a material
adverse effect on our business or financial affairs or our reputation; (ii) failure to cooperate with us in any investigation or formal proceeding;
(iii) the commission of, or a plea of guilty or nolo contendere with respect to, or conviction for, a felony (or any lesser included offense or
crime in exchange for withdrawal of a felony indictment or charged crime that might result in a penalty of incarceration), a crime involving
moral turpitude or any other offense that results in or could result in any prison sentence; (iv) adjudication as an incompetent; (v) a breach of
any material term of the employment agreement; (vi) violation in any material respect of any of our rules, regulations or policies; (vii) gross
insubordination; (viii) engaging in any conduct, action or behavior that, in the reasonable opinion of our Board, has had a material adverse
effect on our reputation; (ix) any continued or repeated absence; or (x) misappropriation of any funds or property.
Termination for “good reason” under Dr. Patroneva’s employment agreement generally means termination by Dr. Patroneva for (i) a
reassignment to a location outside the greater Philadelphia area; (ii) any material failure by us to comply with any material term of the
employment agreement; (iii) the demotion of Dr. Patroneva to a lesser position or a substantial diminution of Dr. Patroneva’s authority, duties
or responsibilities or (iv) a material diminution of her base salary and benefits, except under certain limited circumstances.
Dr. Patroneva is entitled to participate in all of our group welfare plans, subject to the terms and conditions applicable to such plans as
approved from time to time by our Board. Dr. Patroneva’s employment agreement contains customary non-solicitation and non-competition
covenants, which covenants remain in effect for six months following any cessation of employment with respect to Dr. Patroneva. Further,
Dr. Patroneva has executed a Confidentiality Agreement which expires five years after the last disclosure of confidential information by the
Company.
68
Table of Contents
PART III
Item 10. Directors and Executive Officers and Corporat e Governance.
We incorporate the information required by this Item 10 by reference to the definitive proxy statement for our 2015 annual meeting of
shareholders, to be filed with the SEC.
Item 11. Executive Compensatio n.
We incorporate the information required by this Item 11 by reference to the definitive proxy statement for our 2015 annual meeting of
shareholders, to be filed with the SEC.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockhol der Matters.
We incorporate the information required by this Item 12 by reference to the definitive proxy statement for our 2015 annual meeting of
shareholders, to be filed with the SEC.
Item 13. Certain Relationships and Related Transactions and Di rector Independence.
We incorporate the information required by this Item 13 by reference to the definitive proxy statement for our 2015 annual meeting of
shareholders, to be filed with the SEC.
Item 14. Principal Accountants Fees an d Services.
We incorporate the information required by this Item 14 by reference to the definitive proxy statement for our 2015 annual meeting of
shareholders, to be filed with the SEC.
Item 15. Exhibits and Financial Statement S chedules.
(a) Documents filed as part of this report:
1. Financial Statements. The financial statements as set forth under Item 8 of this Annual Report on Form 10-K are incorporated
herein.
2. Financial Statement Schedules. All financial statement schedules have been omitted because they are not applicable, not required,
or the information is shown in the financial statements or related notes.
3. Exhibits. See (b) below.
(b) Exhibits:
Exhibit
No.
3.1
3.2
4.1
4.2
10.1+
10.2+
10.3+
10.4+
10.5+
Description of Exhibit
Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current
report filed on August 7, 2014.)
Amended and Restated By-laws. (Incorporated by reference to Exhibit 3.2 to Form 8-K current report filed on August 7,
2014.)
Specimen Certificate evidencing shares of the Company’s common stock. (Incorporated by reference to Exhibit 4.1 to
Form S-1/A registration statement filed on July 18, 2014.)
Form of Third Amended and Restated Investors’ Rights Agreement by and among the Company and the parties listed therein.
(Incorporated by reference to Exhibit 4.2 to Form S-1/A registration statement filed on July 9, 2014.)
Marinus Pharmaceuticals, Inc. 2005 Stock Option and Incentive Plan, as amended. (Incorporated by reference to Exhibit 10.1
to Form S-1 registration statement filed on May 12, 2014.)
Forms of Stock Option Agreement under the 2005 Stock Option and Incentive Plan. (Incorporated by reference to
Exhibit 10.2 to Form S-1 registration statement filed on May 12, 2014.)
Amended and Restated Employment Agreement dated as of March 11, 2015 between the Company and Christopher M.
Cashman. (Filed herewith.)
Amended and Restated Employment Agreement dated as of March 11, 2015 between
Employment Agreement dated as of November 2, 2012 between the Company and Gail M. Farfel. (Incorporated by reference
to Exhibit 10.5 to Form S-1 registration statement filed on May 12, 2014.)
69
Table of Contents
Exhibit
No.
10.6*
10.7
10.8
10.9
10.10
10.11
10.12*
10.13+
10.14
10.15+
10.16+
10.17+
10.18+
23.1
31.1
31.2
32.1
101.INS
101.SCH
101.CAL
101.DEF
101.LAB
101.PRE
Description of Exhibit
the Company and Edward F. Smith. (Filed herewith.)
Technology Transfer Agreement dated December 4, 2012 between Domain Russia Investments Limited and the Company.
(Incorporated by reference to Exhibit 10.6 to Form S-1 registration statement filed on May 12, 2014.)
Assignment and Assumption Agreement dated as of December 4, 2012 among Domain Russia Investments Limited, the
Company and NovaMedica, LLC. (Incorporated by reference to Exhibit 10.7 to Form S-1 registration statement filed on
May 12, 2014.)
Clinical Development and Collaboration Agreement dated as of June 25, 2013 between NovaMedica, LLC and the Company.
(Incorporated by reference to Exhibit 10.8 to Form S-1 registration statement filed on May 12, 2014.)
Loan and Security Agreement dated as of April 2, 2014 between Square 1 Bank and the Company. (Incorporated by reference
to Exhibit 10.9 to Form S-1 registration statement filed on May 12, 2014.)
Form of Amended and Restated Indemnification Agreement (VC Directors). (Incorporated by reference to Exhibit 10.10 to
Form S-1 registration statement filed on May 12, 2014.)
Form of Amended and Restated Indemnification Agreement (Non-VC Directors). (Incorporated by reference to Exhibit 10.11
to Form S-1 registration statement filed on May 12, 2014.)
Amended and Restated Agreement dated as of May 23, 2008 between the Company and Purdue Neuroscience Company.
(Incorporated by reference to Exhibit 10.12 to Form S-1 registration statement filed on May 12, 2014.)
Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, effective as of August 5, 2014. (Filed herewith in corrected form.)
First Amendment to Loan and Security Agreement dated as of December 3, 2014 between Square 1 Bank and the Company.
(Incorporated by reference to Exhibit 10.1 to Form 8-K current report filed on August 7, 2014.)
Employment Agreement dated as of March 11, 2015 between the Company and Albena Patroneva. (Filed herewith.)
Form of Incentive Stock Option Agreement for Officers Under 2014 Equity Incentive Plan. (Filed herewith.)
Form of Incentive Stock Option Agreement for Employees Under 2014 Equity Incentive Plan. (Filed herewith.)
Form of Nonqualified Stock Option Agreement Under 2014 Equity Incentive Plan. (Filed herewith.)
Consent of KPMG LLP. (Filed herewith.)
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (Filed herewith.)
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (Filed herewith.)
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Filed herewith.)
XBRL Instance Taxonomy
XBRL Taxonomy Extension Schema Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Labels Linkbase Document
XBRL Taxonomy Extension Presentation Linkbase Document
+ Indicates management contract or compensatory plan.
* Portions of this exhibit (indicated by asterisks) have been omitted pursuant to an order granting confidential treatment under the Securities
Act of 1933.
(c) None.
70
Table of Contents
SIGNATURES
In accordance with the requirements Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant duly caused this report to
be signed on its behalf by the undersigned, thereunto duly authorized.
Date: March 12, 2015
Marinus Pharmaceuticals, Inc.
By: /s/ Christopher M. Cashman
Christopher M. Cashman
President and Chief Executive Officer
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated:
Name
Capacity
/s/ Christopher M. Cashman
Christopher M. Cashman
/s/ Edward F. Smith
Edward F. Smith
/s/ Stephen Bloch
Stephen Bloch, M.D.
/s/ Enrique J. Carrazana
Enrique J. Carrazana, M.D.
/s/ Anton Gopka
Anton Gopka
/s/ Tim M. Mayleben
Tim M. Mayleben
/s/ Anand Mehra
Anand Mehra, M.D.
/s/ Jay P. Shepard
Jay P. Shepard
/s/ Nicole Vitullo
Nicole Vitullo
President, Chief Executive Officer (Principal Executive
Officer) and Chairman
Vice President, Chief Financial Officer, Secretary and
Treasurer (Principal Finance
and Accounting Officer)
Director
Director
Director
Director
Director
Director
Director
71
Date
March 12, 2015
March 12, 2015
March 12, 2015
March 12, 2015
March 12, 2015
March 12, 2015
March 12, 2015
March 12, 2015
March 12, 2015
Table of Contents
FINANCIAL STATEMENTS
MARINUS PHARMACEUTICALS, INC.
INDEX TO FINANCIAL STATEMENT S
CONTENTS
Report of Independent Registered Public Accounting Firm
Balance Sheets as of December 31, 2014 and 2013
Statements of Operations for the Years Ended December 31, 2014 and 2013
Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
for the Years Ended December 31, 2014 and 2013
Statements of Cash Flows for the Years Ended December 31, 2014 and 2013
Notes to Financial Statements
F-1
Page
F-2
F-3
F-4
F-5
F-6
F-7
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders
Marinus Pharmaceuticals, Inc.
We have audited the accompanying balance sheets of Marinus Pharmaceuticals, Inc. as of December 31, 2014 and 2013, and the related
statements of operations, convertible preferred stock and stockholders’ equity (deficit), and cash flows for the years then ended. These financial
statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit
includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Marinus
Pharmaceuticals, Inc. as of December 31, 2014 and 2013, and the results of its operations and its cash flows for the years then ended, in
conformity with U.S. generally accepted accounting principles.
/s/ KPMG LLP
Philadelphia, Pennsylvania
March 12, 2015
F-2
MARINUS PHARMACEUTICALS, INC.
BALANCE SHEETS
(In thousands, except share and per share amounts)
ASSETS
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Table of Contents
Current assets:
Cash and cash equivalents
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Other assets
Total assets
Current liabilities:
Accounts payable
Accrued expenses
Warrant liability
Total current liabilities
Notes payable
Other long term liabilities
Total liabilities
Commitments and contingencies (Note 9)
Series A convertible preferred stock, $0.001 par value; 18,777,860 shares authorized, issued and
outstanding at December 31, 2013
Series B convertible preferred stock, $0.001 par value; 15,275,824 shares authorized, 12,220,661 shares
issued and outstanding at December 31, 2013
Series C convertible preferred stock, $0.001 par value; 18,900,000 shares authorized, 18,381,463 shares
issued and outstanding at December 31, 2013
Stockholders’ equity (deficit):
Preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding
Common stock, $0.001 par value; 100,000,000 shares authorized, 14,036,985 issued and 14,007,754
outstanding at December 31, 2014 and 494,260 issued and 465,029 outstanding at December 31,
2013
Additional paid-in capital
Treasury stock at cost, 29,231 shares at December 31, 2014 and 2013
Accumulated deficit
Total stockholders’ equity (deficit)
Total liabilities and stockholders’ equity (deficit)
See accompanying notes to financial statements.
F-3
$
$
$
December 31,
2014
2013
49,720 $
428
50,148
44
21
50,213
$
536 $
1,503
—
2,039
7,000
20
9,059
—
—
—
—
10,037
1,762
11,799
16
9
11,824
78
1,096
1,192
2,366
—
—
2,366
30,596
17,929
21,314
—
14
113,476
—
(72,336 )
41,154
50,213
$
1
1,121
—
(61,503 )
(60,381 )
11,824
$
Table of Contents
MARINUS PHARMACEUTICALS, INC.
STATEMENTS OF OPERATIONS
(In thousands, except share and per share amounts)
Expenses:
Research and development
General and administrative
Loss from operations
Change in fair value of warrant liability
Interest income
Interest expense
Net loss
Cumulative preferred stock dividends
Net loss applicable to common stockholders
Per share information:
Net loss per share of common stock—basic and diluted
Basic and diluted weighted average shares outstanding
See accompanying notes to financial statements.
F-4
Year Ended December 31,
2013
2014
$
$
$
8,690 $
3,230
(11,920 )
1,192
12
(117 )
(10,833 )
(2,545 )
(13,378 ) $
4,150
1,229
(5,379 )
153
47
(91 )
(5,270 )
(3,804 )
(9,074 )
(2.17 ) $
6,152,669
(19.60 )
462,972
Table of Contents
STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKH OLDERS’ EQUITY (DEFICIT)
MARINUS PHARMACEUTICALS, INC.
(In thousands, except share amounts)
Convertible Preferred Stock
Stockholders’ Equity (Deficit)
Additional
Common Stock Paid-in
Capital
Amount
Shares
Treasury
Stock
Shares
Amount
Total
Stockholders’
Accumulated Equity
(Deficit)
Deficit
Series A
Shares
Amount
Balance,
Series B
Series C
Shares
Amount
Shares
Amount
December 31,
2012
Stock-based
18,777,860 $ 30,596 12,220,661 $ 17,929 9,654,443 $ 11,023
478,745 $
1 $
867 29,231 $ — $
(56,233 ) $ (55,365 )
compensation
expense
Issuance of
preferred
stock and
conversion
of notes
Exercise of
stock
options
Net loss
Balance,
—
—
—
—
—
—
— —
236 — —
—
236
—
—
—
— 8,727,020 10,291
— —
— — —
—
—
—
—
—
—
—
—
—
—
—
—
—
—
15,515 —
— —
18 — —
— — —
—
(5,270 )
18
(5,270 )
December 31,
2013
Stock-based
18,777,860 30,596 12,220,661 17,929 18,381,463 21,314
494,260
1
1,121 29,231 —
(61,503 )
(60,381 )
—
—
—
—
—
—
— —
698 — —
—
698
—
—
—
—
422,119
500
— —
— — —
—
—
—
—
—
—
122,634 —
128 — —
—
—
—
128
(18,777,860 ) (30,596 ) (12,220,661 ) (17,929 ) (18,803,582 ) (21,814 ) 7,661,871
7 70,333 — —
—
70,340
—
—
—
—
—
—
220 —
— — —
—
—
—
—
—
—
—
—
—
—
—
—
— 5,758,000
—
— —
6 41,196 — —
— — —
—
(10,833 )
41,202
(10,833 )
compensation
expense
Issuance of
Series C
Preferred
Stock
Exercise of
stock
options
Conversion of
convertible
preferred
stock into
common
stock
Exercise and
conversion
of
convertible
preferred
stock
warrants
into
common
stock
Issuance of
common
stock in
connection
with initial
public
offering
($8.00 per
share), net
of expenses
of $4,862
Net loss
Balance,
December 31,
2014
—
$ —
—
$ —
—
$ —
14,036,985
$
14
$ 113,476
29,231
$ —
$
(72,336 ) $ 41,154
See accompanying notes to financial statements.
F-5
Table of Contents
MARINUS PHARMACEUTICALS, INC.
STATEMENTS OF CASH FLOWS
(In thousands)
Cash flows from operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation
Stock-based compensation expense
Noncash interest on convertible notes payable
Change in fair value of warrant liability
Amortization of debt issuance costs
Changes in operating assets and liabilities:
Prepaid expenses and other assets
Accounts payable and accrued expenses
Net cash used in operating activities
Cash flows from investing activities
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities
Proceeds from exercise of stock options
Proceeds from initial public offering, net of offering costs
Proceeds from notes payable, net of issuance costs
Proceeds from investor deposit
Proceeds from issuance of convertible preferred stock, net of issuance costs
Net cash provided by financing activities
Net increase in cash and cash equivalents
Cash and cash equivalents—beginning of year
Cash and cash equivalents—end of year
Supplemental disclosure of cash flow information
Conversion of preferred stock to common stock
Conversion of notes principal and accrued interest to preferred stock
Cash paid for interest
Issuance of Series C Preferred Stock
See accompanying notes to financial statements.
F-6
Year Ended December 31,
2013
2014
$
(10,833 ) $
(5,270 )
5
698
—
(1,192 )
4
1,344
1,385
(8,589 )
(33 )
(33 )
128
41,202
6,975
—
—
48,305
39,683
10,037
49,720
$
70,340
—
89
500
$
$
$
$
10
236
91
(153 )
—
(1,731 )
189
(6,628 )
(17 )
(17 )
18
—
—
500
7,530
8,048
1,403
8,634
10,037
—
2,761
—
—
$
$
$
$
$
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
1. Organization and Description of the Business
We are a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics. Our clinical stage
product candidate, ganaxolone, is a synthetic small molecule that is an analog of allopregnanolone, a natural occurring neurosteriod produced by
type receptors in the brain, which
the human body. Allopregnanolone modulates the activity of gammaaminobutyric acid (GABA) at GABA
has been identified as playing an important role in certain seizure, psychiatric and developmental disorders. Our primary focus to date since our
inception has been directed towards developing business strategies, raising capital, research and development activities and conducting preclinical
testing and human clinical trials of our product candidates.
A
Liquidity
We have not generated any product revenues and have incurred operating losses since inception. There is no assurance that profitable
operations will ever be achieved, and if achieved, could be sustained on a continuing basis. In addition, development activities, clinical and
preclinical testing, and commercialization of our product candidates will require significant additional financing. Our accumulated deficit as of
December 31, 2014 was $72.3 million and we expect to incur substantial losses in future periods. We plan to finance our future operations with a
combination of proceeds from the issuance of equity securities, the issuance of additional debt, potential collaborations and revenues from
potential future product sales, if any. We have not generated positive cash flows from operations, and there are no assurances that we will be
successful in obtaining an adequate level of financing for the development and commercialization of our planned product candidates.
In connection with the closing our initial public offering during the third quarter of 2014, we issued a total of 5,758,000 shares of
common stock and received aggregate net proceeds, after underwriting discounts and commissions and other estimated offering expenses, of
approximately $41.2 million. Our cash and cash equivalents balance as of December 31, 2014 is adequate to fund our operations into the second
half of 2016.
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with generally accepted accounting principles (GAAP) requires management to
make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the
date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from
such estimates.
Recapitalization
Our board of directors and stockholders approved a reverse stock split of our common stock at a ratio of one share for every six and one-
half shares previously held. The reverse stock split was effected on July 16, 2014. All common stock share and per-share data included in these
financial statements reflect the reverse stock split. In addition, the board of directors approved an increase in the authorized shares of our common
stock to 100,000,000 shares.
Fair Value of Financial Instruments and Credit Risk
At December 31, 2014 and 2013, our financial instruments included cash and cash equivalents, accounts payable, accrued expenses,
notes payable and derivative liabilities. The carrying amount of cash and cash equivalents, accounts payable and accrued expenses approximated
fair value, given their short-term nature. The carrying amount of our notes payable approximate fair value because the interest rates on these
instruments are reflective of rates that we could obtain on debt with similar terms and conditions. The carrying value of the derivative liabilities
was the estimated fair value of the liability as more fully described below.
F-7
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
Cash and cash equivalents subject us to concentrations of credit risk. However, we invest our cash in accordance with a policy objective
that seeks to ensure both liquidity and safety of principal. The policy limits investments to instruments issued by the U.S. government and certain
SEC-registered money market funds that invest only in U.S. government obligations and places restrictions on portfolio maturity terms.
Cash and Cash Equivalents
We consider all highly liquid investments that have maturities of three months or less when acquired to be cash equivalents. As of
December 31, 2014 and 2013, we invested a portion of our cash balances in money market investments, which we have included as cash
equivalents on our balance sheets.
Property and Equipment
Property and equipment consist of laboratory and office equipment and are recorded at cost. Property and equipment are depreciated on a
straight-line basis over their estimated useful lives. We estimate a life of three years for computer equipment, including software, and five years
for laboratory equipment, office equipment, and furniture. When property and equipment are sold or otherwise disposed of, the cost and related
accumulated depreciation are removed from the accounts and the resulting gain or loss is included in operating expenses.
Impairment of Long-Lived Assets
We review long-lived assets, including property and equipment, for impairment whenever events or changes in business circumstances
indicate that the carrying amount of an asset may not be fully recoverable. If the estimated undiscounted future cash flows expected to result from
the use of the asset and its eventual disposition is less than its carrying amount an impairment loss would be recognized if the carrying value of the
asset exceeded its fair value. Fair value is generally determined using discounted cash flows. Through December 31, 2014, no impairment has
occurred.
Research and Development
Research and development costs are expensed as incurred. Costs for certain development activities, such as clinical trials, are recognized
based on an evaluation of the progress to completion of specific tasks using data such as subject enrollment, clinical site activations, or
information provided to us by our vendors with respect to their actual costs incurred. Payments for these activities are based on the terms of the
individual arrangements, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued
research and development expense, as the case may be.
Income Taxes
We recognize deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of our
assets and liabilities and the expected benefits of net operating loss carryforwards. The impact of changes in tax rates and laws on deferred taxes,
if any, applied during the years in which temporary differences are expected to be settled, is reflected in the financial statements in the period of
enactment. The measurement of deferred tax assets is reduced, if necessary, if, based on weight of the evidence, it is more likely than not that
some, or all, of the deferred tax assets will not be realized. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in
the period that such tax rate changes are enacted. At December 31, 2014 and 2013, we have concluded that a full valuation allowance is necessary
for our net deferred tax assets. We had no material amounts recorded for uncertain tax positions, interest or penalties in the accompanying
consolidated financial statements.
Loss Per Share of Common Stock
Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of
common stock outstanding during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of
securities, such as convertible preferred stock, convertible notes payable, warrants, stock options, and unvested restricted stock, which would
result in the issuance of
F-8
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted
average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the
calculation. These potentially dilutive securities are more fully described in Note 7.
The following table sets forth the computation of basic and diluted earnings per share for the years ended December 31, 2014 and 2013
(in thousands, except share and per share amounts):
Basic and diluted net loss per share of common stock:
Net loss
Dividends on Series B and C Preferred Stock
Net loss applicable to common stockholders
Weighted average shares of common stock outstanding
Net loss per share of common stock—basic and diluted
Year Ended December 31,
2013
2014
$
$
$
(10,833 ) $
(2,545 )
(13,378 ) $
6,152,669
(2.17 ) $
(5,270 )
(3,804 )
(9,074 )
462,972
(19.60 )
The following potentially dilutive securities outstanding at December 31, 2014 and 2013 have been excluded from the computation of
diluted weighted average shares outstanding, as they would be antidilutive:
Convertible preferred stock
Warrants
Stock options
Comprehensive Loss
December 31,
2014
—
—
1,670,574
1,670,574
2013
7,596,927
470,026
1,093,208
9,160,161
Comprehensive loss is defined as the change in equity of a business enterprise during a period from transactions and other events and
circumstances from non-owner sources. Comprehensive loss was equal to net loss for all periods presented.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by
the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We view our
operations and manage our business in one segment, which is the identification and development of neuropsychiatric therapeutics.
Stock-Based Compensation
We account for stock-based compensation in accordance with the provisions of Accounting Standards Codification (ASC) Topic 718,
Compensation—Stock Compensation, or ASC 718, which requires the recognition of expense related to the fair value of stock-based awards in the
statements of operations. For stock options issued to employees and members of our board of directors for their services on our board of directors,
we estimate the grant-date fair value of options using the Black-Scholes option pricing model. The use of the Black-Scholes option pricing model
requires management to make assumptions with respect to the expected term of the option, the
F-9
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
expected volatility of the common stock consistent with the expected life of the option, risk-free interest rates, and the value of the common stock.
For awards subject to time-based vesting, we recognize stock-based compensation expense, net of estimated forfeitures, on a straight-line basis
over the requisite service period, which is generally the vesting term of the award. For awards subject to performance-based vesting conditions,
we recognize stock-based compensation expense when it is probable that the performance condition will be achieved. Stock-based awards issued
to non-employees are recorded at their fair values, and are periodically revalued as the equity instruments vest and are recognized as expense over
the related service period in accordance with the provisions of ASC 718 and ASC Topic 505, Equity.
Clinical Trial Expense Accruals
As part of the process of preparing our financial statements, we are required to estimate our expenses resulting from our obligations
under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting
clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment
flows that do not match the periods over which materials or services are provided under such contracts. Our objective is to reflect the appropriate
trial expenses in our financial statements by matching those expenses with the period in which services are performed and efforts are expended.
We account for these expenses according to the progress of the trial as measured by patient progression and the timing of various aspects of the
trial. We determine accrual estimates through financial models taking into account discussion with applicable personnel and outside service
providers as to the progress or state of consummation of trials. During the course of a clinical trial, we adjust our clinical expense recognition if
actual results differ from its estimates. We make estimates of our accrued expenses as of each balance sheet date based on the facts and
circumstances known at that time. Our clinical trial accruals are dependent upon the timely and accurate reporting of contract research
organizations and other third-party vendors. Although we do not expect our estimates to be materially different from amounts actually incurred,
our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may
result in reporting amounts that are too high or too low for any particular period. For the years ended December 31, 2014 and 2013, there were no
material adjustments to our prior period estimates of accrued expenses for clinical trials.
Recent Accounting Pronouncements
In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-10, Elimination
of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation ,
which eliminates all incremental financial reporting requirements for development stage entities by removing Accounting Standards Codification
(ASC) Topic 915, Development Stage Entities , from the FASB Accounting Standards Codification. ASC Topic 915 is removed effective for
annual periods beginning after December 15, 2014 and early adoption is permitted. The Company adopted the ASU effective with the issuance of
the June 30, 2014 interim financial statements.
In August 2014, the FASB issued ASU No. 2014-15, Disclosure of Uncertainties About an Entity’s Ability to Continue as a Going
Concern , which provides guidance on determining when and how to disclose going-concern uncertainties in the financial statements. The new
standard requires management to perform interim and annual assessments of an entity’s ability to continue as a going concern within one year of
the date the financial statements are issued. An entity must provide certain disclosures if conditions or events raise substantial doubt about the
entity’s ability to continue as a going concern. The ASU applies to all entities and is effective for annual periods ending after December 15, 2016,
and interim periods thereafter, with early adoption permitted. The Company is currently evaluating the impact the adoption of this ASU will have
on its financial statements.
3. Fair Value Measurements
FASB accounting guidance defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit
price) in an orderly transaction between market participants at the measurement date. The accounting guidance outlines a valuation framework and
creates a fair value hierarchy in order to increase the consistency and comparability of fair value measurements and the
F-10
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
related disclosures. In determining fair value, we use quoted prices and observable inputs. Observable inputs are inputs that market participants
would use in pricing the asset or liability based on market data obtained from independent sources.
The fair value hierarchy is broken down into three levels based on the source of inputs as follows:
• Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.
• Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.
• Level 3—Valuations based on inputs that are unobservable and models that are significant to the overall fair value measurement.
The following fair value hierarchy table presents information about each major category of our financial assets and liabilities measured at
fair value on a recurring basis (in thousands):
December 31, 2014
Assets
Money market funds (cash equivalents)
Total assets
December 31, 2013
Assets
Money market funds (cash equivalents)
Total assets
Liabilities
Warrant liability
Total liabilities
Level 1
Level 2
Level 3
Total
$
$
$
$
$
$
48,960 $
$
48,960
9,251 $
$
9,251
— $
$
—
— $
$
—
— $
$
—
— $
$
—
— $
$
—
— $
$
—
1,192 $
$
1,192
48,960
48,960
9,251
9,251
1,192
1,192
We had outstanding warrants to purchase our Series B Preferred Stock, or the Series B Warrants, as of December 31, 2013. While the
Series B Preferred Stock was outstanding, holders were able to redeem for cash upon an event that was not within our control, such as the
liquidation of our preferred stock, as the preferred stockholders had voting control of our company and control of our board of directors, and
therefore had the ability to trigger the liquidation of our preferred stock. As a result, the Series B Warrants were recorded as a warrant liability on
our balance sheet with subsequent changes to fair value recorded on our statements of operations as change in fair value of warrant liability. In
connection with our initial public offering during the third quarter of 2014, these warrants expired unexercised, and the Series B Preferred Stock
underlying the Series B Warrants converted to common stock. As a result, the fair value of the Series B warrants recorded as a liability as of
December 31, 2013 was reduced to zero in 2014. On the grant date and in subsequent periods, we estimated the fair value of the preferred stock
warrant liability using an option-pricing model, which required inputs such as the expected volatility based on comparable public companies (75%
- 80%), the estimated fair value of the Series B Preferred Stock ($0.63 - $1.51 per share), and the estimated time to liquidity (0.2 - 4 years). For
this liability, we developed our own assumptions that do not have observable inputs or available market data to support the fair value.
The following tables set forth a summary of changes in the fair value of Level 3 preferred stock warrant liability for the years ended
December 31, 2014 and 2013 (in thousands):
Year ended December 31, 2014
Year ended December 31, 2013
Beginning
of
Year
$
$
1,192 $
1,345 $
F-11
Issuances
Exercises
— $
— $
— $
— $
Change in Fair
Value
(1,192 ) $
(153 ) $
End of Year
—
1,192
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
4. Property and Equipment
Property and equipment consisted of the following (in thousands):
Laboratory equipment
Office equipment
Less: accumulated depreciation
December 31,
2013
2014
$
$
326
74
400
(356 )
44
$
$
369
76
445
(429 )
16
Depreciation expense, in thousands, was $5 and $10 for the years ended December 31, 2014 and 2013, respectively.
5. Accrued Expenses
At December 31, 2014 and 2013, accrued expenses consisted of the following (in thousands):
Investor deposit
Payroll and related costs
Clinical trials and drug development
Professional fees
Other
December 31,
2013
2014
$
$
—
419
777
186
121
1,503
$
$
500
204
73
295
24
1,096
Investor deposit represents funds received from an investor for 422,119 shares of Series C Preferred Stock. The shares were issued in
April 2014.
6. Notes Payable
In April 2014, we borrowed $2.0 million in connection with a term loan pursuant to a Loan and Security Agreement (LSA) we entered
into with a financial institution. In connection with this term loan, we issued to the financial institution warrants to purchase 37,991 shares of our
Series C Preferred Stock with a term of 8 years. The warrants were net exercised and converted into 220 shares of common stock in connection
with the closing our initial public offering during the third quarter of 2014. Pursuant to the terms of the LSA, we made monthly interest-only
payments for outstanding borrowings at an interest rate equal to the greater of (a) prime plus 2.25% or (b) 5.5% until the LSA was amended in
December 2014.
In December 2014, we entered into a First Amendment to Loan and Security Agreement (Amended LSA) with the same financial
institution. The Amended LSA increased the total term loan availability from $2.0 million to $12.0 million, available in four tranches (in
thousands):
Tranche
A
B
C
D
$
$
Term
Loan
Available
Term
Loan
Borrowed
2,000
5,000
2,500
2,500
12,000
$
$
F-12
2,000
5,000
—
—
7,000
Borrowed Date
April 2014
December 2014
*
*
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
* Our ability to borrow under the remaining tranches of $2.5 million each depends upon meeting certain clinical trial milestones. The
availability end dates of Tranches C and D are September 1, 2015 and March 31, 2016, respectively.
In connection with the Amended LSA, we borrowed $5.0 million available to us under Tranche B. Pursuant to the terms of the
Amended LSA, we are required to make monthly interest-only payments for all outstanding borrowings at an interest rate equal to the greater of
(a) prime plus 3.25% or (b) 6.5% until December 2015. Commencing in January 2016 and continuing through December 2017, we are required to
make monthly payments of 1/24th of our principal borrowings plus interest with the remaining principal balance due in December 2017. If we
achieve certain clinical trial milestones by August 2015, both the interest-only period and principal maturity dates will be extended by six months.
As of December 31, 2014, our outstanding term loan balance of $7.0 million was classified as long-term debt on our balance sheet. In
connection with the execution of both the LSA and Amended LSA, we paid debt costs to the financial institution of $25 thousand, which are being
amortized into interest expense over the remaining term of the loans. Interest expense related to the loans was $117 thousand for the year ended
December 31, 2014. As of December 31, 2014, we had accrued interest of $39 thousand. There are no financial covenants associated with these
term loans. As of December 31, 2014, we were in compliance with all non-financial covenants.
Maturities of our debt obligations over the next five years are as follows (in thousands):
2015
2016
2017
Total minimum lease payments
7. Convertible Preferred Stock
Debt
Maturities
—
3,500
3,500
7,000
$
$
In June 2013, we issued 6,396,065 shares of Series C Preferred Stock at $1.1845 per share for proceeds of $7.5 million, net of issuance
costs of $46 thousand. In addition, we issued 2,330,955 shares of Series C Preferred Stock from the conversion of the remaining outstanding $2.8
million in Series C Convertible Notes, including related accrued interest of $461 thousand. In April 2014, we issued 422,119 shares of Series C
Preferred Stock. Proceeds of $500 thousand related to this issuance were received in 2013 and were reflected as an investor deposit in accrued
expenses on the balance sheet as of December 31, 2013.
In connection with the closing our initial public offering during the third quarter of 2014, all outstanding shares of convertible preferred
stock were converted to 7,661,871 shares of common stock.
F-13
Table of Contents
8. Stock Option and Incentive Plans
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
In 2005, we adopted the 2005 Stock Option and Incentive Plan (2005 Plan) that authorizes us to grant options, restricted stock and other
equity-based awards. As of December 31, 2014, 970,574 options to purchase shares of common stock were outstanding pursuant to grants in
connection with the 2005 Plan. No addtional shares are available for issuance under the 2005 plan. The amount, terms of grants, and exercisability
provisions are determined and set by our board of directors.
Effective in August 2014, we adopted our 2014 Equity Incentive Plan (2014 Plan) that authorizes us to grant options, restricted stock and
other equity-based awards, subject to adjustment in accordance with the plan. As of December 31, 2014, 700,000 options to purchase shares of
common stock were outstanding pursuant to grants in connection with the 2014 Plan; and no shares of common stock were available for future
issuance. In accordance with the 2014 Plan, on January 1, 2015, 560,310 shares of common stock became available for future grant under the
plan.
There were 1,670,574 stock options outstanding as of December 31, 2014 at a weighted average exercise price of $4.37 per share, and
54,000 options were granted to nonemployee directors and consultants during the year ended December 31, 2014. Total compensation cost
recognized for all stock option awards in the statements of operations is as follows (in thousands):
Research and development
General and administrative
Total stock-based compensation expense
Stock Options
Year Ended
December 31,
2013
2014
$
$
137 $
561
698
$
15
221
236
Options issued under both the 2005 Plan and 2014 Plan may have a contractual life of up to 10 years and may be exercisable in cash or as
otherwise determined by the board of directors. Vesting generally occurs over a period of not greater than four years. A summary of activity for
the years ended December 31, 2014 and 2013 is presented below (in thousands, except share and per share amounts):
Outstanding—December 31, 2012
Outstanding—December 31, 2013
Granted
Exercised
Forfeited
Granted
Exercised
Outstanding—December 31, 2014
Exercisable—December 31, 2014
Exercisable and Expected to vest—December 31, 2014
Weighted-
Average
Exercise
Price
Per Share
Aggregate
Intrinsic
Value
—
—
1.04
—
1.04
8.99
1.04
4.37
1.75
4.37
$
$
$
10,357
6,740
10,357
Shares
689,663
589,719
(15,515 )
(170,659 )
1,093,208
700,000
(122,634 )
1,670,574
764,338
1,670,574
$
$
$
F-14
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
The weighted average remaining contractual term of options outstanding and exercisable as of December 31, 2014 is 8.6 and 7.4 years,
respectively. The aggregate intrinsic value in the preceding tables represent the total intrinsic value that would have been received had all option
holders exercised their options on December 31, 2014. Intrinsic value is determined by calculating the difference between the fair value of our
common stock on the last day of the year and the exercise price, multiplied by the number of options.
The weighted-average grant date fair value of options granted was $6.09 and $0.85 per share in 2014 and 2013 and was estimated at the
date of grant using the Black-Scholes option-pricing model with the following weighted-average assumptions:
Expected stock price volatility
Expected term of options
Risk-free interest rate
Expected annual dividend yield
2014
77.66 — 86.08%
5.5 — 6.06 years
1.75 — 1.98%
0%
2013
103.9 - 118.0%
5 - 6.25 years
0.84 - 1.75%
0%
The weighted-average valuation assumptions were determined as follows:
• Expected stock price volatility: The expected volatility is based on historical volatilities of similar entities within our industry which
were commensurate with our expected term assumption as described in the SEC’s Staff Accounting Bulletin, or SAB, No. 107.
• Expected term of options: We estimated the expected term of our stock options with service-based vesting using the “simplified”
method, as prescribed in SAB No. 107, whereby the expected life equals the average of the vesting tranches and the original
contractual term of the option due to our lack of sufficient historical data.
• Risk-free interest rate: We base the risk-free interest rate on the interest rate payable on U.S. Treasury securities in effect at the time
of grant for a period that is commensurate with the assumed expected option term.
• Expected annual dividend yield: The estimated annual dividend yield is 0% because we have not historically paid, and do not expect
for the foreseeable future to pay, a dividend on our common stock.
As of December 31, 2014, there was $4.1 million of total unrecognized compensation expense related to unvested stock options granted
under the 2005 Plan and 2014 Plan. That expense is expected to be recognized in the years ended as follows, in thousands:
December 31, 2015
December 31, 2016
December 31, 2017
December 31, 2018
9. Commitments and Contingencies
Leases
$
$
1,448
1,302
929
403
4,082
In October 2014, we entered into a five-year operating lease agreement for office space in Radnor, Pennsylvania. Rent payments under
this lease commence May 1, 2015, with payment amounts escalating each May 1 thereafter through the end of the lease term. In February 2013,
we entered into a two-year operating lease agreement for office space in New Haven, Connecticut and pay a flat rent per month over the term of
the lease which ends in June 2015. Prior to that and through April 2013, we leased a facility in Branford, Connecticut. Rent
F-15
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
expense under these operating leases, in thousands, was $50 and $34 for the years ended 2014 and 2013, respectively. All leases are non-
cancelable.
Our annual future minimum lease payments under these leases are as follows (in thousands):
2015
2016
2017
2018
2019
Thereafter
Total minimum lease payments
Employee Benefit Plan
Operating
Lease
Payments
100
130
132
135
138
46
681
$
$
We maintain a Section 401(k) retirement plan for all employees. Employees can contribute up to 50% of their eligible pay, subject to
maximum amounts allowed under law. We may make discretionary profit sharing contributions, which vest over a period of four years from each
employee’s commencement of employment with us. We have not made any discretionary contributions.
License Agreement
We are obligated to pay royalties pursuant to a license agreement with Purdue as a percentage of net product sales for direct licensed
products, such as ganaxolone. The obligation to pay royalties expires, on a country-by-country basis, 10 years from the first commercial sale of a
licensed product in each country. The agreement also requires that we pay Purdue a percentage of the non-royalty consideration that we receive
from a sublicensee and a percentage of milestone payments for indications other than seizure disorders and vascular migraine headaches not
associated with mood disorders. Under the license agreement, we are committed to use commercially reasonable efforts to develop and
commercialize at least one licensed product.
10. Income Taxes
As of December 31, 2014 and 2013, we had approximately $68.0 million and $59.0 million, respectively, of net operating loss, or NOL,
carry forwards available to offset future federal and state taxable income that will expire beginning in 2023. We also have federal research and
development credit carryovers of approximately $2.6 million and state credit carryovers of approximately $0.4 million which expire beginning in
2019.
The State of Connecticut provides companies with the opportunity to exchange certain research and development credit carryforwards for
cash in exchange for foregoing the carryforward. The program provides for such exchange of the research and development credits at a rate of
65% of the annual research and development credit, as defined. During 2014 and 2013, we recorded a net benefit, in thousands, of $2 and $28,
respectively, primarily for the estimated proceeds from the exchange of the research and development credit.
The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL,
and tax credit carry forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of
significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended, or the Code, as well as similar state tax provisions. This could limit the amount of NOLs that we can utilize annually to offset future
taxable income or tax liabilities. The amount of the annual limitation, if any, will be determined based on the value of our company immediately
prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. Additionally, U.S. tax laws limit the
time during which these carry forwards may be
F-16
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
applied against future taxes, therefore, we may not be able to take full advantage of these carry forwards for federal income tax purposes. We are
currently evaluating the ownership history of our company to determine if there were any ownership changes as defined under Section 382(g) of
the Code and the effects any ownership change may have had.
The components of the net deferred tax asset are as follows (in thousands):
Gross deferred tax assets:
Net operating loss carryovers
Accrued expenses
Contributions
Stock-based compensation
Research and development and other credits
Total gross deferred tax assets
Gross deferred tax liabilities:
Depreciation
Total gross deferred tax liabilities
Net deferred tax assets
Less: valuation allowance
Net deferred tax assets after valuation allowance
December 31,
2014
2013
$
26,505 $
—
5
211
3,075
29,796
(1 )
(1 )
29,795
(29,795 )
$
—
$
23,006
18
1
143
2,693
25,861
(2 )
(2 )
25,859
(25,859 )
—
In assessing the realizability of deferred tax assets, we consider whether it is more-likely-than-not that some portion or all of the deferred
tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the
periods in which the temporary differences representing net future deductible amounts become deductible. After consideration of all the evidence,
both positive and negative, we have recorded a full valuation allowance against our net deferred tax assets at December 31, 2014 and 2013,
respectively, because our management has determined that is it more likely than not that these assets will not be fully realized. The valuation
allowance increased by $3.9 million and $2.3 million during the years ended December 31, 2014 and 2013, respectively, due primarily to the
generation of NOLs during those periods.
We did not have unrecognized tax benefits as of December 31, 2014 and 2013, and do not expect this to change significantly over the
next twelve months. We recognize interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense. As of
December 31, 2014 and 2013, we have not accrued interest or penalties related to any uncertain tax positions. Our tax returns filed since inception
are still subject to examination by major tax jurisdictions.
A reconciliation of income tax expense (benefit) at the statutory federal income tax rate and income taxes as reflected in the financial
statements is as follows:
Federal income tax expense at statutory rate
Permanent items
State income tax, net of federal benefit
State refundable credit
R&D tax credits
Change in valuation allowance
Effective income tax rate
Year Ended
December 31,
2014
34.0 %
(5.4 )
3.8
0.0
4.2
(36.6 )
0.0 %
2013
34.0 %
(0.3 )
5.0
0.7
(3.3 )
(35.4 )
0.7 %
For all years through December 31, 2014, we generated research credits but have not conducted a study to document the qualified
activities. This study may result in an adjustment to our research and development credit
F-17
Table of Contents
MARINUS PHARMACEUTICALS, INC.
NOTES TO FINANCIAL STATEMENTS
carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position for
these years. A full valuation allowance has been provided against our research and development credits and, if an adjustment is required, this
adjustment to the deferred tax asset established for the research and development credit carryforwards would be offset by an adjustment to the
valuation allowance.
We file income tax returns in the United States, the State of Connecticut, and the Commonwealth of Pennsylvania. The federal and state
income tax returns are generally subject to tax examinations for the tax years ended December 31, 2011 through December 31, 2013. To the extent
we have tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal
Revenue Service or state tax authorities to the extent utilized in a future period.
11. Quarterly Financial Information (unaudited)
2014:
Research and development expenses
General and administrative expenses
Net loss
Cumulative preferred stock dividends
Net loss applicable to common shareholders
Net loss per share, basic and diluted
2013:
Research and development expenses
General and administrative expenses
Net loss
Cumulative preferred stock dividends
Net loss applicable to common shareholders
Net loss per share, basic and diluted
First
Quarter
Second
Quarter
Third
Quarter
Fourth
Quarter
Total Year
$
$
$
$
$
$
$
$
$
$
$
$
2,149 $
517 $
(2,235 ) $
(1,071 ) $
(3,306 ) $
(7.09 ) $
747 $
180 $
(970 ) $
(786 ) $
(1,756 ) $
(3.82 ) $
F-18
2,805 $
458 $
(3,323 ) $
(1,102 ) $
(4,425 ) $
(7.98 ) $
1,327 $
314 $
(1,682 ) $
(940 ) $
(2,622 ) $
(5.66 ) $
1,569 $
868 $
(1,668 ) $
(372 )
(2,040 ) $
(0.22 ) $
1,008 $
313 $
(1,224 ) $
(1,029 ) $
(2,253 ) $
(4.58 ) $
2,167 $
1,387 $
(3,607 ) $
— $
(3,607 ) $
(0.26 ) $
1,068 $
422 $
(1,394 ) $
(1,049 ) $
(2,443 ) $
(5.54 ) $
8,690
3,230
(10,833 )
(2,543 )
(13,378 )
(2.17 )
4,150
1,229
(5,270 )
(3,804 )
(9,074 )
(19.60 )
Table of Contents
Exhibit
No.
3.1
3.2
4.1
4.2
10.1+
10.2+
10.3+
10.4+
10.5+
10.6*
10.7
10.8
10.9
10.10
10.11
10.12*
10.13+
10.14
10.15+
10.16+
10.17+
10.18+
Fourth Amended and Restated Certificate of Incorporation. (Incorporated by reference to Exhibit 3.1 to Form 8-K current
report filed on August 7, 2014.)
Description of Exhibit
Amended and Restated By-laws. (Incorporated by reference to Exhibit 3.2 to Form 8-K current report filed on August 7, 2014.)
Specimen Certificate evidencing shares of the Company’s common stock. (Incorporated by reference to Exhibit 4.1 to Form S-
1/A registration statement filed on July 18, 2014.)
Form of Third Amended and Restated Investors’ Rights Agreement by and among the Company and the parties listed therein.
(Incorporated by reference to Exhibit 4.2 to Form S-1/A registration statement filed on July 9, 2014.)
Marinus Pharmaceuticals, Inc. 2005 Stock Option and Incentive Plan, as amended. (Incorporated by reference to Exhibit 10.1
to Form S-1 registration statement filed on May 12, 2014.)
Forms of Stock Option Agreement under the 2005 Stock Option and Incentive Plan. (Incorporated by reference to Exhibit 10.2
to Form S-1 registration statement filed on May 12, 2014.)
Amended and Restated Employment Agreement dated as of March 11, 2015 between the Company and Christopher M.
Cashman. (Filed herewith.)
Amended and Restated Employment Agreement dated as of March 11, 2015 between the Company and Edward F. Smith.
(Filed herewith.)
Employment Agreement dated as of November 2, 2012 between the Company and Gail M. Farfel. (Incorporated by reference
to Exhibit 10.5 to Form S-1 registration statement filed on May 12, 2014.)
Technology Transfer Agreement dated December 4, 2012 between Domain Russia Investments Limited and the Company.
(Incorporated by reference to Exhibit 10.6 to Form S-1 registration statement filed on May 12, 2014.)
Assignment and Assumption Agreement dated as of December 4, 2012 among Domain Russia Investments Limited, the
Company and NovaMedica, LLC. (Incorporated by reference to Exhibit 10.7 to Form S-1 registration statement filed on
May 12, 2014.)
Clinical Development and Collaboration Agreement dated as of June 25, 2013 between NovaMedica, LLC and the Company.
(Incorporated by reference to Exhibit 10.8 to Form S-1 registration statement filed on May 12, 2014.)
Loan and Security Agreement dated as of April 2, 2014 between Square 1 Bank and the Company. (Incorporated by reference
to Exhibit 10.9 to Form S-1 registration statement filed on May 12, 2014.)
Form of Amended and Restated Indemnification Agreement (VC Directors). (Incorporated by reference to Exhibit 10.10 to
Form S-1 registration statement filed on May 12, 2014.)
Form of Amended and Restated Indemnification Agreement (Non-VC Directors). (Incorporated by reference to Exhibit 10.11
to Form S-1 registration statement filed on May 12, 2014.)
Amended and Restated Agreement dated as of May 23, 2008 between the Company and Purdue Neuroscience Company.
(Incorporated by reference to Exhibit 10.12 to Form S-1 registration statement filed on May 12, 2014.)
Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan, effective as of August 5, 2014. (Filed herewith in corrected form.)
First Amendment to Loan and Security Agreement dated as of December 3, 2014 between Square 1 Bank and the Company.
(Incorporated by reference to Exhibit 10.1 to Form 8-K current report filed on August 7, 2014.)
Employment Agreement dated as of March 11, 2015 between the Company and Albena Patroneva. (Filed herewith.)
Form of Incentive Stock Option Agreement for Officers Under 2014 Equity Incentive Plan. (Filed herewith.)
Form of Incentive Stock Option Agreement for Employees Under 2014 Equity Incentive Plan. (Filed herewith.)
Form of Nonqualified Stock Option Agreement Under 2014 Equity Incentive Plan. (Filed herewith.)
Table of Contents
Exhibit
No.
23.1
31.1
31.2
32.1
101.INS
101.SCH
101.CAL
101.DEF
101.LAB
101.PRE
Description of Exhibit
Consent of KPMG LLP. (Filed herewith.)
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (Filed herewith.)
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. (Filed herewith.)
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (Filed herewith.)
XBRL Instance Taxonomy
XBRL Taxonomy Extension Schema Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Labels Linkbase Document
XBRL Taxonomy Extension Presentation Linkbase Document
+ Indicates management contract or compensatory plan.
* Portions of this exhibit (indicated by asterisks) have been omitted pursuant to an order granting confidential treatment under the
Securities Act of 1933.
AMENDED AND RESTATED
EMPLOYMENT AGREEMENT
EXHIBIT 10.3
EMPLOYMENT AGREEMENT effective as of March 11, 2015 between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware
corporation, and Christopher M. Cashman (the “Employee”).
Recital:
The Employee has been employed by the Company pursuant to an Employment Agreement dated as of November 2, 2012 (the “Prior
Agreement”). The parties desire to enter into this Agreement to amend and restate the Prior Agreement so as to provide for the continued
employment of the Employee by the Company and for certain other matters in connection with such employment, all as set forth more fully in this
Agreement.
NOW, THEREFORE, in consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the
parties to this Agreement hereby agree as follows:
1. Duties. The Company agrees that the Employee shall be employed by the Company to serve as Chief Executive Officer of the
Company. The Employee shall report to the Board of Directors of the Company. The Employee agrees to be so employed by the Company and to
devote his best efforts to advance the interests of the Company and to perform such executive, managerial, administrative and financial functions
as are required to develop the Company’s business and to perform other duties assigned to the Employee by the Board of Directors of the
Company (the “Board”) that are consistent with the Employee’s position as Chief Executive Officer.
2. Term. The Employee’s employment under this Agreement shall continue in effect until terminated pursuant to Section 4 of
this Agreement.
3. Compensation.
(a) Salary. During the term of the Employee’s employment under this Agreement, the Employee shall be paid an annual
salary at the rate of not less than $470,000 (the “Base Salary”). The Base Salary may be increased from time to time by the Board. The Board
shall review the Base Salary at least annually at the end of each fiscal year of the Company. The Base Salary shall be paid in accordance with the
Company’s regular payroll practices.
(b) Annual Bonus. At the end of each fiscal year of the Company that ends during the term of this Agreement, the
Board shall consider the award of a performance bonus to the Employee for such fiscal year in an amount of up to 50% of the Employee’s Base
Salary (the “Target Bonus”) based upon the achievement of performance objectives established annually by the Board or its Compensation
Committee. Whether the performance objectives for any year have been achieved by the Employee shall be determined by the Board or its
Compensation Committee. Notwithstanding the foregoing, all bonuses shall be paid within two and one-half months after the close of each year.
(c) Equity Incentive Programs. The Employee shall be eligible to participate in equity incentive programs established
by the Company from time to time to provide stock options and other equity-based incentives to key employees of the Company in accordance
with the terms of those programs. All stock options and restricted stock awards granted to the Employee that vest over time shall, if the
Employee’s employment is terminated by the Company without Cause in accordance with Section 4(d) or the Employee resigns from the
Company’s employ for Good Reason in accordance with Section 4(e), in each case upon or during the twelve-month period that immediately
follows a Change of Control (as defined in Section 4(h)), become fully vested upon the termination of the Employee’s employment to the extent
permitted by the terms of the applicable plan and subject to the satisfaction by the Employee of the requirements of Section 4(g) of this
Agreement.
(d) Vacation and Fringe Benefits. The Employee shall be entitled to 20 days’ paid vacation, plus an additional two
floating holidays and two personal days, as per Company policy to be established. The Employee shall be entitled to participate in all insurance
and other fringe benefit programs of the Company to the extent and on the same terms and conditions as are accorded to other officers and key
employees of the Company.
(e) Reimbursement of Expenses. The Employee shall be reimbursed for all normal items of travel, entertainment and
miscellaneous business expenses reasonably incurred by the Employee on behalf of the Company, provided that such expenses are documented
and submitted in accordance with the reimbursement policies of the Company as in effect from time to time.
4. Termination.
(a) Death. This Agreement shall automatically terminate effective as of the date of the Employee’s death, in which event
the Company shall not have any further obligation or liability under this Agreement except that the Company shall pay to the Employee’s estate:
(i) any portion of the Employee’s Base Salary for the period up to the Employee’s date of death that has been earned but remains unpaid; and
(ii) any benefits that have accrued to the Employee under the terms of the employee benefit plans of the Company, which benefits shall be paid in
accordance with the terms of those plans.
(b) Total Disability. The Company may terminate the employment of the Employee immediately upon written notice to
the Employee in the event of the Disability (as that term is hereinafter defined) of the Employee, in which event, the Company shall not have any
further obligation or liability under this Agreement except that the Company shall pay to the Employee: (i) any portion of the Employee’s Base
Salary for the period up to the date of termination that has been earned but remains unpaid; and (ii) any benefits that have accrued to the Employee
under the terms of the employee benefit plans of the Company, which benefits shall be paid in accordance with the terms of those plans. The term
“Disability,” when used herein, shall mean an illness, incapacity or a mental or physical condition that renders the Employee unable or
incompetent to carry out the job responsibilities that the Employee held or the tasks that the Employee was assigned at the time the disability
commenced, as determined by the Board and supported by the opinion of a physician. The Employee shall fully cooperate with
2
the physician retained to furnish such opinion, including submitting to such examinations and tests as may be requested by the physician.
(c) Termination by the Company for Cause. The Company may terminate the Employee’s employment hereunder
upon written notice to the Employee for any of the following reasons: (i) the Employee’s misuse of alcoholic beverages, controlled substances or
other narcotics, which misuse has had or is reasonably likely to have a material adverse effect on the business or financial affairs of the Company
or the reputation of the Company; (ii) failure by the Employee to cooperate with the Company in any investigation or formal proceeding; (iii) the
commission by the Employee of, or a plea by the Employee of guilty or nolo contendere with respect to, or conviction of the Employee for, a
felony (or any lesser included offense or crime in exchange for withdrawal of a felony indictment or charged crime that might result in a penalty
of incarceration), a crime involving moral turpitude, or any other offense that results in or could result in any prison sentence; (iv) adjudication as
an incompetent; (v) a breach by the Employee of any material term of this Agreement, including the Employee’s failure to faithfully, diligently
and adequately perform the Employee’s duties under this Agreement, that is not corrected within ten days after written notice from the Company,
which notice shall set forth the nature of the breach; (vi) violation in any material respect of any of the Company’s rules, regulations or policies;
(vii) gross insubordination by the Employee in the performance of the Employee’s duties under this Agreement; (viii) engaging in any conduct,
action or behavior that, in the reasonable opinion of the Board, has had a material adverse effect on the reputation of the Company or the
Employee; (ix) any continued or repeated absence from the Company, unless the absence is approved or excused by the Board or the result of the
Employee’s illness, disability or incapacity (in which event the provisions of Section 4(b) hereof shall control); or (x) misappropriation of any
funds or property of the Company, theft, embezzlement or fraud. In the event that the Company shall discharge the Employee pursuant to this
Section 4(c), the Company shall not have any further obligation or liability under this Agreement, except that the Company shall pay to the
Employee: (i) any portion of the Employee’s Base Salary for the period up to the date of termination that has been earned but remains unpaid; and
(ii) any benefits that have accrued to the Employee under the terms of the employee benefit plans of the Company, which benefits shall be paid in
accordance with the terms of those plans.
(d) Other Termination by the Company. The Company may terminate the employment of the Employee for any
reason other than one specified in Section 4(b) or 4(c) hereof immediately upon written notice to the Employee, in which event the Employee shall
be entitled to receive: (i) any portion of the Employee’s Base Salary for the period up to the date of termination that has been earned but remains
unpaid; (ii) any benefits that have accrued to the Employee under the terms of any employee benefit plans of the Company, which benefits shall
be paid in accordance with the terms of those plans; and (iii) subject to the satisfaction of the provisions of Section 4(g) and the compliance by the
Employee with all terms and provisions of this Agreement that survive the termination of the Employee’s employment by the Company, (A) the
Employee’s Base Salary for a period of twelve months, less applicable taxes and withholdings, payable in accordance with the Company’s regular
payroll practices, with an accelerated payment of any balance upon the occurrence of a Change in Control; provided, however, that if such
termination of employment shall occur within three months before or within twelve months after the occurrence of a Change in Control (such
period being referred to herein as the “Change in Control Period”), the severance payable to the Employee shall be
3
increased to an amount equal to the Employee’s Base Salary for a period of 24 months and be payable in a single lump sum payment, less
applicable taxes and withholdings; (B) payment or reimbursement (upon presentation of proof of payment) of the Employee’s medical insurance
premiums at the same level as was in effect on the termination date for a period of twelve months, which period shall increase to 24 months if
such termination of employment shall occur within the Change in Control Period; and (C) if such termination of employment shall occur within
the Change in Control Period, an amount equal to the Employee’s Target Bonus for the year in which such employment termination shall occur,
prorated based on the relative number of days in such year during which the Employee was employed by the Company and/or its successor in the
Change in Control, payable in a single lump sum payment, less applicable taxes and withholdings. Any severance payments and lump sum
payments due hereunder shall commence as soon as administratively feasible within 60 days after the date of the Employee’s termination of
employment provided the Employee has timely executed and returned the Release referred to in Section 4(g) and, if a revocation period is
applicable, the Employee has not revoked the Release; provided, however, that if the 60-day period begins in one calendar year and ends in a
second calendar year, the severance payments shall begin to be paid in the second calendar year. On the date that severance payments commence,
the Company will pay the Employee in a single lump sum payment, less applicable taxes and withholding, the severance payments that the
Employee would have received on or prior to such date but for the delay imposed by the immediately preceding sentence, with the balance of the
severance payments to be paid as originally scheduled.
(e) Termination by the Employee for Good Reason. The Employee may terminate the Employee’s employment by
providing written notice to the Company of a breach constituting Good Reason. “Good Reason” shall be deemed to exist with respect to any
termination of employment by the Employee for any of the following reasons: (i) a reassignment of the Employee to a location outside the
Greater Philadelphia area; (ii) any material failure by the Company to comply with any material term of this Agreement; (iii) the demotion of the
Employee to a lesser position than described in Section 1 hereof or a substantial diminution of the Employee’s authority, duties or responsibilities
as in effect on the date of this Agreement or as hereafter increased; or (iv) a material diminution of the Executive’s Base Salary and benefits, in
the aggregate, unless such reduction is part of a Company-wide reduction in compensation and/or benefits for all of its senior executives. If the
Employee shall terminate the Employee’s employment hereunder for Good Reason, the Employee shall be entitled to receive the same payments
and benefits on the same terms and conditions as would be applicable upon a termination of the Employee’s employment by the Company without
Cause, as provided in Section 4(d) and subject to the satisfaction of the other provisions of this Section 4(e). The Employee may not resign with
Good Reason pursuant to this Section 4(e), and shall not be considered to have done so for any purpose of this Agreement, unless (A) the
Employee, within 60 days after the initial existence of the act or failure to act by the Company that constitutes “Good Reason” within the meaning
of this Agreement, provides the Company with written notice that describes, in particular detail, the act or failure to act that the Employee believes
to constitute “Good Reason” and identifies the particular clause of this Section 4(e) that the Employee contends is applicable to such act or failure
to act; (B) the Company, within 30 days after its receipt of such notice, fails or refuses to rescind such act or remedy such failure to act so as to
eliminate “Good Reason” for the termination by the Employee of the Employee’s employment relationship with the Company, and (C) the
Employee actually resigns from the
4
employ of the Company on or before that date that is six calendar months after the initial existence of the act or failure to act by the Company that
constitutes “Good Reason.” If the requirements of the preceding sentence are not fully satisfied on a timely basis, then the resignation by the
Employee from the employ of the Company shall not be deemed to have been for “Good Reason,” the Employee shall not be entitled to any of the
benefits to which the Employee would have been entitled if the Employee had resigned from the employ of the Company for “Good Reason,” and
the Company shall not be required to pay any amount or provide any benefit that would otherwise have been due to the Employee under this
Section 4(e) had the Employee resigned with “Good Reason.”
(f) Other Termination by the Employee. The Employee may terminate the Employee’s employment for any reason
other than one specified in Section 4(e) upon at least 30 days’ prior written notice to the Company, which notice shall specify the effective date of
the termination. In the event the Employee shall terminate the Employee’s employment pursuant to this Section 4(f), the Company shall not have
any further obligation or liability under this Agreement, except that the Company shall pay to the Employee: (i) any portion of the Employee’s
Base Salary for the period up to the date of termination that has been earned but remains unpaid; and (ii) any benefits that have accrued to the
Employee under the terms of the employee benefit plans of the Company, which benefits shall be paid in accordance with the terms of those plans.
(g) Execution of Release. The Employee shall not be entitled to any payments or benefits under Sections 4(d) or 4
(e) unless the Employee executes and does not revoke a Release and Agreement (the “Release”), as drafted at the time of the Employee’s
termination of employment, including, but not limited to:
(i) an unconditional release of all rights to any claims, charges, complaints, grievances, known or unknown to
the Employee, against the Company, its affiliates or assigns, through the date of the Employee’s termination from employment other than post-
termination payments and benefits pursuant to this Agreement;
grievances against the Company, its affiliates, or assigns;
(ii) a representation and warranty that the Employee has not filed or assigned any claims, charges, complaints, or
to return any such confidential information and property to the Company upon execution of the Release;
(iii) an agreement not to use, disclose or make copies of any confidential information of the Company, as well as
of employment;
(iv) a mutual agreement to maintain the confidentiality of the Release or disclose the reasons for any termination
(v) an agreement not to disparage the Company or its officers, directors, stockholders, products or business; and
any portion of this Agreement or the Release.
(vi) an agreement to indemnify the Company, or its affiliates or assigns, in the event that the Employee breaches
5
Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Employee’s execution of the Release, directly
or indirectly, result in the Employee designating the calendar year of payment, and if a payment that is subject to execution of the Release could
be made in more than one taxable year, payment shall be made in the later taxable year.
(h) Definition of Change in Control. As used in this Agreement, the term “Change in Control” means:
(i) any merger or consolidation in which voting securities of the Company possessing more than 50% of the total
combined voting power of the Company’s outstanding securities are transferred to a person or persons different from the person holding those
securities immediately prior to such transaction and the composition of the Board following such transaction is such that the directors of the
Company prior to the transaction constitute less than 50% of the Board membership following the transaction;
(ii) any acquisition, directly or indirectly, by a person or related group of persons (other than the Company or a
person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership of voting
securities of the Company possessing more than 50% of the total combined voting power of the Company’s outstanding securities; provided,
however, that, no Change in Control shall be deemed to occur by reason of the acquisition of shares of the Company’s capital stock by an investor
or group of investors in the Company in a capital-raising transaction; or
the Company; or
(iii) any sale, transfer, exclusive worldwide license or other disposition of all or substantially all of the assets of
(iv) within any 24-month period beginning on or after the date hereof, the persons who were directors of the
Company immediately before the beginning of such period (the “Incumbent Directors”) shall cease (for any reason other than death) to constitute
at least a majority of the Board of Directors of the Company or the board of directors of any successor to the Company, provided that any director
who was not a director as of the date hereof shall be deemed to be an Incumbent Director if such director was elected to the Board by, or on the
recommendation of or with the approval of, at least two-thirds of the directors who then qualified as Incumbent Directors either actually or by
prior operation of this Section 4(h)(iv), unless such election, recommendation or approval was the result of an actual or threatened contested
election of directors pursuant to Regulation 14A under the Securities Exchange Act of 1934 or any successor provision.
(i) Base Salary Continuation. The Base Salary continuation set forth in Sections 4(d) and (e) above shall be intended
either (i) to satisfy the safe harbor set forth in the regulations issued under section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”) (Treas. Regs. 1.409A-1(n)(2)(ii)) or (ii) be treated as a Short-term Deferral as that term is defined under Code section 409A (Treas. Regs.
1.409A-1(b)(4)). To the extent such continuation payments exceed the applicable safe harbor amount or do not constitute a Short-term Deferral,
the excess amount shall be treated as deferred compensation under Code section 409A and as such shall be payable pursuant to the following
schedule: such excess amount shall
6
be paid via standard payroll in periodic installments in accordance with the Company’s usual practice for its senior executives. Solely for
purposes of Code section 409A, each installment payment is considered a separate payment. Notwithstanding any provision in this Agreement to
the contrary, in the event that the Employee is a “specified employee” as defined in Section 409A, any continuation payment, continuation
benefits or other amounts payable under this Agreement that would be subject to the special rule regarding payments to “specified employees”
under Section 409A(a)(2)(B) of the Code shall not be paid before the expiration of a period of six months following the date of the Employee’s
termination of employment or before the date of the Employee’s death, if earlier.
(j) Parachute Provisions. Notwithstanding any provisions of this Agreement to the contrary:
(i) If any of the payments or benefits received or to be received by the Employee in connection with the
Employee’s termination of employment in respect of a Change in Control, whether pursuant to the terms of this Agreement or any other plan,
arrangement or agreement with the Company (all such payments and benefits, being hereinafter referred to as the “Total Payments”), would be
subject to the excise tax (the “Excise Tax”) imposed under Section 4999 of the Code, the Employee shall receive the Total Payments and be
responsible for the Excise Tax; provided, however that the Employee shall not receive the Total Payments and the Total Payments shall be
reduced to the Safe Harbor Amount (defined below) if (A) the net amount of such Total Payments, as so reduced to the Safe Harbor Amount (and
after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments) is greater than or equal to (B) the net
amount of such Total Payment without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total
Payments and the amount of Excise Tax to which the Employee would be subject in respect of such unreduced Total Payments). The “Safe
Harbor Amount” is the amount to which the Total Payments would hypothetically have to be reduced so that no portion of the Total Payments
would be subject to the Excise Tax.
(ii) For purposes of determining whether any of the Total Payments will be subject to the Excise Tax and the
amount of such Excise Tax, (A) all of the Total Payments shall be treated as “parachute payments” (within the meaning of Section 280G(b)(2) of
the Code) unless, in the opinion of tax counsel (“Tax Counsel”) selected by the accounting firm that was, immediately prior to the Change in
Control, the Company’s independent auditor (the “Auditor”), such payments or benefits (in whole or in part) do not constitute parachute
payments, including by reason of Section 280G(b)(4)(A) of the Code, (B) all “excess parachute payments” within the meaning of Section 280G(b)
(1) of the Code shall be treated as subject to the Excise Tax unless, in the opinion of Tax Counsel, such excess parachute payments (in whole or in
part) represent reasonable compensation for services actually rendered (within the meaning of Section 280G(b)(4)(B) of the Code) in excess of the
base amount (within the meaning of Section 280G(b)(3) of the Code) allocable to such reasonable compensation, or are otherwise not subject to
the Excise Tax, and (C) the value of any noncash benefits or any deferred payment or benefit shall be determined by the Auditor in accordance
with the principles of Sections 280G(d)(3) and (4) of the Code. If the Auditor is prohibited by applicable law or regulation from performing the
duties assigned to it hereunder, then a different auditor, acceptable to both the Company and
7
Employee, shall be selected. The fees and expenses of Tax Counsel and the Auditor shall be paid by the Company.
(iii) In the event it is determined that the Safe Harbor Amount is payable to Employee, then the severance
payments provided under this Agreement that are cash shall first be reduced on a pro rata basis, and the non-cash severance payments shall
thereafter be reduced on a pro rata basis, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax.
5. Non-Disclosure and Non-Competition.
(a) Non-Disclosure. The Employee acknowledges that in the course of performing services for the Company, the
Employee will obtain knowledge of the Company’s business plans, products, processes, software, know-how, trade secrets, formulas, methods,
models, prototypes, discoveries, inventions, improvements, disclosures, names and positions of employees and/or other proprietary and/or
confidential information (collectively the “Confidential Information”). The Employee agrees to keep the Confidential Information secret and
confidential and not to publish, disclose or divulge to any other party, and the Employee agrees not to use any of the Confidential Information for
the Employee’s own benefit or to the detriment of the Company without the prior written consent of the Company, whether or not such
Confidential Information was discovered or developed by the Employee. The Employee also agrees not to divulge, publish or use any proprietary
and/or confidential information of others that the Company is obligated to maintain in confidence.
(b) Non-Competition. The Employee agrees that, during the Employee’s employment by the Company hereunder and
for an additional period of one year after the termination of the Employee’s employment hereunder, neither the Employee nor any corporation or
other entity in which the Employee may be interested as a partner, trustee, director, officer, employee, agent, shareholder, lender of money or
guarantor, or for which the Employee performs services in any capacity (including as a consultant or independent contractor) shall at any time
during such period (i) be engaged, directly or indirectly, in any Competitive Business (as that term is hereinafter defined) or (ii) solicit, hire,
contract for services or otherwise employ, directly or indirectly, any of the employees of the Company. For purposes of this Section 5(b) the term
“Competitive Business” shall mean any firm or business organization that competes with the Company in the development and/or
commercialization of drugs that prevent or treat partial complex seizures, post-traumatic stress disorder or fragile-x syndrome or any other
Ganaxolone-related technology, product or service being developed, manufactured, marketed, distributed or planned in writing by the Company at
the time of termination of the Employee’s employment with the Company. The foregoing prohibition shall not prevent any employment or
engagement of the Employee, after termination of employment with the Company, by any company or business organization not substantially
engaged in a Competitive Business as long as the activities of any such employment or engagement, in any capacity, do not involve work on
matters related to any product or service being developed, manufactured, marketed, distributed or planned in writing by the Company at the time
of termination of Employee’s employment with the Company. The Employee’s ownership of no more than 5% of the outstanding voting stock of
a publicly traded company shall not constitute a violation of this Section 5(b). The Employee is entering into this covenant not to compete to
continue the Employee’s undertaking
8
in the Prior Agreement and in consideration of the additional agreements of the Company in this Agreement, including but not limited to the rights
of the Employee set forth in Sections 4(d) and 4(e).
6. Inventions and Discoveries.
(a) Disclosure. The Employee shall promptly and fully disclose to the Company, with all necessary detail, all
developments, know-how, discoveries, inventions, improvements, concepts, ideas, formulae, processes and methods (whether copyrightable,
patentable or otherwise) made, received, conceived, acquired or written by the Employee (whether or not at the request or upon the suggestion of
the Company, solely or jointly with others), during the period of the Employee’s employment with the Company that (i) result from, arise out of,
or relate to any work, assignment or task performed by the Employee on behalf of the Company, whether undertaken voluntarily or assigned to the
Employee within the scope of the Employee’s responsibilities to the Company, or (ii) were developed using the Company’s facilities or other
resources or in Company time, or (iii) result from the Employee’s use or knowledge of the Company’s Confidential Information, or (iv) relate to
the Company’s business or any of the products or services being developed, manufactured or sold by the Company or that may be used in relation
therewith (collectively referred to as “Inventions”). The Employee hereby acknowledges that all original works of authorship that are made by the
Employee (solely or jointly with others) within the above terms and that are protectable by copyright are “works made for hire,” as that term is
defined in the United States Copyright Act. The Employee understands and hereby agrees that the decision whether or not to commercialize or
market any Invention developed by the Employee solely or jointly with others is within the Company’s sole discretion and for the Company’s sole
benefit and that no royalty shall be due to the Employee as a result of the Company’s efforts to commercialize or market any such Invention.
(b) Assignment and Transfer. The Employee agrees to assign and transfer to the Company all of the Employee’s right,
title and interest in and to the Inventions, and the Employee further agrees to deliver to the Company any and all drawings, notes, specifications
and data relating to the Inventions, and to sign, acknowledge and deliver all such further papers, including applications for and assignments of
copyrights and patents, and all renewals thereof, as may be necessary to obtain copyrights and patents for any Inventions in any and all countries
and to vest title thereto in the Company and its successors and assigns and to otherwise protect the Company’s interests therein. The Employee
shall not charge the Company for time spent in complying with these obligations. If the Company is unable because of the Employee’s mental or
physical incapacity or for any other reason to secure the Employee’s signature to apply for or to pursue any application for any United States or
foreign patents or copyright registrations covering Inventions or original works of authorship assigned to the Company as above, then the
Employee hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as the Employee’s agent and
attorney in fact, to act for and in the Employee’s behalf and stead to execute and file any such applications and to do all other lawfully permitted
acts to further the prosecution and issuance of letters patent or copyright registrations thereon with the same legal force and effect as if executed
by the Employee.
the Company, the Employee will maintain careful,
(c) Records. The Employee agrees that in connection with any research, development or other services performed for
9
adequate and contemporaneous written records of all Inventions, which records shall be the property of the Company.
7. Company Documentation. The Employee shall hold in a fiduciary capacity for the benefit of the Company all
documentation, disks, programs, data, records, drawings, manuals, reports, sketches, blueprints, letters, notes, notebooks and all other writings,
electronic data, graphics and tangible information and materials of a secret, confidential or proprietary information nature relating to the Company
or the Company’s business that are in the possession or under the control of the Employee.
8. Injunctive Relief. The Employee acknowledges that the Employee’s compliance with the agreements in Sections 5, 6 and 7
hereof is necessary to protect the good will and other proprietary interests of the Company and that the Employee is one of the principal
executives of the Company and conversant with its affairs, its trade secrets and other proprietary information. The Employee acknowledges that a
breach of any of the Employee’s agreements in Sections 5, 6 and 7 hereof will result in irreparable and continuing damage to the Company for
which there will be no adequate remedy at law; and the Employee agrees that in the event of any breach of the aforesaid agreements, the Company
and its successors and assigns shall be entitled to injunctive relief and to such other and further relief as may be proper.
9. Full Agreement. This Agreement amends, restates and supersedes the Prior Agreement and all other consulting and
employment arrangements between the Employee and the Company, but shall not supersede any existing confidentiality, nondisclosure, invention
assignment or non-compete agreement between the Employee and the Company. Except as set forth in the preceding sentence, this Agreement
constitutes the entire agreement of the parties concerning its subject matter and supersedes all other oral or written understandings, discussions,
and agreements, and may be modified only in a writing signed by both parties. The parties acknowledge that they have read and fully understand
the contents of this Agreement and execute it after having an opportunity to consult with legal counsel.
10. Amendments. Any amendment to this Agreement shall be made in writing and signed by the parties hereto.
11. Enforceability. If any provision of this Agreement shall be invalid or unenforceable, in whole or in part, then such provision
shall be deemed to be modified or restricted to the extent and in the manner necessary to render the same valid and enforceable, or shall be
deemed excised from this Agreement, as the case may require, and this Agreement shall be construed and enforced to the maximum extent
permitted by law as if such provision had been originally incorporated herein as so modified or restricted or as if such provision had not been
originally incorporated herein, as the case may be.
12. Construction. This Agreement shall be construed and interpreted in accordance with the internal laws of the Commonwealth
of Pennsylvania.
13. Assignment.
shall be binding upon, the successors and assigns of
(a) By the Company. The rights and obligations of the Company under this Agreement shall inure to the benefit of, and
10
the Company. This Agreement may be assigned by the Company without the consent of the Employee.
(b) By the Employee. This Agreement and the obligations created hereunder may not be assigned by the Employee, but
all rights of the Employee hereunder shall inure to the benefit of and be enforceable by the Employee’s heirs, devisees, legatees, executors,
administrators and personal representatives.
14. Notices. All notices required or permitted to be given hereunder shall be in writing and shall be deemed to have been given
when mailed by certified mail, return receipt requested, or delivered by a national overnight delivery service addressed to the intended recipient as
follows:
If to the Company:
Marinus Pharmaceuticals, Inc.
Three Radnor Corporate Center
100 Matsonford Road, Suite 304
Radnor, PA 19087
Attention: Chairman of the Board
If to the Employee:
Christopher M. Cashman
1502 East Grand Oak Lane
West Chester, PA 19380
Any party may from time to time change its address for the purpose of notices to that party by a similar notice specifying a new address, but no
such change shall be deemed to have been given until it is actually received by the party sought to be charged with its contents.
15. Waivers. No claim or right arising out of a breach or default under this Agreement shall be discharged in whole or in part by a
waiver of that claim or right unless the waiver is supported by consideration and is in writing and executed by the aggrieved party hereto or such
party’s duly authorized agent. A waiver by any party hereto of a breach or default by the other party hereto of any provision of this Agreement
shall not be deemed a waiver of future compliance therewith, and such provisions shall remain in full force and effect.
16. Section 409A. It is intended that this Agreement be drafted and administered in compliance with section 409A of the Code,
including, but not limited to, any future amendments to Code section 409A, and any other Internal Revenue Service or other governmental rulings
or interpretations (together, “Section 409A”) issued pursuant to Section 409A so as not to subject the Employee to payment of interest or any
additional tax under Code section 409A. The parties intend for any payments under this Agreement to either satisfy the requirements of
Section 409A or to be exempt from the application of Section 409A, and this Agreement shall be construed and interpreted accordingly. In
furtherance thereof, if payment or provision of any amount or benefit hereunder that is subject to Section 409A at the time specified herein would
subject such amount
11
or benefit to any additional tax under Section 409A, the payment or provision of such amount or benefit shall be postponed to the earliest
commencement date on which the payment or provision of such amount or benefit could be made without incurring such additional tax. In
addition, to the extent that any Internal Revenue Service guidance issued under Section 409A would result in the Employee being subject to the
payment of interest or any additional tax under Section 409A, the parties agree, to the extent reasonably possible, to amend this Agreement in
order to avoid the imposition of any such interest or additional tax under Section 409A, which amendment shall have the minimum economic
effect necessary and be reasonably determined in good faith by the Company and the Employee.
17. Survival of Covenants. The provisions of Sections 4, 5, 6, 7 and 8 hereof shall survive the termination of this Agreement.
Furthermore, each other provision of this Agreement that, by its terms, is intended to continue beyond the termination of the Employee’s
employment shall continue in effect thereafter.
(Signature page follows.)
12
IN WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first above written.
MARINUS PHARMACEUTICALS, INC.
By:
/s/ Jay P. Shepard
Title: Chairman, Compensation Committee
Christopher M. Cashman
/s/ Christopher M. Cashman
13
AMENDED AND RESTATED
EMPLOYMENT AGREEMENT
EXHIBIT 10.4
EMPLOYMENT AGREEMENT effective as of March 11, 2015 between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware
corporation, and Edward F. Smith (the “Employee”).
Recital:
The Employee has been employed by the Company pursuant to an Employment Agreement dated as of November 2, 2012 (the “Prior
Agreement”). The parties desire to enter into this Agreement to amend and restate the Prior Agreement so as to provide for the continued
employment of the Employee by the Company and for certain other matters in connection with such employment, all as set forth more fully in this
Agreement.
NOW, THEREFORE, in consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the
parties to this Agreement hereby agree as follows:
1. Duties. The Company agrees that the Employee shall be employed by the Company to serve as Chief Financial Officer of the
Company. The Employee shall report to the Chief Executive Officer of the Company (the “CEO”). The Employee agrees to be so employed by
the Company and to devote his best efforts to advance the interests of the Company and to perform the duties customarily incident to the position
of Chief Financial Officer and such other duties assigned to the Employee by the CEO, provided such other duties are commensurate with the
Employee’s employment level at the Company. Notwithstanding anything in this Agreement to the contrary, the Employee shall be permitted to
serve of the board of directors (or equivalent governing bodies) of one company that is unrelated to, and not competitive with the business of, the
Company, provided such service does not materially interfere with the Employee’s duties and responsibilities to the Company. Participation on
more than one board shall be subject to the approval by the CEO.
2. Term. The Employee’s employment under this Agreement shall continue in effect until terminated pursuant to Section 4 of
this Agreement.
3. Compensation.
(a) Salary. During the term of the Employee’s employment under this Agreement, the Employee shall be paid an annual
salary at the rate of not less than $350,000 (the “Base Salary”). The Base Salary may be increased from time to time by the Board of Directors
(the “Board”). The Board shall review the Base Salary at least annually at the end of each fiscal year of the Company. The Base Salary shall be
paid in accordance with the Company’s regular payroll practices.
(b) Annual Bonus. At the end of each fiscal year of the Company that ends during the term of this Agreement, the
Board shall consider the award of a performance bonus to the Employee for such fiscal year in an amount of up to 35% of the Employee’s Base
Salary (the
“Target Bonus”) based upon the achievement of performance objectives established annually by the Board or its Compensation Committee.
Whether the performance objectives for any year have been achieved by the Employee shall be determined by the Board or its Compensation
Committee. Notwithstanding the foregoing, all bonuses shall be paid within two and one-half months after the close of each year.
(c) Equity Incentive Programs. The Employee shall be eligible to participate in equity incentive programs established
by the Company from time to time to provide stock options and other equity-based incentives to key employees of the Company in accordance
with the terms of those programs. All stock options and restricted stock awards granted to the Employee that vest over time shall, if the
Employee’s employment is terminated by the Company without Cause in accordance with Section 4(d) or the Employee resigns from the
Company’s employ for Good Reason in accordance with Section 4(e), in each case upon or during the twelve-month period that immediately
follows a Change in Control (as defined in Section 4(h)), become fully vested upon the termination of the Employee’s employment to the extent
permitted by the terms of the applicable plan and subject to the satisfaction by the Employee of the requirements of Section 4(g) of this
Agreement.
(d) Vacation and Fringe Benefits. The Employee shall be entitled to 20 days’ paid vacation, plus an additional two
floating holidays and two personal days, as per Company policy to be established. The Employee shall be entitled to participate in all insurance
and other fringe benefit programs of the Company to the extent and on the same terms and conditions as are accorded to other officers and key
employees of the Company.
(e) Reimbursement of Expenses. The Employee shall be reimbursed for all normal items of travel, entertainment and
miscellaneous business expenses reasonably incurred by the Employee on behalf of the Company, provided that such expenses are documented
and submitted in accordance with the reimbursement policies of the Company as in effect from time to time.
4. Termination.
(a) Death. This Agreement shall automatically terminate effective as of the date of the Employee’s death, in which event
the Company shall not have any further obligation or liability under this Agreement except that the Company shall pay to the Employee’s estate:
(i) any portion of the Employee’s Base Salary for the period up to the Employee’s date of death that has been earned but remains unpaid; and
(ii) any benefits that have accrued to the Employee under the terms of the employee benefit plans of the Company, which benefits shall be paid in
accordance with the terms of those plans.
(b) Total Disability. The Company may terminate the employment of the Employee immediately upon written notice to
the Employee in the event of the Disability (as that term is hereinafter defined) of the Employee, in which event, the Company shall not have any
further obligation or liability under this Agreement except that the Company shall pay to the Employee: (i) any portion of the Employee’s Base
Salary for the period up to the date of termination that has been earned but remains unpaid; and (ii) any benefits that have accrued to the Employee
under the terms of the employee benefit plans of the Company, which benefits
2
shall be paid in accordance with the terms of those plans. For purposes of this Agreement, the term “Disability” shall mean an illness, incapacity
or a mental or physical condition that renders the Employee unable or incompetent to carry out the job responsibilities that the Employee held or
the tasks that the Employee was assigned at the time the disability commenced, as determined by the Board and supported by the opinion of a
physician. The Employee shall fully cooperate with the physician retained to furnish such opinion, including submitting to such examinations and
tests as may be requested by the physician.
(c) Termination by the Company for Cause. The Company may terminate the Employee’s employment hereunder
upon written notice to the Employee for any of the following reasons: (i) the Employee’s misuse of alcoholic beverages, controlled substances or
other narcotics, which misuse has had or is reasonably likely to have a material adverse effect on the business or financial affairs of the Company
or the reputation of the Company; (ii) failure by the Employee to cooperate with the Company in any investigation or formal proceeding; (iii) the
commission by the Employee of, or a plea by the Employee of guilty or nolo contendere with respect to, or conviction of the Employee for, a
felony (or any lesser included offense or crime in exchange for withdrawal of a felony indictment or charged crime that might result in a penalty
of incarceration), a crime involving moral turpitude, or any other offense that results in or could result in any prison sentence; (iv) adjudication as
an incompetent; (v) a breach by the Employee of any material term of this Agreement, including the Employee’s failure to faithfully, diligently
and adequately perform the Employee’s duties under this Agreement, that is not corrected within ten days after written notice from the Company,
which notice shall set forth the nature of the breach; (vi) violation in any material respect of any of the Company’s rules, regulations or policies;
(vii) gross insubordination by the Employee in the performance of the Employee’s duties under this Agreement; (viii) engaging in any conduct,
action or behavior that, in the reasonable opinion of the Company, has had a material adverse effect on the reputation of the Company or the
Employee; (ix) any continued or repeated absence from the Company, unless the absence is approved or excused by the CEO or the result of the
Employee’s illness, disability or incapacity (in which event the provisions of Section 4(b) hereof shall control); or (x) misappropriation of any
funds or property of the Company, theft, embezzlement or fraud. For the avoidance of doubt, “Cause” shall not mean a failure to achieve
scientific goals, financial goals or forecasted timelines. In the event that the Company shall discharge the Employee pursuant to this Section 4(c),
the Company shall not have any further obligation or liability under this Agreement, except that the Company shall pay to the Employee: (i) any
portion of the Employee’s Base Salary for the period up to the date of termination that has been earned but remains unpaid; and (ii) any benefits
that have accrued to the Employee under the terms of the employee benefit plans of the Company, which benefits shall be paid in accordance with
the terms of those plans.
(d) Other Termination by the Company. The Company may terminate the employment of the Employee for any
reason other than one specified in Section 4(b) or 4(c) hereof immediately upon written notice to the Employee, in which event the Employee shall
be entitled to receive: (i) any portion of the Employee’s Base Salary for the period up to the date of termination that has been earned but remains
unpaid; (ii) any benefits that have accrued to the Employee under the terms of any employee benefit plans of the Company, which benefits shall
be paid in accordance with the terms of those plans; and (iii) subject to the satisfaction of the provisions of Section 4(g) and the compliance by the
Employee with all terms and provisions of
3
this Agreement that survive the termination of the Employee’s employment by the Company, (A) the Employee’s Base Salary for a period of nine
months, less applicable taxes and withholdings, payable in accordance with the Company’s regular payroll practices, with an accelerated payment
of any balance upon the occurrence of a Change in Control; provided, however, that if such termination of employment shall occur within three
months before or within twelve months after the occurrence of a Change in Control (such period being referred to herein as the “Change of
Control Period”), the severance payable to the Employee shall be increased to an amount equal to the Employee’s Base Salary for a period of
eighteen months and be payable in a single lump sum payment, less applicable taxes and withholdings; (B) payment or reimbursement (upon
presentation of proof of payment) of the Employee’s medical insurance premiums at the same level as was in effect on the termination date for a
period of nine months, which period shall increase to eighteen months if such termination of employment shall occur within the Change in Control
Period; and (C) if such termination shall occur within the Change in Control Period, an amount equal to the Employee’s Target Bonus for the year
in which such employment termination shall occur prorated based on the relative number of days in such year during which the Employee was
employed by the Company and/or its successor in the Change in Control, payable in a single lump sum payment, less applicable taxes and
withholdings. Any severance payments and lump sum payments due hereunder shall commence as soon as administratively feasible within 60
days after the date of the Employee’s termination of employment provided the Employee has timely executed and returned the Release referred to
in Section 4(g) and, if a revocation period is applicable, the Employee has not revoked the Release; provided, however, that if the 60-day period
begins in one calendar year and ends in a second calendar year, the severance payments shall begin to be paid in the second calendar year. On the
date that severance payments commence, the Company will pay the Employee in a single lump sum payment, less applicable taxes and
withholding, the severance payments that the Employee would have received on or prior to such date but for the delay imposed by the
immediately preceding sentence, with the balance of the severance payments to be paid as originally scheduled.
(e) Termination by the Employee for Good Reason. The Employee may terminate the Employee’s employment by
providing written notice to the Company of a breach constituting Good Reason. “Good Reason” shall be deemed to exist with respect to any
termination of employment by the Employee for any of the following reasons: (i) a reassignment of the Employee to a location outside the
Greater Philadelphia area; (ii) any material failure by the Company to comply with any material term of this Agreement; (iii) the demotion of the
Employee to a lesser position than described in Section 1 hereof or a substantial diminution of the Employee’s authority, duties or responsibilities
as in effect on the date of this Agreement or as hereafter increased; or (iv) a material diminution of the Executive’s Base Salary and benefits, in
the aggregate, unless such reduction is part of a Company-wide reduction in compensation and/or benefits for all of its senior executives. If the
Employee shall terminate the Employee’s employment hereunder for Good Reason, the Employee shall be entitled to receive the same payments
and benefits on the same terms and conditions as would be applicable upon a termination of the Employee’s employment by the Company without
Cause, as provided in Section 4(d) and subject to the satisfaction of the other provisions of this Section 4(e). The Employee may not resign with
Good Reason pursuant to this Section 4(e), and shall not be considered to have done so for any purpose of this Agreement, unless (A) the
Employee, within 60 days after the initial existence of the act or failure to act by the Company that constitutes
4
“Good Reason” within the meaning of this Agreement, provides the Company with written notice that describes, in particular detail, the act or
failure to act that the Employee believes to constitute “Good Reason” and identifies the particular clause of this Section 4(e) that the Employee
contends is applicable to such act or failure to act; (B) the Company, within 30 days after its receipt of such notice, fails or refuses to rescind such
act or remedy such failure to act so as to eliminate “Good Reason” for the termination by the Employee of the Employee’s employment
relationship with the Company, and (C) the Employee actually resigns from the employ of the Company on or before that date that is six calendar
months after the initial existence of the act or failure to act by the Company that constitutes “Good Reason.” If the requirements of the preceding
sentence are not fully satisfied on a timely basis, then the resignation by the Employee from the employ of the Company shall not be deemed to
have been for “Good Reason,” the Employee shall not be entitled to any of the benefits to which the Employee would have been entitled if the
Employee had resigned from the employ of the Company for “Good Reason,” and the Company shall not be required to pay any amount or
provide any benefit that would otherwise have been due to the Employee under this Section 4(e) had the Employee resigned with “Good Reason.”
(f) Other Termination by the Employee. The Employee may terminate the Employee’s employment for any reason
other than one specified in Section 4(e) upon at least 30 days’ prior written notice to the Company, which notice shall specify the effective date of
the termination. In the event the Employee shall terminate the Employee’s employment pursuant to this Section 4(f), the Company shall not have
any further obligation or liability under this Agreement, except that the Company shall pay to the Employee: (i) any portion of the Employee’s
Base Salary for the period up to the date of termination that has been earned but remains unpaid; and (ii) any benefits that have accrued to the
Employee under the terms of the employee benefit plans of the Company, which benefits shall be paid in accordance with the terms of those plans.
(g) Execution of Release. The Employee shall not be entitled to any payments or benefits under Sections 4(d) or 4
(e) unless the Employee executes and does not revoke a Release and Agreement (the “Release”), as drafted at the time of the Employee’s
termination of employment, including, but not limited to:
(i) an unconditional release of all rights to any claims, charges, complaints, grievances, known or unknown to
the Employee, against the Company, its affiliates or assigns, through the date of the Employee’s termination from employment other than post-
termination payments and benefits pursuant to this Agreement;
grievances against the Company, its affiliates, or assigns;
(ii) a representation and warranty that the Employee has not filed or assigned any claims, charges, complaints, or
to return any such confidential information and property to the Company upon execution of the Release;
(iii) an agreement not to use, disclose or make copies of any confidential information of the Company, as well as
5
of employment;
(iv) a mutual agreement to maintain the confidentiality of the Release or disclose the reasons for any termination
(v) an agreement not to disparage the Company or its officers, directors, stockholders, products or business; and
any portion of this Agreement or the Release.
(vi) an agreement to indemnify the Company, or its affiliates or assigns, in the event that the Employee breaches
Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Employee’s execution of the Release, directly
or indirectly, result in the Employee designating the calendar year of payment, and if a payment that is subject to execution of the Release could
be made in more than one taxable year, payment shall be made in the later taxable year.
(h) Definition of Change in Control. As used in this Agreement, the term “Change in Control” means:
(i) any merger or consolidation in which voting securities of the Company possessing more than 50% of the total
combined voting power of the Company’s outstanding securities are transferred to a person or persons different from the person holding those
securities immediately prior to such transaction and the composition of the Board following such transaction is such that the directors of the
Company prior to the transaction constitute less than 50% of the Board membership following the transaction;
(ii) any acquisition, directly or indirectly, by a person or related group of persons (other than the Company or a
person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership of voting
securities of the Company possessing more than 50% of the total combined voting power of the Company’s outstanding securities; provided,
however, that, no Change in Control shall be deemed to occur by reason of the acquisition of shares of the Company’s capital stock by an investor
or group of investors in the Company in a capital-raising transaction; or
the Company; or
(iii) any sale, transfer, exclusive worldwide license or other disposition of all or substantially all of the assets of
(iv) within any 24-month period beginning on or after the date hereof, the persons who were directors of the
Company immediately before the beginning of such period (the “Incumbent Directors”) shall cease (for any reason other than death) to constitute
at least a majority of the Board of Directors of the Company or the board of directors of any successor to the Company, provided that any director
who was not a director as of the date hereof shall be deemed to be an Incumbent Director if such director was elected to the Board by, or on the
recommendation of or with the approval of, at least two-thirds of the directors who then qualified as Incumbent Directors either actually or by
prior operation of this Section 4(h)(iv), unless such election, recommendation or approval was the result of an actual or threatened contested
election of directors pursuant to Regulation 14A under the Securities Exchange Act of 1934 or any successor provision.
6
(i) Base Salary Continuation. The Base Salary continuation set forth in Sections 4(d) and (e) above shall be intended
either (i) to satisfy the safe harbor set forth in the regulations issued under section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”) (Treas. Regs. 1.409A-1(n)(2)(ii)) or (ii) be treated as a Short-term Deferral as that term is defined under Code section 409A (Treas. Regs.
1.409A-1(b)(4)). To the extent such continuation payments exceed the applicable safe harbor amount or do not constitute a Short-term Deferral,
the excess amount shall be treated as deferred compensation under Code section 409A and as such shall be payable pursuant to the following
schedule: such excess amount shall be paid via standard payroll in periodic installments in accordance with the Company’s usual practice for its
senior executives. Solely for purposes of Code section 409A, each installment payment is considered a separate payment. Notwithstanding any
provision in this Agreement to the contrary, in the event that the Employee is a “specified employee” as defined in Section 409A, any continuation
payment, continuation benefits or other amounts payable under this Agreement that would be subject to the special rule regarding payments to
“specified employees” under Section 409A(a)(2)(B) of the Code shall not be paid before the expiration of a period of six months following the
date of the Employee’s termination of employment or before the date of the Employee’s death, if earlier.
(j) Parachute Provisions. Notwithstanding any provisions of this Agreement to the contrary:
(i) If any of the payments or benefits received or to be received by the Employee in connection with the
Employee’s termination of employment in respect of a Change in Control, whether pursuant to the terms of this Agreement or any other plan,
arrangement or agreement with the Company (all such payments and benefits, being hereinafter referred to as the “Total Payments”), would be
subject to the excise tax (the “Excise Tax”) imposed under Section 4999 of the Code, the Employee shall receive the Total Payments and be
responsible for the Excise Tax; provided, however that the Employee shall not receive the Total Payments and the Total Payments shall be
reduced to the Safe Harbor Amount (defined below) if (A) the net amount of such Total Payments, as so reduced to the Safe Harbor Amount (and
after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments) is greater than or equal to (B) the net
amount of such Total Payment without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total
Payments and the amount of Excise Tax to which the Employee would be subject in respect of such unreduced Total Payments). The “Safe
Harbor Amount” is the amount to which the Total Payments would hypothetically have to be reduced so that no portion of the Total Payments
would be subject to the Excise Tax.
(ii) For purposes of determining whether any of the Total Payments will be subject to the Excise Tax and the
amount of such Excise Tax, (A) all of the Total Payments shall be treated as “parachute payments” (within the meaning of Section 280G(b)(2) of
the Code) unless, in the opinion of tax counsel (“Tax Counsel”) selected by the accounting firm that was, immediately prior to the Change in
Control, the Company’s independent auditor (the “Auditor”), such payments or benefits (in whole or in part) do not constitute parachute
payments, including by reason of Section 280G(b)(4)(A) of the Code, (B) all “excess parachute payments” within the meaning of Section 280G(b)
(1) of the Code shall be treated as subject to the Excise Tax unless, in the opinion of Tax Counsel, such excess parachute payments (in whole or in
part)
7
represent reasonable compensation for services actually rendered (within the meaning of Section 280G(b)(4)(B) of the Code) in excess of the base
amount (within the meaning of Section 280G(b)(3) of the Code) allocable to such reasonable compensation, or are otherwise not subject to the
Excise Tax, and (C) the value of any noncash benefits or any deferred payment or benefit shall be determined by the Auditor in accordance with
the principles of Sections 280G(d)(3) and (4) of the Code. If the Auditor is prohibited by applicable law or regulation from performing the duties
assigned to it hereunder, then a different auditor, acceptable to both the Company and Employee, shall be selected. The fees and expenses of Tax
Counsel and the Auditor shall be paid by the Company.
(iii) In the event it is determined that the Safe Harbor Amount is payable to Employee, then the severance
payments provided under this Agreement that are cash shall first be reduced on a pro rata basis, and the non-cash severance payments shall
thereafter be reduced on a pro rata basis, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax.
5. Non-Disclosure and Non-Competition.
(a) Non-Disclosure. The Employee acknowledges that in the course of performing services for the Company, the
Employee will obtain knowledge of the Company’s business plans, products, processes, software, know-how, trade secrets, formulas, methods,
models, prototypes, discoveries, inventions, improvements, disclosures, names and positions of employees and/or other proprietary and/or
confidential information (collectively the “Confidential Information”). The Employee agrees to keep the Confidential Information secret and
confidential and not to publish, disclose or divulge to any other party, and the Employee agrees not to use any of the Confidential Information for
the Employee’s own benefit or to the detriment of the Company without the prior written consent of the Company, whether or not such
Confidential Information was discovered or developed by the Employee. The Employee also agrees not to divulge, publish or use any proprietary
and/or confidential information of others that the Company is obligated to maintain in confidence.
(b) Non-Competition. The Employee agrees that, during the Employee’s employment by the Company hereunder and
for an additional period of twelve months after the termination of the Employee’s employment hereunder, neither the Employee nor any
corporation or other entity in which the Employee may be interested as a partner, trustee, director, officer, employee, agent, shareholder, lender of
money or guarantor, or for which the Employee performs services in any capacity (including as a consultant or independent contractor) shall at
any time during such period (i) be engaged, directly or indirectly, in any Competitive Business (as that term is hereinafter defined) or (ii) solicit,
hire, contract for services or otherwise employ, directly or indirectly, any of the employees of the Company. For purposes of this Section 5(b), the
term “Competitive Business” shall mean any firm or business organization that competes with the Company in the development and/or
commercialization of drugs that prevent or treat partial complex seizures, post-traumatic stress disorder or fragile-x syndrome or any other
Ganaxolone-related technology, product or service being developed, manufactured, marketed, distributed or planned in writing by the Company at
the time of termination of the Employee’s employment with the Company. The foregoing prohibition shall not prevent any employment or
engagement of the Employee, after termination of employment with the Company, by any
8
company or business organization not substantially engaged in a Competitive Business as long as the activities of any such employment or
engagement, in any capacity, do not involve work on matters related to any product or service being developed, manufactured, marketed,
distributed or planned in writing by the Company at the time of termination of Employee’s employment with the Company. The Employee’s
ownership of no more than 5% of the outstanding voting stock of a publicly traded company shall not constitute a violation of this Section 5(b).
The Employee is entering into this covenant not to compete to continue the Employee’s undertaking in the Prior Agreement and in consideration
of the additional agreements of the Company in this Agreement, including but not limited to the rights of the Employee set forth in Sections 4
(d) and 4(e).
6. Inventions and Discoveries.
(a) Disclosure. The Employee shall promptly and fully disclose to the Company, with all necessary detail, all
developments, know-how, discoveries, inventions, improvements, concepts, ideas, formulae, processes and methods (whether copyrightable,
patentable or otherwise) made, received, conceived, acquired or written by the Employee (whether or not at the request or upon the suggestion of
the Company, solely or jointly with others), during the period of the Employee’s employment with the Company that (i) result from, arise out of,
or relate to any work, assignment or task performed by the Employee on behalf of the Company, whether undertaken voluntarily or assigned to the
Employee within the scope of the Employee’s responsibilities to the Company, or (ii) were developed using the Company’s facilities or other
resources or in Company time, or (iii) result from the Employee’s use or knowledge of the Company’s Confidential Information, or (iv) relate to
the Company’s business or any of the products or services being developed, manufactured or sold by the Company or that may be used in relation
therewith (collectively referred to as “Inventions”). The Employee hereby acknowledges that all original works of authorship that are made by the
Employee (solely or jointly with others) within the above terms and that are protectable by copyright are “works made for hire,” as that term is
defined in the United States Copyright Act. The Employee understands and hereby agrees that the decision whether or not to commercialize or
market any Invention developed by the Employee solely or jointly with others is within the Company’s sole discretion and for the Company’s sole
benefit and that no royalty shall be due to the Employee as a result of the Company’s efforts to commercialize or market any such Invention.
(b) Assignment and Transfer. The Employee agrees to assign and transfer to the Company all of the Employee’s right,
title and interest in and to the Inventions, and the Employee further agrees to deliver to the Company any and all drawings, notes, specifications
and data relating to the Inventions, and to sign, acknowledge and deliver all such further papers, including applications for and assignments of
copyrights and patents, and all renewals thereof, as may be necessary to obtain copyrights and patents for any Inventions in any and all countries
and to vest title thereto in the Company and its successors and assigns and to otherwise protect the Company’s interests therein. The Employee
shall not charge the Company for time spent in complying with these obligations. If the Company is unable because of the Employee’s mental or
physical incapacity or for any other reason to secure the Employee’s signature to apply for or to pursue any application for any United States or
foreign patents or copyright registrations covering Inventions or original works of authorship assigned to the Company as above, then the
Employee hereby irrevocably designates and appoints the Company and its duly authorized
9
officers and agents as the Employee’s agent and attorney in fact, to act for and in the Employee’s behalf and stead to execute and file any such
applications and to do all other lawfully permitted acts to further the prosecution and issuance of letters patent or copyright registrations thereon
with the same legal force and effect as if executed by the Employee.
(c) Company Documentation. The Employee shall hold in a fiduciary capacity for the benefit of the Company all
documentation, disks, programs, data, records, drawings, manuals, reports, sketches, blueprints, letters, notes, notebooks and all other writings,
electronic data, graphics and tangible information and materials of a secret, confidential or proprietary information nature relating to the Company
or the Company’s business that are in the possession or under the control of the Employee. The Employee agrees that in connection with any
research, development or other services performed for the Company, the Employee will maintain careful, adequate and contemporaneous written
records of all Inventions, which records shall be the property of the Company.
7. Injunctive Relief. The Employee acknowledges that the Employee’s compliance with the agreements in Sections 5 and 6
hereof is necessary to protect the good will and other proprietary interests of the Company and that the Employee is one of the principal
executives of the Company and conversant with its affairs, its trade secrets and other proprietary information. The Employee acknowledges that a
breach of any of the Employee’s agreements in Sections 5 and 6 hereof will result in irreparable and continuing damage to the Company for which
there will be no adequate remedy at law; and the Employee agrees that in the event of any breach of the aforesaid agreements, the Company and
its successors and assigns shall be entitled to injunctive relief and to such other and further relief as may be proper.
8. Full Agreement. This Agreement amends, restates and supersedes the Prior Agreement and all other consulting and
employment arrangements between the Employee and the Company, but shall not supersede any existing confidentiality, nondisclosure, invention
assignment or non-compete agreement between the Employee and the Company. Except as set forth in the preceding sentence, this Agreement
constitutes the entire agreement of the parties concerning its subject matter and supersedes all other oral or written understandings, discussions,
and agreements, and may be modified only in a writing signed by both parties. The parties acknowledge that they have read and fully understand
the contents of this Agreement and execute it after having an opportunity to consult with legal counsel.
9. Amendments. Any amendment to this Agreement shall be made in writing and signed by the parties hereto.
10. Enforceability. If any provision of this Agreement shall be invalid or unenforceable, in whole or in part, then such provision
shall be deemed to be modified or restricted to the extent and in the manner necessary to render the same valid and enforceable, or shall be
deemed excised from this Agreement, as the case may require, and this Agreement shall be construed and enforced to the maximum extent
permitted by law as if such provision had been originally incorporated herein as so modified or restricted or as if such provision had not been
originally incorporated herein, as the case may be.
10
11. Construction. This Agreement shall be construed and interpreted in accordance with the internal laws of the Commonwealth
of Pennsylvania.
12. Assignment.
(a) By the Company. The rights and obligations of the Company under this Agreement shall inure to the benefit of, and
shall be binding upon, the successors and assigns of the Company. This Agreement may be assigned by the Company without the consent of the
Employee.
(b) By the Employee. This Agreement and the obligations created hereunder may not be assigned by the Employee, but
all rights of the Employee hereunder shall inure to the benefit of and be enforceable by the Employee’s heirs, devisees, legatees, executors,
administrators and personal representatives.
13. Notices. All notices required or permitted to be given hereunder shall be in writing and shall be deemed to have been given
when mailed by certified mail, return receipt requested, or delivered by a national overnight delivery service addressed to the intended recipient as
follows:
If to the Company:
Marinus Pharmaceuticals, Inc.
Three Radnor Corporate Center
100 Matsonford Road, Suite 304
Radnor, PA 19087
Attention: Chief Executive Officer
If to the Employee, to address stated on the signature page to this Agreement.
Any party may from time to time change its address for the purpose of notices to that party by a similar notice specifying a new address, but no
such change shall be deemed to have been given until it is actually received by the party sought to be charged with its contents.
14. Waivers. No claim or right arising out of a breach or default under this Agreement shall be discharged in whole or in part by a
waiver of that claim or right unless the waiver is supported by consideration and is in writing and executed by the aggrieved party hereto or such
party’s duly authorized agent. A waiver by any party hereto of a breach or default by the other party hereto of any provision of this Agreement
shall not be deemed a waiver of future compliance therewith, and such provisions shall remain in full force and effect.
15. Section 409A. It is intended that this Agreement be drafted and administered in compliance with section 409A of the Code,
including, but not limited to, any future amendments to Code section 409A, and any other Internal Revenue Service or other governmental rulings
or interpretations (together, “Section 409A”) issued pursuant to Section 409A so as not to subject the Employee to payment of interest or any
additional tax under Code section 409A. The parties intend for any payments under this Agreement to either satisfy the requirements of
Section 409A
11
or to be exempt from the application of Section 409A, and this Agreement shall be construed and interpreted accordingly. In furtherance thereof,
if payment or provision of any amount or benefit hereunder that is subject to Section 409A at the time specified herein would subject such amount
or benefit to any additional tax under Section 409A, the payment or provision of such amount or benefit shall be postponed to the earliest
commencement date on which the payment or provision of such amount or benefit could be made without incurring such additional tax. In
addition, to the extent that any Internal Revenue Service guidance issued under Section 409A would result in the Employee being subject to the
payment of interest or any additional tax under Section 409A, the parties agree, to the extent reasonably possible, to amend this Agreement in
order to avoid the imposition of any such interest or additional tax under Section 409A, which amendment shall have the minimum economic
effect necessary and be reasonably determined in good faith by the Company and the Employee.
16. Survival of Covenants. The provisions of Sections 4, 5, 6 and 7 hereof shall survive the termination of this Agreement.
Furthermore, each other provision of this Agreement that, by its terms, is intended to continue beyond the termination of the Employee’s
employment shall continue in effect thereafter.
(Signature page follows.)
12
IN WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first above written.
MARINUS PHARMACEUTICALS, INC.
By: /s/ Christopher M. Cashman
Christopher M. Cashman,
President and CEO
/s/ Edward F. Smith
Edward F. Smith
13
MARINUS PHARMACEUTICALS, INC.
2014 EQUITY INCENTIVE PLAN
EXHIBIT 10.13
The purpose of the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan is to provide (i) designated employees of Marinus
Pharmaceuticals, Inc. (the “Company”) and its parents and subsidiaries, (ii) certain consultants and advisors who perform services for the
Company or its parents or subsidiaries and (iii) non-employee members of the Board of Directors of the Company (the “Board”) with the
opportunity to receive grants of incentive stock options, nonqualified stock options, stock awards, stock units, stock appreciation rights and other
equity-based awards. The Company believes that this Plan will encourage the participants to contribute materially to the growth of the Company,
thereby benefitting the Company’s stockholders, and will align the economic interests of the participants with those of the stockholders.
1. Administration and Delegation .
(a) Committee . This Plan shall be administered by a committee consisting of two or more members of the Board, which shall
consist of “outside directors” as defined under section 162(m) of the Internal Revenue Code of 1986, as amended (the “Code”), and related
Treasury regulations, “non-employee directors” as defined under Rule 16b-3 under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”) and, when applicable, by “independent directors” as defined by the rules of any national securities exchange (the “Exchange”)
upon which shares of the Company’s capital stock shall be listed. However, the Board may ratify or approve any grants as it deems appropriate,
and the Board shall approve and administer all grants made to non-employee directors. The committee may delegate authority to one or more
subcommittees as it deems appropriate. To the extent that a committee or subcommittee administers this Plan, references in this Plan to the
“Board” shall be deemed to refer to the committee or subcommittee.
(b) Board Authority . The Board shall have the sole authority to (i) determine the individuals to whom grants shall be made
under this Plan, (ii) determine the type, size and terms of the grants to be made to each such individual, (iii) determine the time when the grants
will be made and the duration of any applicable exercise or restriction period, including the criteria for exercisability and the acceleration of
exercisability, (iv) amend the terms of any previously issued grant, and (v) deal with any other matters arising under this Plan.
(c) Board Determinations . The Board shall have full power and authority to administer and interpret this Plan, to make factual
determinations and to adopt or amend such rules, regulations, agreements and instruments for implementing this Plan and for the conduct of its
business as it deems necessary or advisable, in its sole discretion. The Board’s interpretations of this Plan and all determinations made by the
Board pursuant to the powers vested in it hereunder shall be conclusive and binding on all persons having any interest in this Plan or in any
awards granted hereunder. All powers of the Board shall be executed in its sole discretion, in the best interest of the Company, not as a fiduciary,
and in keeping with the objectives of this Plan and need not be uniform as to similarly situated individuals.
(d) Delegation to Officers . To the extent permitted by applicable law, the Board may delegate to one or more officers of the
Company the power to grant Options and other Grants that constitute rights under Delaware law (subject to any limitations under this Plan) to
employees or officers of the Company and to exercise such other powers under this Plan as the Board may determine, provided that the Board
shall fix the terms of such Grants to be granted by such officers (including the exercise price of such Grants, which may include a formula by
which the exercise price will be determined) and the maximum number of shares subject to such Grants that the officers may grant; provided
further, however, that no officer shall be authorized to grant such Grants to any “executive officer” of the Company (as defined by Rule 3b-7
under the Exchange Act) or to any “officer” of the Company (as defined by Rule 16a-1 under the Exchange Act). Notwithstanding anything to the
contrary set forth above, the Board may not delegate authority under this Section 1(d) to grant Stock Awards, unless Delaware law then permits
such delegation.
2. Grants . Awards under this Plan may consist of grants of incentive stock options as described in Section 5 (“Incentive Stock
Options”), nonqualified stock options as described in Section 5 (“Nonqualified Stock Options”) (Incentive Stock Options and Nonqualified Stock
Options are collectively referred to as “Options”), stock awards as described in Section 6 (“Stock Awards”), stock units as described in Section 7
(“Stock Units”), stock appreciation rights as described in Section 8 (“SARs”), and other equity-based awards as described in Section 9 (“Other
Equity Awards”), the foregoing sometimes referred to herein collectively as “Grants” and individually as a “Grant.” All Grants shall be subject to
the terms and conditions set forth herein and to such other terms and conditions consistent with this Plan as the Board deems appropriate and as
are specified in writing by the Board to the individual in a grant instrument or an amendment to the grant instrument (the “Grant Instrument”). All
Grants shall be made conditional upon the acknowledgement of the Grantee (as defined in Section 4(b)), in writing or by acceptance of the Grant,
that all decisions and determinations of the Board shall be final and binding on the Grantee, his or her beneficiaries and any other person having or
claiming an interest under such Grant. Grants under a particular Section of this Plan need not be uniform as among the grantees.
3. Shares Subject to This Plan .
(a) Shares Authorized . Subject to adjustment as described below, the aggregate number of shares of common stock of the
Company (“Company Stock”) that may be issued pursuant to Grants under this Plan is 700,000 shares, each of which may be issued under this
Plan as an Incentive Stock Option. In addition, the number of shares of Company Stock that may be issued pursuant to Grants under this Plan and
the number of shares of Company Stock that may be issued under this Plan as Incentive Stock Options shall be increased annually on January 1 of
each year, commencing January 1, 2015, until the expiration of this Plan by a number equal to the lesser of (i) 1,120,000 shares of Company
Stock, (ii) an amount equal to 4% of the total number of shares of the Company’s capital stock outstanding on such date, calculated on a common-
equivalent basis, or (iii) an amount determined by the Board. Shares issued under this Plan may be authorized but unissued shares of Company
Stock or reacquired shares of Company Stock, including shares purchased by the Company on the open market for purposes of this Plan.
2
(b) Individual Limits . The maximum aggregate number of shares of Company Stock that shall be subject to Grants made under
this Plan to any individual during any calendar year shall be 700,000 shares.
(c) Share Counting . If and to the extent Options or SARs granted under this Plan terminate, expire, or are canceled, forfeited,
exchanged or surrendered without having been exercised or if any Stock Awards, Stock Units or Other Equity Awards are forfeited, the shares
subject to such Grants shall again be available for purposes of this Plan.
(d) Adjustments . If there is any change in the number or kind of shares of Company Stock outstanding (i) by reason of a stock
dividend, spinoff, recapitalization, stock split, or combination or exchange of shares, (ii) by reason of a merger, reorganization or consolidation,
(iii) by reason of a reclassification or change in par value, or (iv) by reason of any other extraordinary or unusual event affecting the outstanding
Company Stock as a class without the Company’s receipt of consideration, or if the value of outstanding shares of Company Stock is substantially
reduced as a result of a spinoff or the Company’s payment of an extraordinary dividend or distribution, the maximum number of shares of
Company Stock available for issuance under this Plan, the maximum number of shares of Company Stock for which any individual may receive
Grants in any year, the kind and number of shares covered by outstanding Grants, the kind and number of shares issued and to be issued under this
Plan, and the price per share or the applicable market value of such Grants shall be equitably adjusted by the Board to reflect any increase or
decrease in the number of, or change in the kind or value of, issued shares of Company Stock to preclude, to the extent practicable, the
enlargement or dilution of rights and benefits under such Grants; provided, however, that any fractional shares resulting from such adjustment
shall be eliminated. In addition, in the event of a Change of Control of the Company (as defined in Section 12(a)), the provisions of Section 13 of
this Plan shall apply. Any adjustment to outstanding Grants shall be consistent with section 409A and section 424 of the Code, to the extent
applicable. Any adjustments determined by the Board shall be final, binding and conclusive.
4. Eligibility for Participation .
(a) Eligible Persons . All employees of the Company and its parents or subsidiaries (“Employees”), including Employees who are
officers or members of the Board, and members of the Board who are not Employees (“Non-Employee Directors”) shall be eligible to participate
in this Plan. Consultants and advisors, as such terms are defined and interpreted for purposes of Form S-8 under the Securities Act of 1933, as
amended (the “Securities Act”) (or any successor form or rule) who perform services for the Company or any of its parents or subsidiaries (“Key
Advisors”) shall be eligible to participate in this Plan.
(b) Selection of Grantees . The Board shall select the Employees, Non-Employee Directors and Key Advisors to receive Grants
and shall determine the number of shares of Company Stock subject to a particular Grant in such manner as the Board determines. Employees,
Key Advisors and Non-Employee Directors who receive Grants under this Plan shall hereinafter be referred to as “Grantees.”
3
5. Options . The Board may grant Options to Employees, Non-Employee Directors, and Key Advisors upon such terms as the
Board deems appropriate. The following provisions are applicable to Options:
(a) Number of Shares . The Board shall determine the number of shares of Company Stock that will be subject to each Grant of
Options to Employees, Non-Employee Directors and Key Advisors.
(b) Type of Option and Price .
(i) The Board may grant Incentive Stock Options that are intended to qualify as “incentive stock options” within the
meaning of section 422 of the Code or Nonqualified Stock Options that are not intended so to qualify or any combination of Incentive Stock
Options and Nonqualified Stock Options, all in accordance with the terms and conditions set forth herein. Incentive Stock Options may be
granted only to employees of the Company or its parents or subsidiaries, as defined in section 424 of the Code. Nonqualified Stock Options may
be granted to Employees, Non-Employee Directors and Key Advisors.
(ii) The purchase price (the “Exercise Price”) of Company Stock subject to an Option shall be determined by the Board
and shall be equal to or greater than the Fair Market Value (as defined below) of a share of Company Stock on the date the Option is granted;
provided, however, that an Incentive Stock Option may not be granted to an Employee who, at the time of grant, owns stock possessing more than
10% of the total combined voting power of all classes of stock of the Company or any parent or subsidiary of the Company, unless the Exercise
Price per share is not less than 110% of the Fair Market Value of Company Stock on the date of grant.
(iii) If the Company Stock is publicly traded, then the Fair Market Value per share shall be determined as follows: (x) if
the principal trading market for the Company Stock is an Exchange, the last reported sale price thereof on the relevant date or (if there were no
trades on that date) the latest preceding date upon which a sale was reported, or (y) if the Company Stock is not principally traded on an
Exchange, the mean between the last reported “bid” and “asked” prices of Company Stock on the relevant date, as reported on the Exchange or, if
not so reported, as reported by the over-the-counter quotation system on which the Company Stock is then quoted or as reported in a customary
financial reporting service, as applicable and as the Board determines. If the Company Stock is not publicly traded or, if publicly traded, is not
subject to reported transactions or “bid” or “asked” quotations as set forth above, the Fair Market Value per share shall be as determined by the
Board.
(c) Option Term . The Board shall determine the term of each Option. The term of any Option shall not exceed ten years from
the date of grant. However, an Incentive Stock Option that is granted to an Employee who, at the time of grant, owns stock possessing more than
10% of the total combined voting power of all classes of stock of the Company, or any parent or subsidiary of the Company, may not have a term
that exceeds five years from the date of grant.
4
(d) Exercisability of Options .
(i) Options shall become exercisable in accordance with such terms and conditions, consistent with this Plan, as may be
determined by the Board and specified in the Grant Instrument. The Board may accelerate the exercisability of any or all outstanding Options at
any time for any reason.
(ii) The Board may provide in a Grant Instrument that the Grantee may elect to exercise part or all of an Option before it
otherwise has become exercisable. Any shares so purchased shall be restricted shares and shall be subject to a repurchase right in favor of the
Company during a specified restriction period, with the repurchase price equal to the lesser of (i) the Exercise Price or (ii) the Fair Market Value
of such shares at the time of repurchase, or such other restrictions as the Board deems appropriate.
(e) Grants to Non-Exempt Employees . Notwithstanding the foregoing, unless expressly approved by the Board, Options
granted to persons who are non-exempt employees under the Fair Labor Standards Act of 1938, as amended, (the “FLSA”) may not be exercisable
for at least six months after the date of grant (except that such Options may become exercisable, as determined by the Board, upon the Grantee’s
death, Disability (as defined in Section 5(f)(v)(C)) or Retirement (as defined in Section 5(f)(v)(E)), or upon a Change of Control or other
circumstances permitted by applicable regulations).
(f) Termination of Employment, Disability or Death .
(i) Except as provided below, an Option may be exercised only while the Grantee is employed by, or providing service to,
the Employer (as defined in Section 5(f)(v)(A)) as an Employee, Key Advisor or member of the Board. In the event that a Grantee ceases to be
employed by, or provide service to, the Employer for any reason other than Disability, death, Retirement or termination for Cause (as defined in
Section 5(f)(v)(D)), except as otherwise provided by the Board, any Option that is otherwise exercisable by the Grantee shall terminate unless
exercised within 90 days after the date on which the Grantee ceases to be employed by, or provide service to, the Employer (or within such other
period of time as may be specified by the Board), but in any event no later than the date of expiration of the Option term. Except as otherwise
provided by the Board, any of the Grantee’s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed
by, or provide service to, the Employer shall terminate as of such date.
(ii) In the event the Grantee ceases to be employed by, or provide service to, the Employer on account of a termination for
Cause by the Employer, any Option held by the Grantee shall terminate as of the date the Grantee ceases to be employed by, or provide service to,
the Employer. In addition, notwithstanding any other provisions of this Section 5, if the Board determines that the Grantee has engaged in
conduct that constitutes Cause at any time while the Grantee is employed by, or providing service to, the Employer or after the Grantee’s
termination of employment or service, any Option held by the Grantee shall immediately terminate, and the Grantee shall automatically forfeit all
shares underlying any exercised portion of an Option for which the Company has not yet delivered the share certificates, upon refund by the
Company of the Exercise Price paid by the Grantee for such shares. Upon any exercise of an
5
Option, the Company may withhold delivery of share certificates pending resolution of an inquiry that could lead to a finding resulting in a
forfeiture.
(iii) In the event the Grantee ceases to be employed by, or provide service to, the Employer because of the Grantee’s
Disability or Retirement, any Option that is otherwise exercisable by the Grantee shall terminate unless exercised within one year after the date on
which the Grantee ceases to be employed by, or provide service to, the Employer (or within such other period of time as may be specified by the
Board), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Board, any of the Grantee’s
Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to, the Employer shall
terminate as of such date. In the event that an Incentive Stock Option is exercised more than 90 days after Retirement, the Option shall lose its
status as an Incentive Stock Option and shall be treated as a Nonqualified Stock Option.
(iv) If the Grantee dies while employed by, or providing service to, the Employer or within 90 days after the date on which
the Grantee ceases to be employed or provide service on account of a termination specified in Section 5(f)(i) above (or within such other period of
time as may be specified by the Board), any Option that is otherwise exercisable by the Grantee shall terminate unless exercised within one year
after the date on which the Grantee ceases to be employed by, or provide service to, the Employer (or within such other period of time as may be
specified by the Board), but in any event no later than the date of expiration of the Option term. Except as otherwise provided by the Board, any
of the Grantee’s Options that are not otherwise exercisable as of the date on which the Grantee ceases to be employed by, or provide service to,
the Employer shall terminate as of such date.
(v) For purposes of this Section 5(f) and Section 6:
(A) The term “Employer” shall include the Company and its parent and subsidiary corporations, as determined by the
Board.
(B) “Employed by, or provide service to, the Employer” shall mean employment or service as an Employee, Key Advisor
or member of the Board (so that, for purposes of exercising Options and satisfying conditions with respect to other Grants, a Grantee
shall not be considered to have terminated employment or service until the Grantee ceases to be an Employee, Key Advisor or member of
the Board), unless the Board determines otherwise.
(C) “Disability” shall mean a Grantee’s becoming disabled within the meaning of section 22(e)(3) of the Code, within the
meaning of the Employer’s long-term disability plan applicable to the Grantee, or as otherwise determined by the Board.
(D) “Cause” shall mean, except to the extent specified otherwise by the Board, a finding by the Board that the Grantee
(i) has breached his or her employment or service contract with the Employer in any material respect, (ii) has engaged in disloyalty to the
Company, including, without limitation, fraud, embezzlement, theft, commission of a felony or proven dishonesty, (iii) has disclosed
trade secrets or confidential information of the Employer to persons not entitled to receive such information, (iv) has breached any
6
written noncompetition or nonsolicitation agreement between the Grantee and the Employer or (v) has engaged in such other behavior
detrimental to the interests of the Employer as the Board determines.
(E) “Retirement” shall mean a termination of employment by reason of an Employee’s retirement at or after the
Employee’s earliest permissible retirement date pursuant to and in accordance with a regular retirement plan or the personnel practices of
the Employer.
(g) Exercise of Options . A Grantee may exercise an Option that has become exercisable, in whole or in part, by delivering a
notice of exercise to the Company. The Grantee shall pay the Exercise Price for an Option as specified by the Board (w) in cash, (x) with the
approval of the Board, by delivering shares of Company Stock owned by the Grantee (including Company Stock acquired in connection with the
exercise of an Option, subject to such restrictions as the Board deems appropriate) and having a Fair Market Value on the date of exercise equal to
the Exercise Price or by attestation (on a form prescribed by the Board) to ownership of shares of Company Stock having a Fair Market Value on
the date of exercise equal to the Exercise Price, (y) payment through a broker in accordance with procedures permitted by applicable regulations
of the Board of Governors of the Federal Reserve System, or (z) by such other method as the Board may approve. Shares of Company Stock used
to exercise an Option shall have been held by the Grantee for the requisite period of time to avoid adverse accounting consequences to the
Company with respect to the Option. The Grantee shall pay the Exercise Price and the amount of any withholding tax due (pursuant to
Section 10) at the time of exercise.
(h) Limits on Incentive Stock Options . Each Incentive Stock Option shall provide that, if the aggregate Fair Market Value of the
stock on the date of the grant with respect to which Incentive Stock Options are exercisable for the first time by a Grantee during any calendar
year, under this Plan or any other stock option plan of the Company or a parent or subsidiary, exceeds $100,000, then the Option, as to the excess,
shall be treated as a Nonqualified Stock Option. An Incentive Stock Option shall not be granted to any person who is not an Employee of the
Company or a parent or subsidiary (within the meaning of section 424(f) of the Code) of the Company.
(i) Limitation on Repricing . If the Company Stock is listed on an Exchange, unless such action is approved by the Company’s
stockholders, the Company may not (except as provided for under Section 3(d)): (A) amend any outstanding Option granted under this Plan to
provide an exercise price per share that is lower than the then-current exercise price per share of such outstanding Option, (B) cancel any
outstanding Option (whether or not granted under the Plan) and grant in substitution therefor new Grants under this Plan (other than adjustments
made pursuant to Section 3(d)) covering the same or a different number of shares of Company Stock and having an exercise price per share lower
than the then-current exercise price per share of the cancelled option, (C) cancel in exchange for a cash payment any outstanding Option with an
exercise price per share above the then-current Fair Market Value, other than pursuant to Section 3(d), or (D) take any other action under this Plan
that constitutes a “repricing” within the meaning of the rules of the Exchange.
7
6. Stock Awards . The Board may issue shares of Company Stock to an Employee, Non-Employee Director or Key Advisor
under a Stock Award, upon such terms as the Board deems appropriate. The following provisions are applicable to Stock Awards:
(a) General Requirements . Shares of Company Stock issued or transferred pursuant to Stock Awards may be issued or
transferred for cash consideration or for no cash consideration, and subject to restrictions or no restrictions, as determined by the Board. The
Board may, but shall not be required to, establish conditions under which restrictions on Stock Awards shall lapse over a period of time or
according to such other criteria as the Board deems appropriate, including without limitation restrictions based on the achievement of specific
performance goals. The period of time during which the Stock Award will remain subject to restrictions will be designated in the Grant
Instrument as the “Restriction Period.”
(b) Number of Shares . The Board shall determine the number of shares of Company Stock to be issued or transferred pursuant
to a Stock Award and the restrictions applicable to such shares.
(c) Requirement of Employment or Service . Unless the Board determines otherwise, if the Grantee ceases to be employed by,
or provide service to, the Employer (as defined in Section 5(f)(v)(A)) during a period designated in the Grant Instrument as the Restriction Period,
or if other specified conditions are not met, the Stock Award shall terminate as to all shares covered by the Grant as to which the restrictions have
not lapsed, and those shares of Company Stock must be immediately returned to the Company. The Board may, however, provide for complete or
partial exceptions to this requirement as it deems appropriate.
(d) Restrictions on Transfer and Legend on Stock Certificate . During the Restriction Period, a Grantee may not sell, assign,
transfer, pledge or otherwise dispose of the shares of the Stock Award except to a successor under Section 11(a). Each certificate representing a
Stock Award shall contain a legend giving appropriate notice of the restrictions in the Grant. The Grantee shall be entitled to have the legend
removed from the stock certificate covering the shares subject to restrictions when all restrictions on such shares have lapsed. The Board may
determine that the Company will not issue a certificate for a Stock Award until all restrictions on such shares have lapsed, or that the Company
will retain possession of certificates for Stock Awards until all restrictions on such shares have lapsed.
(e) Right to Vote and to Receive Dividends . Unless the Board determines otherwise, during the Restriction Period, the Grantee
shall have the right to vote shares subject to Stock Awards and to receive any dividends or other distributions paid on such shares, subject to any
restrictions deemed appropriate by the Board, including without limitation the achievement of specific performance goals.
(f) Lapse of Restrictions . All restrictions imposed on Stock Awards shall lapse upon the expiration of the applicable Restriction
Period and the satisfaction of all conditions imposed by the Board. The Board may determine, as to any or all Stock Awards, that the restrictions
shall lapse without regard to any Restriction Period.
8
7. Stock Units . The Board may grant Stock Units representing one or more shares of Company Stock to an Employee, Non-
Employee Director or Key Advisor, upon such terms and conditions as the Board deems appropriate, provided, however, that all such grants shall
comply with section 409A of the Code. The following provisions are applicable to Stock Units:
(a) Crediting of Units . Each Stock Unit shall represent the right of the Grantee to receive an amount based on the value of a
share of Company Stock, if specified conditions are met. All Stock Units shall be credited to bookkeeping accounts established on the Company’s
records for purposes of this Plan.
(b) Terms of Stock Units . The Board may grant Stock Units that are payable if specified performance goals or other conditions
are met, or under other circumstances. Stock Units may be paid at the end of a specified performance period or other period, or payment may be
deferred to a date authorized by the Board. The Board shall determine the number of Stock Units to be granted and the requirements applicable to
such Stock Units.
(c) Requirement of Employment or Service . Unless the Board determines otherwise, if the Grantee ceases to be employed by,
or provide service to, the Employer during a specified period, or if other conditions established by the Board are not met, the Grantee’s Stock
Units shall be forfeited. The Board may, however, provide for complete or partial exceptions to this requirement as it deems appropriate.
(d) Payment with Respect to Stock Units . Payments with respect to Stock Units may be made in cash, in Company Stock, or in
a combination of the two, as determined by the Board.
8. Stock Appreciation Rights . The Board may grant SARs to an Employee, Non-Employee Director or Key Advisor separately
or in tandem with any Option. The following provisions are applicable to SARs:
(a) Base Amount . The Board shall establish the base amount of the SAR at the time the SAR is granted. The base amount of
each SAR shall not be less than the Fair Market Value of a share of Company Stock on the date of Grant of the SAR.
(b) Tandem SARs . In the case of tandem SARs, the number of SARs granted to a Grantee that shall be exercisable during a
specified period shall not exceed the number of shares of Company Stock that the Grantee may purchase upon the exercise of the related Option
during such period. Upon the exercise of an Option, the SARs relating to the Company Stock covered by such Option shall terminate. Upon the
exercise of SARs, the related Option shall terminate to the extent of an equal number of shares of Company Stock.
(c) Exercisability . An SAR shall be exercisable during the period specified by the Board in the Grant Instrument and shall be
subject to such vesting and other restrictions as may be specified in the Grant Instrument. The Board may accelerate the exercisability of any or
all outstanding SARs at any time for any reason. SARs may only be exercised while the Grantee is employed by, or providing service to, the
Employer or during the applicable period after termination of employment or service as described in Section 5(f) above. A tandem SAR shall be
exercisable only during the period when the Option to which it is related is also exercisable.
9
(d) Grants to Non-Exempt Employees . Notwithstanding the foregoing, SARs granted to persons who are non-exempt
employees under the FLSA may not be exercisable for at least six months after the date of grant (except that such SARs may become exercisable,
as determined by the Board, upon the Grantee’s death, Disability or retirement, or upon a Change of Control or other circumstances permitted by
applicable regulations).
(e) Value of SARs . When a Grantee exercises SARs, the Grantee shall receive in settlement of such SARs an amount equal to
the value of the stock appreciation for the number of SARs exercised. The stock appreciation for an SAR is the amount by which the Fair Market
Value of the underlying Company Stock on the date of exercise of the SAR exceeds the base amount of the SAR as described in Section 8(a).
(f) Form of Payment . The appreciation in an SAR shall be paid in shares of Company Stock, cash or any combination of the
foregoing, as the Board shall determine. For purposes of calculating the number of shares of Company Stock to be received, shares of Company
Stock shall be valued at their Fair Market Value on the date of exercise of the SAR.
9. Other Equity Awards . The Board may grant Other Equity Awards, which are awards (other than those described in Sections
5, 6, 7 and 8 of this Plan) that are based on, measured by or payable in Company Stock, including, without limitation, stock appreciation rights, to
any Employee, Non-Employee Director or Key Advisor, on such terms and conditions as the Board shall determine. Other Equity Awards may be
awarded subject to the achievement of performance goals or other conditions and may be payable in cash, Company Stock or any combination of
the foregoing, as the Board shall determine.
10. Withholding of Taxes .
(a) Required Withholding . All Grants under this Plan shall be subject to applicable federal (including FICA), state and local tax
withholding requirements. The Employer may require that the Grantee or other person receiving or exercising Grants pay to the Employer the
amount of any federal, state or local taxes that the Employer is required to withhold with respect to such Grants, or the Employer may deduct from
other wages paid by the Employer the amount of any withholding taxes due with respect to such Grants.
(b) Election to Withhold Shares . If the Board so permits, a Grantee may elect to satisfy the Employer’s tax withholding
obligation with respect to Grants paid in Company Stock by having shares withheld up to an amount that does not exceed the Grantee’s minimum
applicable withholding tax rate for federal (including FICA), state and local tax liabilities. The election must be in a form and manner prescribed
by the Board and may be subject to the prior approval of the Board.
11. Transferability of Grants .
(a) Nontransferability of Grants . Except as provided below, only the Grantee may exercise rights under a Grant during the
Grantee’s lifetime. A Grantee may not transfer those rights except (i) by will or by the laws of descent and distribution or (ii) with respect to
Grants other than Incentive Stock Options, if permitted in any specific case by the Board, pursuant to a domestic relations order or otherwise as
permitted by the Board. When a Grantee dies, the
10
personal representative or other person entitled to succeed to the rights of the Grantee may exercise such rights. Any such successor must furnish
proof satisfactory to the Company of his or her right to receive the Grant under the Grantee’s will or under the applicable laws of descent and
distribution.
(b) Transfer of Nonqualified Stock Options . Notwithstanding the foregoing, the Board may provide, in a Grant Instrument,
that a Grantee may transfer Nonqualified Stock Options to family members, or one or more trusts or other entities for the benefit of or owned by
family members, consistent with applicable securities laws, according to such terms as the Board may determine; provided that the Grantee
receives no consideration for the transfer of an Option and the transferred Option shall continue to be subject to the same terms and conditions as
were applicable to the Option immediately before the transfer.
12. Change of Control of the Company .
(a) Change of Control . As used herein, a “Change of Control” shall be deemed to have occurred if:
(i) Any “person,” as such term is used in sections 13(d) and 14(d) of the Exchange Act becomes a “beneficial owner” (as
defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing more than 50% of the voting
power of the then outstanding securities of the Company; provided that a Change of Control shall not be deemed to occur as a result of (A) a
transaction in which the Company becomes a subsidiary of another corporation and in which the stockholders of the Company, immediately prior
to the transaction, will beneficially own, immediately after the transaction, shares entitling such stockholders to more than 50% of all votes to
which all stockholders of the parent corporation would be entitled in the election of directors, or (B) the acquisition of securities of the Company
by an investor of the Company in a capital-raising transaction; or
(ii) The consummation of (A) a merger or consolidation of the Company with another corporation where the stockholders
of the Company, immediately prior to the merger or consolidation, will not beneficially own, immediately after the merger or consolidation,
shares entitling such stockholders to more than 50% of all votes to which all stockholders of the surviving corporation would be entitled in the
election of directors, (B) a sale or other disposition of all or substantially all of the assets of the Company, or (C) a liquidation or dissolution of the
Company.
(b) Other Definition . The Board may modify the definition of Change of Control for a particular Grant as the Board deems
appropriate to comply with section 409A of the Code or otherwise.
13. Consequences of a Change of Control .
(a) Acceleration . In the event of a Change of Control, the Board may determine whether and to what extent (i) outstanding
Options and SARs shall accelerate and become exercisable, and (ii) outstanding Stock Awards, Stock Units and Other Equity Awards shall vest
and shall be payable. The Board may condition any such acceleration on such terms as the Board determines.
11
(b) Other Alternatives . In the event of a Change of Control, the Board may take any of the following actions with respect to any
or all outstanding Grants: the Board may (i) determine that all outstanding Options and SARs that are not exercised shall be assumed by, or
replaced with comparable options by the surviving corporation (or a parent or subsidiary of the surviving corporation), and other outstanding
Grants that remain in effect after the Change of Control shall be converted to similar grants of the surviving corporation (or a parent or subsidiary
of the surviving corporation), (ii) require that Grantees surrender their outstanding Options and SARs in exchange for one or more payments, in
cash or Company Stock as determined by the Board, in an amount, if any, equal to the amount by which the then Fair Market Value of the shares
of Company Stock subject to the Grantee’s unexercised Options and SARs exceeds the Exercise Price or base amount of the Options and SARs,
on such terms as the Board determines, or (iii) after giving Grantees an opportunity to exercise their outstanding Options and SARs, terminate any
or all unexercised Options and SARs at such time as the Board deems appropriate. Such assumption, surrender or termination shall take place as
of the date of the Change of Control or such other date as the Board may specify.
14. Limitations on Issuance or Transfer of Shares .
(a) Stockholders Agreement/Voting Agreement . The Board may require that a Grantee execute a stockholders agreement
and/or a voting agreement, in each case, with such terms as the Board deems appropriate, with respect to any Company Stock issued or transferred
pursuant to this Plan. If such stockholders agreement or voting agreement contains any lock-up or market standoff provisions that differ from the
provisions of Section 14(c) of this Plan, for as long as the provisions of such agreement are in effect, the provisions of Section 14(c) shall not
apply to such Company Stock, unless the Board determines otherwise.
(b) Limitations on Issuance or Transfer of Shares . No Company Stock shall be issued or transferred in connection with any
Grant hereunder unless and until all legal requirements applicable to the issuance or transfer of such Company Stock have been complied with to
the satisfaction of the Board. The Board shall have the right to condition any Grant made to any Grantee hereunder on such Grantee’s undertaking
in writing to comply with such restrictions on his or her subsequent disposition of such shares of Company Stock as the Board shall deem
necessary or advisable, and certificates representing such shares may be legended to reflect any such restrictions. Certificates representing shares
of Company Stock issued or transferred under this Plan will be subject to such stop-transfer orders and other restrictions as may be required by
applicable laws, regulations and interpretations, including any requirement that a legend be placed thereon.
(c) Lock-Up Period . If so requested by the Company or any representative of the underwriters (the “Managing Underwriter”) in
connection with any underwritten offering of securities of the Company under the Securities Act, and subject to Section 14(a) of this Plan, a
Grantee (including any successor or assigns) shall not sell or otherwise transfer any shares or other securities of the Company during the 30-day
period preceding and the 180-day period following the effective date of a registration statement of the Company filed under the Securities Act for
such underwriting (or such shorter period as may be requested by the Managing Underwriter and agreed to by the Company) (the “Market
Standoff Period”). If so requested by the Company or the Managing Underwriter, the Grantee shall enter into a separate written
12
agreement to such effect in form and substance requested by the Company or the Managing Underwriter. The Company may impose stop-transfer
instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff Period.
15. Amendment and Termination .
(a) Amendment of This Plan . The Board may amend, suspend or terminate this Plan or any portion thereof at any time provided
that (i) to the extent required by section 162(m) of the Code, no Grant that is intended to comply with section 162(m) after the date of such
amendment shall become exercisable, realizable or vested, as applicable to such Grant, unless and until the Company’s stockholders approve such
amendment in the manner required by section 162(m); and (ii) if shares of the Company’s capital stock are listed on the Exchange, no amendment
that would require stockholder approval under the rules of the Exchange may be made effective unless and until the Company’s stockholders
approve such amendment. In addition, if at any time the approval of the Company’s stockholders is required as to any other modification or
amendment under section 422 of the Code or any successor provision with respect to Incentive Stock Options, the Board may not effect such
modification or amendment without such approval. Unless otherwise specified in the amendment, any amendment to this Plan adopted in
accordance with this Section 15(a) shall apply to, and be binding on the holders of, all Grants outstanding under this Plan at the time the
amendment is adopted, provided the Board determines that such amendment, taking into account any related action, does not materially and
adversely affect the rights of Grantees under this Plan. No Grant shall be made that is conditioned upon stockholder approval of any amendment
to this Plan unless the Grant provides that (i) it will terminate or be forfeited if stockholder approval of such amendment is not obtained within no
more than 12 months from the date of grant and (ii) it may not be exercised or settled (or otherwise result in the issuance of Company Stock) prior
to such stockholder approval.
(b) Termination of This Plan . This Plan shall terminate on the day immediately preceding the tenth anniversary of its effective
date, unless this Plan is terminated earlier by the Board or is extended by the Board with the approval of the stockholders.
(c) Termination and Amendment of Outstanding Grants . The Board may amend, modify or terminate any outstanding Grant,
including but not limited to substituting therefor another Grant of the same or a different type, changing the date of exercise or realization, and/or
converting an Incentive Stock Option into a Nonqualified Stock Option. A termination or amendment of this Plan that occurs after a Grant is
made shall not materially impair the rights of a Grantee unless the Grantee consents or unless the Board acts under Section 21(b). The termination
of this Plan shall not impair the power and authority of the Board with respect to an outstanding Grant. The Board may at any time provide that
any Grant shall become immediately exercisable in whole or in part, free of some or all restrictions or conditions, or otherwise realizable in whole
or in part, as the case may be.
(d) Governing Document . This Plan shall be the controlling document. No other statements, representations, explanatory
materials or examples, oral or written, may amend this Plan in any manner. This Plan shall be binding upon and enforceable against the Company
and its successors and assigns.
13
16. Funding of This Plan . This Plan shall be unfunded. The Company shall not be required to establish any special or separate
fund or to make any other segregation of assets to assure the payment of any Grants under this Plan.
17. Rights of Participants . Nothing in this Plan shall entitle any Employee, Key Advisor, Non-Employee Director or other
person to any claim or right to be granted a Grant under this Plan. Neither this Plan nor any action taken hereunder shall be construed as giving
any individual any rights to be retained by or in the employ of the Employer or any other employment rights.
18. No Fractional Shares . No fractional shares of Company Stock shall be issued or delivered pursuant to this Plan or any Grant.
The Board shall determine whether cash, other awards or other property shall be issued or paid in lieu of such fractional shares or whether such
fractional shares or any rights thereto shall be forfeited or otherwise eliminated.
19. Headings . Section headings are for reference only. In the event of a conflict between a title and the content of a Section, the
content of the Section shall control.
20. Effective Date of This Plan . This Plan shall be effective on the date on which this Plan is approved by the Company’s
stockholders.
21. Miscellaneous .
(a) Grants in Connection with Corporate Transactions and Otherwise . Nothing contained in this Plan shall be construed to
(i) limit the right of the Board to make Grants under this Plan in connection with the acquisition, by purchase, lease, merger, consolidation or
otherwise, of the business or assets of any corporation, firm or association, including Grants to employees thereof who become Employees, or for
other proper corporate purposes, or (ii) limit the right of the Company to grant stock options or make other awards outside of this Plan. Without
limiting the foregoing, the Board may make a Grant to an employee, director or advisor of another corporation who becomes an Employee, Non-
Employee Director or Key Advisor by reason of a corporate merger, consolidation, acquisition of stock or property, reorganization or liquidation
involving the Company, the Parent or any of their subsidiaries in substitution for a stock option or stock award grant made by such corporation.
The terms and conditions of the substitute grants may vary from the terms and conditions required by this Plan and from those of the substituted
stock incentives. The Board shall prescribe the provisions of the substitute grants.
(b) Compliance with Law . This Plan, the exercise of Options and the obligations of the Company to issue shares of Company
Stock under Grants shall be subject to all applicable laws and to approvals by any governmental or regulatory agency as may be required. With
respect to persons subject to section 16 of the Exchange Act, it is the intent of the Company that this Plan and all transactions under this Plan
comply with all applicable provisions of Rule 16b-3 or its successors under the Exchange Act and section 162(m) of the Code. It is the intent of
the Company that this Plan and applicable Grants under this Plan comply with the applicable provisions of section 422 of the Code and that, to the
extent applicable, Grants made under this Plan comply with the requirements of section 409A of the Code and the regulations thereunder. To the
extent that any legal requirement set forth in this Plan ceases to be required under
14
applicable law, the Board may determine that such Plan provision shall cease to apply. The Board may revoke any Grant if it is contrary to law or
modify a Grant or this Plan to bring the Grant or this Plan into compliance with any applicable law or regulation.
(c) Employees Subject to Taxation Outside the United States . With respect to Grantees who are subject to taxation in
countries other than the United States, the Board may make Grants on such terms and conditions as the Board deems appropriate to comply with
the laws of the applicable countries, and the Board may create such procedures, addenda and subplans and make such modifications as may be
necessary or advisable to comply with such laws.
(d) Governing Law . The validity, construction, interpretation and effect of this Plan and Grant Instruments issued under this Plan
shall be governed and construed by and determined in accordance with the laws of the State of Delaware, without giving effect to the conflict of
laws provisions thereof.
Effective Date: August 5, 2014
15
EMPLOYMENT AGREEMENT
EXHIBIT 10.15
EMPLOYMENT AGREEMENT effective as of March 11, 2015 between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware
corporation, and Albena Patroneva (the “Employee”).
Recital:
The parties hereto desire to enter into this Agreement to provide for the employment of the Employee by the Company and for certain
other matters in connection with such employment, all as set forth more fully in this Agreement.
NOW, THEREFORE, in consideration of the premises and covenants set forth herein, and intending to be legally bound hereby, the
parties to this Agreement hereby agree as follows:
1. Duties. The Company agrees that the Employee shall be employed by the Company to serve as Vice President and Chief
Medical Officer of the Company. The Employee shall report to the Chief Executive Officer of the Company (the “CEO”). The Employee agrees
to be so employed by the Company and to devote her best efforts and substantially all of her business time to advance the interests of the
Company and to perform the duties customarily incident to the position of Chief Medical Officer and such other duties assigned to the Employee
by the CEO, provided such other duties are commensurate with the Employee’s employment level at the Company.
2. Term. The Employee’s employment under this Agreement shall continue in effect until terminated pursuant to Section 4 of
this Agreement.
3. Compensation.
(a) Salary. During the term of the Employee’s employment under this Agreement, the Employee shall be paid an annual
salary at the rate of not less than $335,000 (the “Base Salary”). The Base Salary may be increased from time to time by the Board of Directors or
its compensation committee (the “Board”). The Board shall review the Base Salary at least annually after the end of each fiscal year of the
Company. The Base Salary shall be paid in accordance with the Company’s regular payroll practices.
(b) Annual Bonus. At the end of each fiscal year of the Company that ends during the term of this Agreement, the
Board shall consider the award of a performance bonus to the Employee for such fiscal year in an amount of up to 35% of the Employee’s Base
Salary (the “Target Bonus”) based upon the achievement of performance objectives established annually by the Board. Whether the performance
objectives for any year have been achieved by the Employee shall be determined by the Board. Notwithstanding the foregoing, all bonuses shall
be paid within two and one-half months after the close of each year.
documented out-of-pocket expenses for relocating to
(c) Relocation Expenses. The Employer shall reimburse the Employee for the Employee’s reasonable and customary
the Radnor, Pennsylvania area in an amount not to exceed $15,000 in total. The Employee agrees to repay all such relocation expenses in full if
she leaves the Company’s employ, for whatever reason, on or before January 12, 2016.
(d) Equity Incentive Programs. The Employee shall also be eligible to participate in other equity incentive programs
established by the Company from time to time to provide stock options and other equity-based incentives to key employees of the Company in
accordance with the terms of those programs. All stock options and restricted stock awards granted to the Employee that vest over time shall, if
the Employee’s employment is terminated by the Company without Cause in accordance with Section 4(d) or the Employee resigns from the
Company’s employ for Good Reason in accordance with Section 4(e), in each case upon or during the twelve-month period that immediately
follows a Change of Control (as defined in Section 4(h)), become fully vested upon the termination of the Employee’s employment to the extent
permitted by the terms of the applicable plan and subject to the satisfaction by the Employee of the requirements of Section 4(g) of this
Agreement.
(e) Vacation and Fringe Benefits. The Employee shall be entitled to 20 days’ paid vacation, plus an additional two
floating holidays and two personal days, as per Company policy as in effect from time to time. The Employee shall be entitled to participate in all
insurance and other fringe benefit programs of the Company to the extent and on the same terms and conditions as are accorded to other officers
and key employees of the Company.
(f) Reimbursement of Expenses. The Employee shall be reimbursed for all normal items of travel, entertainment and
miscellaneous business expenses reasonably incurred by the Employee on behalf of the Company, provided that such expenses are documented
and submitted in accordance with the reimbursement policies of the Company as in effect from time to time.
services to be rendered by the Employee to the Company hereunder.
(g) Entire Compensation. The compensation provided for in this Agreement shall constitute full payment for the
4. Termination.
(a) Death. This Agreement shall automatically terminate effective as of the date of the Employee’s death, in which event
the Company shall not have any further obligation or liability under this Agreement except that the Company shall pay to the Employee’s estate:
(i) any portion of the Employee’s Base Salary for the period up to the Employee’s date of death that has been earned but remains unpaid; and
(ii) any benefits that have accrued to the Employee under the terms of the employee benefit plans of the Company, which benefits shall be paid in
accordance with the terms of those plans.
(b) Total Disability. The Company may terminate the employment of the Employee immediately upon written notice to
the Employee in the event of the Disability (as that term is hereinafter defined) of the Employee, in which event, the Company shall not have any
further obligation or liability under this Agreement except that the Company shall pay to the Employee: (i) any portion of the Employee’s Base
Salary for the period up to the date of
2
termination that has been earned but remains unpaid; and (ii) any benefits that have accrued to the Employee under the terms of the employee
benefit plans of the Company, which benefits shall be paid in accordance with the terms of those plans. For purposes of this Agreement, the term
“Disability” shall mean an illness, incapacity or a mental or physical condition that renders the Employee unable or incompetent to carry out the
job responsibilities that the Employee held or the tasks that the Employee was assigned at the time the disability commenced, as determined by the
Board and supported by the opinion of a physician. The Employee shall fully cooperate with the physician retained to furnish such opinion,
including submitting to such examinations and tests as may be requested by the physician.
(c) Termination by the Company for Cause. The Company may terminate the Employee’s employment hereunder
upon written notice to the Employee for any of the following reasons: (i) the Employee’s misuse of alcoholic beverages, controlled substances or
other narcotics, which misuse has had or is reasonably likely to have a material adverse effect on the business or financial affairs of the Company
or the reputation of the Company; (ii) failure by the Employee to cooperate with the Company in any investigation or formal proceeding; (iii) the
commission by the Employee of, or a plea by the Employee of guilty or nolo contendere with respect to, or conviction of the Employee for, a
felony (or any lesser included offense or crime in exchange for withdrawal of a felony indictment or charged crime that might result in a penalty
of incarceration), a crime involving moral turpitude, or any other offense that results in or could result in any prison sentence ; (iv) adjudication as
an incompetent; (v) a breach by the Employee of any material term of this Agreement, including the Employee’s failure to faithfully, diligently
and adequately perform the Employee’s duties under this Agreement, that is not corrected within ten days after written notice from the Company,
which notice shall set forth the nature of the breach; (vi) violation in any material respect of any of the Company’s rules, regulations or policies;
(vii) gross insubordination by the Employee in the performance of the Employee’s duties under this Agreement; (viii) engaging in any conduct,
action or behavior that, in the reasonable opinion of the Company, has had a material adverse effect on the reputation of the Company or the
Employee; (ix) any continued or repeated absence from the Company, unless the absence is approved or excused by the CEO or the result of the
Employee’s illness, disability or incapacity (in which event the provisions of Section 4(b) hereof shall control); or (x) misappropriation of any
funds or property of the Company, theft, embezzlement or fraud. In the event that the Company shall discharge the Employee pursuant to this
Section 4(c), the Company shall not have any further obligation or liability under this Agreement, except that the Company shall pay to the
Employee: (i) any portion of the Employee’s Base Salary for the period up to the date of termination that has been earned but remains unpaid; and
(ii) any benefits that have accrued to the Employee under the terms of the employee benefit plans of the Company, which benefits shall be paid in
accordance with the terms of those plans.
(d) Other Termination by the Company. The Company may terminate the employment of the Employee for any
reason other than one specified in Section 4(b) or 4(c) hereof immediately upon written notice to the Employee, in which event the Employee shall
be entitled to receive: (i) any portion of the Employee’s Base Salary for the period up to the date of termination that has been earned but remains
unpaid; (ii) any benefits that have accrued to the Employee under the terms of any employee benefit plans of the Company, which benefits shall
be paid in accordance with the terms of those plans; and (iii) subject to the satisfaction of the provisions of Section 4(g) and the compliance by the
Employee with all terms and provisions of
3
this Agreement that survive the termination of the Employee’s employment by the Company, (A) the Employee’s Base Salary for a period of nine
months, less applicable taxes and withholdings, payable in accordance with the Company’s regular payroll practices, with an accelerated payment
of any balance upon the occurrence of a Change in Control; provided, however, that if such termination of employment shall occur within three
months before or within twelve months after the occurrence of a Change in Control (such period being referred to herein as the “Change of
Control Period”), the severance payable to the Employee shall be increased to an amount equal to the Employee’s Base Salary for a period of
eighteen months and be payable in a single lump sum payment, less applicable taxes and withholdings; (B) payment or reimbursement (upon
presentation of proof of payment) of the Employee’s medical insurance premiums at the same level as was in effect on the termination date for a
period of nine months, which period shall increase to eighteen months if such termination of employment shall occur within the Change in Control
Period; and (C) if such termination shall occur within the Change in Control Period, an amount equal to the Employee’s Target Bonus for the year
in which such employment termination shall occur prorated based on the relative number of days in such year during which the Employee was
employed by the Company and/or its successor in the Change in Control, payable in a single lump sum payment, less applicable taxes and
withholdings. Any severance payments and lump sum payments due hereunder shall commence as soon as administratively feasible within 60
days after the date of the Employee’s termination of employment provided the Employee has timely executed and returned the Release referred to
in Section 4(g) and, if a revocation period is applicable, the Employee has not revoked the Release; provided, however, that if the 60-day period
begins in one calendar year and ends in a second calendar year, the severance payments shall begin to be paid in the second calendar year. On the
date that severance payments commence, the Company will pay the Employee in a single lump sum payment, less applicable taxes and
withholding, the severance payments that the Employee would have received on or prior to such date but for the delay imposed by the
immediately preceding sentence, with the balance of the severance payments to be paid as originally scheduled.
(e) Termination by the Employee for Good Reason. The Employee may terminate her employment by providing
written notice to the Company of a breach constituting Good Reason. “Good Reason” shall be deemed to exist with respect to any termination of
employment by the Employee for any of the following reasons: (i) a reassignment of the Employee to a location outside the Greater Philadelphia
area; (ii) any material failure by the Company to comply with any material term of this Agreement; (iii) the demotion of the Employee to a lesser
position than described in Section 1 hereof or a substantial diminution of the Employee’s authority, duties or responsibilities as in effect on the
date of this Agreement or as hereafter increased; or (iv) a material diminution of the Executive’s Base Salary and benefits, in the aggregate, unless
such reduction is part of a Company-wide reduction in compensation and/or benefits for all of its senior executives; provided, however, that Good
Reason shall not include a termination of the Employee’s employment pursuant to Section 4(b) or 4(c) hereof or, following a Change in Control, a
reduction in title, position, responsibilities or duties solely by virtue of the Company being acquired and made part of a larger entity or operated as
a subsidiary. If the Employee shall terminate the Employee’s employment hereunder for Good Reason, the Employee shall be entitled to receive
the same payments and benefits on the same terms and conditions as would be applicable upon a termination of the Employee’s employment by
the Company without Cause, as provided in Section 4(d) and subject to the satisfaction of the
4
other provisions of this Section 4(e). The Employee may not resign with Good Reason pursuant to this Section 4(e), and shall not be considered
to have done so for any purpose of this Agreement, unless (A) the Employee, within 60 days after the initial existence of the act or failure to act by
the Company that constitutes “Good Reason” within the meaning of this Agreement, provides the Company with written notice that describes, in
particular detail, the act or failure to act that the Employee believes to constitute “Good Reason” and identifies the particular clause of this
Section 4(e) that the Employee contends is applicable to such act or failure to act; (B) the Company, within 30 days after its receipt of such notice,
fails or refuses to rescind such act or remedy such failure to act so as to eliminate “Good Reason” for the termination by the Employee of the
Employee’s employment relationship with the Company, and (C) the Employee actually resigns from the employ of the Company on or before
that date that is six calendar months after the initial existence of the act or failure to act by the Company that constitutes “Good Reason.” If the
requirements of the preceding sentence are not fully satisfied on a timely basis, then the resignation by the Employee from the Employee’s
employment with the Company shall not be deemed to have been for “Good Reason,” the Employee shall not be entitled to any of the benefits to
which the Employee would have been entitled if the Employee had resigned the Employee’s employment with the Company for “Good Reason,”
and the Company shall not be required to pay any amount or provide any benefit that would otherwise have been due to the Employee under this
Section 4(e) had the Employee resigned with “Good Reason.”
(f) Other Termination by the Employee. The Employee may terminate the Employee’s employment for any reason
other than one specified in Section 4(e) upon at least 30 days’ prior written notice to the Company, which notice shall specify the effective date of
the termination. In the event the Employee shall terminate the Employee’s employment pursuant to this Section 4(f), the Company shall not have
any further obligation or liability under this Agreement, except that the Company shall pay to the Employee: (i) any portion of the Employee’s
Base Salary for the period up to the date of termination that has been earned but remains unpaid; and (ii) any benefits that have accrued to the
Employee under the terms of the employee benefit plans of the Company, which benefits shall be paid in accordance with the terms of those plans.
(g) Execution of Release. The Employee shall not be entitled to any payments or benefits under Sections 4(d) or 4
(e) unless the Employee executes and does not revoke a Release and Agreement (the “Release”), as drafted at the time of the Employee’s
termination of employment, including, but not limited to:
(i) an unconditional release of all rights to any claims, charges, complaints, grievances, known or unknown to
the Employee, against the Company, its affiliates or assigns, through the date of the Employee’s termination from employment other than post-
termination payments and benefits pursuant to this Agreement;
grievances against the Company, its affiliates, or assigns;
(ii) a representation and warranty that the Employee has not filed or assigned any claims, charges, complaints, or
5
to return any such confidential information and property to the Company upon execution of the Release;
(iii) an agreement not to use, disclose or make copies of any confidential information of the Company, as well as
of employment;
(iv) a mutual agreement to maintain the confidentiality of the Release or disclose the reasons for any termination
(v) an agreement not to disparage the Company or its officers, directors, stockholders, products or business; and
any portion of this Agreement or the Release.
(vi) an agreement to indemnify the Company, or its affiliates or assigns, in the event that the Employee breaches
Notwithstanding any provision of this Agreement to the contrary, in no event shall the timing of the Employee’s execution of the Release, directly
or indirectly, result in the Employee designating the calendar year of payment, and if a payment that is subject to execution of the Release could
be made in more than one taxable year, payment shall be made in the later taxable year.
(h) Definition of Change in Control. As used in this Agreement, the term “Change in Control” means:
(i) any merger or consolidation in which voting securities of the Company possessing more than 50% of the total
combined voting power of the Company’s outstanding securities are transferred to a person or persons different from the person holding those
securities immediately prior to such transaction and the composition of the Board following such transaction is such that the directors of the
Company prior to the transaction constitute less than 50% of the Board membership following the transaction;
(ii) any acquisition, directly or indirectly, by a person or related group of persons (other than the Company or a
person that directly or indirectly controls, is controlled by, or is under common control with, the Company) of beneficial ownership of voting
securities of the Company possessing more than 50% of the total combined voting power of the Company’s outstanding securities; provided,
however, that, no Change in Control shall be deemed to occur by reason of the acquisition of shares of the Company’s capital stock by an investor
or group of investors in the Company in a capital-raising transaction; or
the Company; or
(iii) any sale, transfer, exclusive worldwide license or other disposition of all or substantially all of the assets of
(iv) within any 24-month period beginning on or after the date hereof, the persons who were directors of the
Company immediately before the beginning of such period (the “Incumbent Directors”) shall cease (for any reason other than death) to constitute
at least a majority of the Board of Directors of the Company or the board of directors of any successor to the Company, provided that any director
who was not a director as of the date hereof shall be deemed to be an Incumbent Director if such director was elected to the Board by, or on the
recommendation of or with the approval of, at least two-thirds of the directors who then qualified as Incumbent Directors either actually or by
prior operation of this Section 4(h)(iv), unless such
6
election, recommendation or approval was the result of an actual or threatened contested election of directors pursuant to Regulation 14A under
the Securities Exchange Act of 1934 or any successor provision.
(i) Base Salary Continuation. The Base Salary continuation set forth in Sections 4(d) and (e) above shall be intended
either (i) to satisfy the safe harbor set forth in the regulations issued under section 409A of the Internal Revenue Code of 1986, as amended (the
“Code”) (Treas. Regs. 1.409A-1(n)(2)(ii)) or (ii) be treated as a Short-term Deferral as that term is defined under Code section 409A (Treas. Regs.
1.409A-1(b)(4)). To the extent such continuation payments exceed the applicable safe harbor amount or do not constitute a Short-term Deferral,
the excess amount shall be treated as deferred compensation under Code section 409A and as such shall be payable pursuant to the following
schedule: such excess amount shall be paid via standard payroll in periodic installments in accordance with the Company’s usual practice for its
senior executives. Solely for purposes of Code section 409A, each installment payment is considered a separate payment. Notwithstanding any
provision in this Agreement to the contrary, in the event that the Employee is a “specified employee” as defined in Section 409A, any continuation
payment, continuation benefits or other amounts payable under this Agreement that would be subject to the special rule regarding payments to
“specified employees” under Section 409A(a)(2)(B) of the Code shall not be paid before the expiration of a period of six months following the
date of the Employee’s termination of employment or before the date of the Employee’s death, if earlier.
(j) Parachute Provisions. Notwithstanding any provisions of this Agreement to the contrary:
(i) If any of the payments or benefits received or to be received by the Employee in connection with the
Employee’s termination of employment in respect of a Change in Control, whether pursuant to the terms of this Agreement or any other plan,
arrangement or agreement with the Company (all such payments and benefits, being hereinafter referred to as the “Total Payments”), would be
subject to the excise tax (the “Excise Tax”) imposed under Section 4999 of the Code, the Employee shall receive the Total Payments and be
responsible for the Excise Tax; provided, however that the Employee shall not receive the Total Payments and the Total Payments shall be
reduced to the Safe Harbor Amount (defined below) if (A) the net amount of such Total Payments, as so reduced to the Safe Harbor Amount (and
after subtracting the net amount of federal, state and local income taxes on such reduced Total Payments) is greater than or equal to (B) the net
amount of such Total Payment without such reduction (but after subtracting the net amount of federal, state and local income taxes on such Total
Payments and the amount of Excise Tax to which the Employee would be subject in respect of such unreduced Total Payments). The “Safe
Harbor Amount” is the amount to which the Total Payments would hypothetically have to be reduced so that no portion of the Total Payments
would be subject to the Excise Tax.
(ii) For purposes of determining whether any of the Total Payments will be subject to the Excise Tax and the
amount of such Excise Tax, (A) all of the Total Payments shall be treated as “parachute payments” (within the meaning of Section 280G(b)(2) of
the Code) unless, in the opinion of tax counsel (“Tax Counsel”) selected by the accounting firm that was, immediately prior to the Change in
Control, the Company’s independent auditor (the
7
“Auditor”), such payments or benefits (in whole or in part) do not constitute parachute payments, including by reason of Section 280G(b)(4)(A) of
the Code, (B) all “excess parachute payments” within the meaning of Section 280G(b)(1) of the Code shall be treated as subject to the Excise Tax
unless, in the opinion of Tax Counsel, such excess parachute payments (in whole or in part) represent reasonable compensation for services
actually rendered (within the meaning of Section 280G(b)(4)(B) of the Code) in excess of the base amount (within the meaning of Section 280G
(b)(3) of the Code) allocable to such reasonable compensation, or are otherwise not subject to the Excise Tax, and (C) the value of any noncash
benefits or any deferred payment or benefit shall be determined by the Auditor in accordance with the principles of Sections 280G(d)(3) and (4) of
the Code. If the Auditor is prohibited by applicable law or regulation from performing the duties assigned to it hereunder, then a different auditor,
acceptable to both the Company and Employee, shall be selected. The fees and expenses of Tax Counsel and the Auditor shall be paid by the
Company.
(iii) In the event it is determined that the Safe Harbor Amount is payable to Employee, then the severance
payments provided under this Agreement that are cash shall first be reduced on a pro rata basis, and the non-cash severance payments shall
thereafter be reduced on a pro rata basis, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax.
5. Restrictive Covenant Agreement. The Non-Disclosure, Invention Assignment, Non-Solicitation and Non-Compete
Agreement executed by the Employee on December 29, 2014 (the “Restrictive Covenant Agreement”) shall remain in full force and effect in
accordance with its terms and shall survive the termination of this Agreement in accordance with the terms of the Restrictive Covenant
Agreement.
6. Supersedes Other Agreements. This Agreement supersedes and is in lieu of any and all other employment arrangements
between the Employee and the Company, but shall not supersede the Restrictive Covenant Agreement or any existing confidentiality,
nondisclosure, invention assignment or non-compete agreement between the Employee and the Company.
7. Amendments. Any amendment to this Agreement shall be made in writing and signed by the parties hereto.
8. Enforceability. If any provision of this Agreement shall be invalid or unenforceable, in whole or in part, then such provision
shall be deemed to be modified or restricted to the extent and in the manner necessary to render the same valid and enforceable, or shall be
deemed excised from this Agreement, as the case may require, and this Agreement shall be construed and enforced to the maximum extent
permitted by law as if such provision had been originally incorporated herein as so modified or restricted or as if such provision had not been
originally incorporated herein, as the case may be.
9. Construction. This Agreement shall be construed and interpreted in accordance with the internal laws of the Commonwealth
of Pennsylvania.
8
10. Assignment.
(a) By the Company. The rights and obligations of the Company under this Agreement shall inure to the benefit of, and
shall be binding upon, the successors and assigns of the Company. This Agreement may be assigned by the Company without the consent of the
Employee.
(b) By the Employee. This Agreement and the obligations created hereunder may not be assigned by the Employee, but
all rights of the Employee hereunder shall inure to the benefit of and be enforceable by the Employee’s heirs, devisees, legatees, executors,
administrators and personal representatives.
11. Notices. All notices required or permitted to be given hereunder shall be in writing and shall be deemed to have been given
when mailed by certified mail, return receipt requested, or delivered by a national overnight delivery service addressed to the intended recipient as
follows:
If to the Company:
Marinus Pharmaceuticals, Inc.
3 Radnor Corporate Center
100 Matsonford Road, Suite 304
Radnor, PA 19087
Attention: Chairman of the Board
If to the Employee:
Albena Patroneva, M.D., MBA
205 Church Street
Wayne, PA 19087
Any party may from time to time change its address for the purpose of notices to that party by a similar notice specifying a new address, but no
such change shall be deemed to have been given until it is actually received by the party sought to be charged with its contents.
12. Waivers. No claim or right arising out of a breach or default under this Agreement shall be discharged in whole or in part by a
waiver of that claim or right unless the waiver is supported by consideration and is in writing and executed by the aggrieved party hereto or such
party’s duly authorized agent. A waiver by any party hereto of a breach or default by the other party hereto of any provision of this Agreement
shall not be deemed a waiver of future compliance therewith, and such provisions shall remain in full force and effect.
13. Section 409A. It is intended that this Agreement be drafted and administered in compliance with section 409A of the Code,
including, but not limited to, any future amendments to Code section 409A, and any other Internal Revenue Service or other governmental rulings
or interpretations (together, “Section 409A”) issued pursuant to Section 409A so as not to subject the Employee to payment of interest or any
additional tax under Code section 409A. The parties
9
intend for any payments under this Agreement to either satisfy the requirements of Section 409A or to be exempt from the application of
Section 409A, and this Agreement shall be construed and interpreted accordingly. In furtherance thereof, if payment or provision of any amount
or benefit hereunder that is subject to Section 409A at the time specified herein would subject such amount or benefit to any additional tax under
Section 409A, the payment or provision of such amount or benefit shall be postponed to the earliest commencement date on which the payment or
provision of such amount or benefit could be made without incurring such additional tax. In addition, to the extent that any Internal Revenue
Service guidance issued under Section 409A would result in the Employee being subject to the payment of interest or any additional tax under
Section 409A, the parties agree, to the extent reasonably possible, to amend this Agreement in order to avoid the imposition of any such interest or
additional tax under Section 409A, which amendment shall have the minimum economic effect necessary and be reasonably determined in good
faith by the Company and the Employee.
14. Survival of Covenants. Each provision of this Agreement that, by its terms, is intended to continue beyond the termination of
the Employee’s employment shall continue in effect thereafter.
(Signature page follows.)
10
IN WITNESS WHEREOF, this Agreement has been executed by the parties as of the date first above written.
MARINUS PHARMACEUTICALS, INC.
By: /s/ Christopher M. Cashman
Christopher M. Cashman,
President and CEO
/s/ Albena Patroneva
Albena Patroneva
11
INCENTIVE STOCK OPTION AGREEMENT
Exhibit 10.16
THIS AGREEMENT, effective as of , 201 , is made by and between Marinus Pharmaceuticals, Inc. (the “Company”), a
Delaware corporation, and «Name» (the “Employee”), an employee of the Company.
Recitals :
WHEREAS, the Company has established the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan (the “Plan”), the terms of which
are hereby incorporated by reference and made a part of this Agreement; and
WHEREAS, the Committee (as hereinafter defined) has determined that it would be in the best interest of the Company to grant an
incentive stock option under the Plan, as provided for herein, to the Employee as an incentive for increased efforts during the Employee’s
employment by the Company, subject to the execution and delivery by the Employee of this Agreement;
NOW, THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of
which is hereby acknowledged, the parties hereto agree as follows:
ARTICLE 1
DEFINITIONS
Whenever the following terms are used in this Agreement, they shall have the meanings specified below:
“Act” shall mean the Securities Act of 1933, as amended.
“Cause” shall have the meaning set forth in the Employment Agreement.
“Change of Control” shall have the meaning set forth in the Employment Agreement.
“Code” shall mean the Internal Revenue Code of 1986, as amended.
“Committee” shall mean the Committee established in accordance with Section 1(a) of the Plan, if one has been appointed, or the Board
of Directors of the Company if no such committee has been appointed.
“Common Stock” shall mean the Company’s Common Stock, $.001 par value.
“Employment Agreement” shall mean the Employment Agreement between the Company and the Employee as in effect at the relevant
time.
“Good Reason” shall have the meaning set forth in the Employment Agreement.
“Option” shall mean the incentive stock option granted under this Agreement.
“Plan” shall have the meaning set forth in the first Recital paragraph above.
“Retirement” shall mean a termination of employment by reason of an Employee’s retirement at or after the Employee’s earliest
permissible retirement date pursuant to and in accordance with a regular retirement plan or the personnel practices of the Company.
“Subsidiary” shall mean any corporation in an unbroken chain of corporations beginning with the Company if each of the corporations
other than the last corporation in the unbroken chain then owns stock possessing 50% or more of the total combined voting power of all classes of
stock in one of the other corporations in such chain.
“Termination of Employment” shall mean the time when the employee-employer relationship between the Employee and the Company
or a Subsidiary is terminated for any reason, including, but not limited to, a termination by resignation, discharge, death or Retirement, but
excluding any termination where there is a simultaneous reemployment by the Company or a Subsidiary. The Committee, in its absolute
discretion, shall determine the effect of all matters and questions relating to Termination of Employment, including, but not limited to, whether a
Termination of Employment resulted from a discharge for Cause and whether a particular leave of absence constitutes a Termination of
Employment; provided, however, that a leave of absence shall constitute a Termination of Employment if, and to the extent that, such leave of
absence interrupts employment for purposes of Section 422(a)(2) of the Code and the then applicable Regulations and Revenue Rulings under
Section 422(a)(2).
Section 2.1 - Grant of Option
ARTICLE 2
GRANT OF OPTION
In consideration of the Employee’s employment by the Company and for other good and valuable consideration, on the date hereof the
Company grants to the Employee the Option to purchase any part or all of a total of «Shares» shares of the Company’s Common Stock upon the
terms and conditions set forth in this Agreement. The Option shall be subject in all respects to the provisions of this Agreement and of the Plan.
The Option is intended to be an incentive stock option under Section 422 of the Code [; provided, however, that any portion of the Option that
does not qualify for incentive stock option treatment shall be treated as a nonqualified stock option in accordance with Section 5(h) of the
Plan.]
Section 2.2 - Purchase Price
The purchase price of the shares of Common Stock covered by the Option shall be US$ [ ] per share without commission or other
charge.
Section 2.3 - Adjustments in Option
The number of shares subject to issuance upon exercise of the Option and the purchase price thereof are subject to adjustment in
accordance with Section 3(d) of the Plan.
2
Section 3.1 - Commencement of Exercisability
ARTICLE 3
EXERCISABILITY OF OPTIONS
(a) Subject to the provisions of this Article 3, the Option shall vest and become exercisable as follows: (i) «First_Installment»
shares shall vest and become exercisable on , 201 and (ii) the remaining «Balance» shares shall vest and become exercisable in 12
consecutive quarterly installments of «Installment_Shares» shares each on the day of each , , and
, beginning , 201 and continuing through , 201 ; provided that the Employee continues to be employed by
the Company on the respective vesting date.
(b) No portion of the Option that is not exercisable at the time of the Employee’s Termination of Employment shall thereafter
become exercisable.
Section 3.2 - Duration of Exercisability
Upon vesting, the installments provided for in Section 3.1 shall be cumulative. Each such installment that vests and becomes exercisable
pursuant to Section 3.1 shall remain exercisable until it becomes unexercisable under Section 3.3.
Section 3.3 - Expiration of Option
The Option may not be exercised to any extent after the first to occur of the following events:
(a) the expiration of ten years from the date the Option was granted;
(b) the expiration of three months after the date of the Employee’s Termination of Employment unless such Termination of
Employment results from the Employee’s (i) death, (ii) Retirement, (iii) disability (within the meaning of Section 22(e)(3) of the Code), or
(iv) Cause;
(c) the expiration of one year from the date of the Employee’s Termination of Employment by reason of the Employee’s death,
Retirement or disability (within the meaning of Section 22(e)(3) of the Code), provided that in the event that the Option is exercised more than
three months after termination of employment due to Retirement, the Option shall lose its status as an incentive stock option and shall be treated
as a nonqualified stock option; or
(d) the date of Employee’s Termination of Employment if the Termination of Employment is for Cause.
Section 3.4 - Acceleration of Exercisability
If a Change of Control shall occur prior to the termination of the Option pursuant to Section 3.3 and the Option is not then vested in full,
and subject to the provisions of Section 3.3, from and after the occurrence of the Change of Control, the Option will continue to vest in accordance
with Section 3.1 until the earlier to occur of (a) a Termination of Employment of the
3
Employee without Cause by the Company or the acquiring or successor entity or (b) a Termination of Employment of the Employee upon a
resignation for Good Reason in accordance with the terms of the Employment Agreement, at which earlier time the entire unvested portion of the
Option shall vest in full and become immediately exercisable, provided that the Employee executes a release of claims in favor of the Company
and/or the acquiring or successor entity and their respective affiliates, as the case may be, and satisfies the other relevant provisions of the
Employment Agreement.
Section 4.1 - Person Eligible to Exercise
ARTICLE 4
EXERCISE OF OPTION
During the lifetime of the Employee, only the Employee may exercise the Option or any portion thereof. After the death of the
Employee, any portion of the Option that is exercisable on the date of the Employee’s death may, prior to the time when the Option may no longer
be exercised pursuant to the provisions of Section 3.3, be exercised by the Employee’s personal representative or by any person empowered to do
so under the Employee’s will or under the then applicable laws of descent and distribution.
Section 4.2 - Partial Exercise
Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised at any time prior to the time
when the Option or portion thereof may no longer be exercised pursuant to the provisions of Article 3; provided, however, that each partial
exercise shall be for whole shares only.
Section 4.3 - Manner of Exercise
The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of the Company of all of the
following prior to the time when the Option or such portion may no longer be exercised pursuant to the provisions of Article 3:
(a) Notice in writing signed by the Employee or the other person then entitled to exercise the Option, stating that the Option or a
portion thereof is thereby exercised, such notice complying with all applicable rules established by the Committee;
(b) (i) Full payment (in cash or by check) for the shares with respect to which the Option or portion is exercised; or
(ii) If the Committee shall so permit, shares of the Company’s Common Stock owned by the Employee duly endorsed for
transfer to the Company with a fair market value on the date of delivery equal to the aggregate purchase price of the shares with respect to which
such Option or portion is exercised; or
4.3(b)(ii).
(iii) If the Committee shall so permit, a combination of the consideration provided in the foregoing Sections 4.3(b)(i) and
4
(c) A bona fide written representation and agreement in a form satisfactory to the Committee, signed by the Employee or other
person then entitled to exercise such Option or portion, stating that the shares of Common Stock are being acquired for the Employee’s own
account, for investment and without any present intention of distributing or reselling said shares or any of them except as may be permitted under
the Act and then applicable rules and regulations thereunder, and that the Employee or other person then entitled to exercise the Option or portion
will indemnify the Company against and hold it free and harmless from any loss, damage, expense or liability resulting to the Company if any sale
or distribution of the shares by such person is contrary to the representation and agreement referred to above. The Committee may, in its absolute
discretion, take whatever additional actions it deems appropriate to ensure the observance and performance of such representation and agreement
and to effect compliance with the Act and any other federal or state securities laws or regulations. Without limiting the generality of the
foregoing, the Committee may require an opinion of counsel acceptable to it to the effect that any subsequent transfer of the shares acquired upon
the exercise of the Option does not violate the Act and may issue stop-transfer orders covering such shares. Share certificates evidencing
Common Stock issued upon the exercise of the Option shall bear an appropriate legend referring to the provisions of this Section 4.3(c) and the
agreements herein and therein. The written representation and agreement referred to in the first sentence of this Section 4.3(c) shall, however, not
be required if the shares to be issued pursuant to such exercise have been registered under the Act and such registration is then effective in respect
of such shares.
(d) In the event the Option or portion shall be exercised pursuant to Section 4.1 by any person or persons other than the Director,
appropriate proof of the right of such person or persons to exercise the Option.
Section 4.4 - Conditions to Issuance of Shares
The shares of Common Stock deliverable upon the exercise of the Option, or any portion thereof, may be either previously authorized but
unissued shares or treasury shares. Such shares shall be fully paid and nonassessable. The Company shall not be required to issue any shares of
Common Stock purchased upon the exercise of the Option or portion thereof prior to fulfillment of all of the following conditions:
(a) The admission of such shares to listing on all stock exchanges on which such class of stock shall then be listed;
(b) The completion of any registration or other qualification of such shares under any state or federal law or under rulings or
regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Committee shall, in its absolute
discretion, deem necessary or advisable;
(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Committee shall, in
its absolute discretion, determine to be necessary or advisable; and
5
(d) The lapse of such reasonable period of time following the exercise of the Option as the Committee may from time to time
establish for reasons of administrative convenience.
Section 4.5 - Rights as Stockholder
The holder of the Option shall not be, and shall not have any of the rights or privileges of, a stockholder of the Company in respect of any
shares purchasable upon the exercise of any part of the Option unless and until such part of the Option is exercised in accordance with its terms.
Section 5.1 - Options Not Transferable
ARTICLE 5
MISCELLANEOUS
Neither the Option nor any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of the Employee
or the Employee’s successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or
any other means whether such disposition shall be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or
any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect;
provided, however, that this Section 5.1 shall not prevent transfers by will or by the applicable laws of descent and distribution in accordance with
the Plan.
Section 5.2 - Administration
The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration,
interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules. All actions taken and all
interpretations and determinations made by the Committee in good faith shall be final and binding upon the Employee, the Company and all other
interested persons. No member of the Committee shall be personally liable for any action, determination or interpretation made in good faith with
respect to the Plan or the Option.
Section 5.3 - Withholding
All amounts that, under federal, state or local law, are required to be withheld from the amount payable with respect to any Option shall
be withheld by the Company. Whenever the Company proposes or is required to issue or transfer shares of Common Stock, the Company shall
have the right to require the recipient to remit to the Company an amount sufficient to satisfy any federal, state or local withholding tax
requirements prior to the delivery of any certificate or certificates for such shares.
Section 5.4 - No Right of Continued Employment
Nothing contained in this Agreement or in the Plan shall confer upon the Employee any right to continue in the employ of the Company
or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and any Subsidiary, which are hereby expressly
6
reserved, to discharge the Employee at any time for any reason whatsoever, with or without Cause.
Section 5.5 - Notices
Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of its Secretary, and
any notice to be given to the Employee shall be addressed to the Employee at the address given beneath the Employee’s signature hereto. By a
notice given pursuant to this Section 5.5, either party may hereafter designate a different address for notices to be given to such party. Any notice
that is required to be given to the Employee shall, if the Employee is then deceased, be given to the Employee’s personal representative if such
representative has previously informed the Company of his or her status and address by written notice under this Section 5.5. Any notice shall
have been deemed duly given when addressed as aforesaid and deposited (with postage prepaid) in the United States mail or sent by overnight
courier (with charges prepaid).
Section 5.6 - Entire Agreement
This Agreement and the Plan set forth the entire understanding of the parties with respect to the subject matter hereof and supersedes all
prior agreements and understandings between the parties regarding the Option.
Section 5.7 - Successors and Assigns
This Agreement shall inure to the successors and assigns of the parties; provided, however, that neither this Agreement nor any rights
hereunder may be assigned by the Employee.
Section 5.8 - Survival
Each provision of this Agreement that, by its terms, is intended to survive beyond the exercise of the Option shall continue in effect
thereafter until such time as such term shall no longer apply.
Section 5.9 - Titles
Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.
Section 5.10 - Counterparts; Electronic Transmission
This Agreement may be executed by the parties on separate counterparts, each of which shall be an original and both of which together
shall constitute one and the same agreement. A facsimile or electronic transmission of a scanned copy of a signed counterpart signature
page hereto shall be deemed to be an originally executed copy for purposes of this Agreement.
(Signature page follows.)
7
IN WITNESS WHEREOF, and intending to be legally bound hereby, this Agreement has been executed and delivered by the parties
hereto.
MARINUS PHARMACEUTICALS, INC.
By:
Title:
«Name»
Address of Employee:
Employee’s Taxpayer
Identification Number:
8
INCENTIVE STOCK OPTION AGREEMENT
Exhibit 10.17
THIS AGREEMENT, effective as of , 201 , is made by and between Marinus Pharmaceuticals, Inc. (the “Company”), a
Delaware corporation, and «Name» (the “Employee”), an employee of the Company.
Recitals :
WHEREAS, the Company has established the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan (the “Plan”), the terms of which
are hereby incorporated by reference and made a part of this Agreement; and
WHEREAS, the Committee (as hereinafter defined) has determined that it would be in the best interest of the Company to grant an
incentive stock option under the Plan, as provided for herein, to the Employee as an incentive for increased efforts during the Employee’s
employment by the Company, subject to the execution and delivery by the Employee of this Agreement;
NOW, THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of
which is hereby acknowledged, the parties hereto agree as follows:
ARTICLE 1
DEFINITIONS
Whenever the following terms are used in this Agreement, they shall have the meanings specified below:
“Act” shall mean the Securities Act of 1933, as amended.
“Cause” shall have the meaning set forth in Section 5(f)(v)(D) of the Plan.
“Change of Control” shall have the meaning set forth in Section 12(a) of the Plan.
“Code” shall mean the Internal Revenue Code of 1986, as amended.
“Committee” shall mean the Committee established in accordance with Section 1(a) of the Plan, if one has been appointed, or the Board
of Directors of the Company if no such committee has been appointed.
“Common Stock” shall mean the Company’s Common Stock, $.001 par value.
“Option” shall mean the incentive stock option granted under this Agreement.
“Plan” shall have the meaning set forth in the first Recital paragraph above.
“Retirement” shall mean a termination of employment by reason of an Employee’s retirement at or after the Employee’s earliest
permissible retirement date pursuant to and in accordance with a regular retirement plan or the personnel practices of the Company.
“Subsidiary” shall mean any corporation in an unbroken chain of corporations beginning with the Company if each of the corporations
other than the last corporation in the unbroken chain then owns stock possessing 50% or more of the total combined voting power of all classes of
stock in one of the other corporations in such chain.
“Termination of Employment” shall mean the time when the employee-employer relationship between the Employee and the Company
or a Subsidiary is terminated for any reason, including, but not limited to, a termination by resignation, discharge, death or Retirement, but
excluding any termination where there is a simultaneous reemployment by the Company or a Subsidiary. The Committee, in its absolute
discretion, shall determine the effect of all matters and questions relating to Termination of Employment, including, but not limited to, whether a
Termination of Employment resulted from a discharge for Cause and whether a particular leave of absence constitutes a Termination of
Employment; provided, however, that a leave of absence shall constitute a Termination of Employment if, and to the extent that, such leave of
absence interrupts employment for purposes of Section 422(a)(2) of the Code and the then applicable Regulations and Revenue Rulings under
Section 422(a)(2).
Section 2.1 - Grant of Option
ARTICLE 2
GRANT OF OPTION
In consideration of the Employee’s employment by the Company and for other good and valuable consideration, on the date hereof the
Company grants to the Employee the Option to purchase any part or all of a total of «Shares» shares of the Company’s Common Stock upon the
terms and conditions set forth in this Agreement. The Option shall be subject in all respects to the provisions of this Agreement and of the Plan.
The Option is intended to be an incentive stock option under Section 422 of the Code [; provided, however, that any portion of the Option that
does not qualify for incentive stock option treatment shall be treated as a nonqualified stock option in accordance with Section 5(h) of the
Plan.]
Section 2.2 - Purchase Price
The purchase price of the shares of Common Stock covered by the Option shall be US$ [ ] per share without commission or other
charge.
Section 2.3 - Adjustments in Option
The number of shares subject to issuance upon exercise of the Option and the purchase price thereof are subject to adjustment in
accordance with Section 3(d) of the Plan.
2
Section 3.1 - Commencement of Exercisability
ARTICLE 3
EXERCISABILITY OF OPTIONS
(a) Subject to the provisions of this Article 3, the Option shall vest and become exercisable as follows: (i) «First_Installment»
shares shall vest and become exercisable on , 201 and (ii) the remaining «Balance» shares shall vest and become exercisable in 12
consecutive quarterly installments of «Installment_Shares» shares each on the day of each , , and
, beginning , 201 and continuing through , 201 ; provided that the Employee continues to be employed by
the Company on the respective vesting date.
(b) No portion of the Option that is not exercisable at the time of the Employee’s Termination of Employment shall thereafter
become exercisable.
Section 3.2 - Duration of Exercisability
Upon vesting, the installments provided for in Section 3.1 shall be cumulative. Each such installment that vests and becomes exercisable
pursuant to Section 3.1 shall remain exercisable until it becomes unexercisable under Section 3.3.
Section 3.3 - Expiration of Option
The Option may not be exercised to any extent after the first to occur of the following events:
(a) the expiration of ten years from the date the Option was granted;
(b) the expiration of three months after the date of the Employee’s Termination of Employment unless such Termination of
Employment results from the Employee’s (i) death, (ii) Retirement, (iii) disability (within the meaning of Section 22(e)(3) of the Code), or
(iv) Cause;
(c) the expiration of one year from the date of the Employee’s Termination of Employment by reason of the Employee’s death,
Retirement or disability (within the meaning of Section 22(e)(3) of the Code), provided that in the event that the Option is exercised more than
three months after termination of employment due to Retirement, the Option shall lose its status as an incentive stock option and shall be treated
as a nonqualified stock option; or
(d) the date of Employee’s Termination of Employment if the Termination of Employment is for Cause.
Section 3.4 - Acceleration of Exercisability
If a Change of Control shall occur prior to the termination of the Option pursuant to Section 3.3 and the Option is not then vested in full,
and subject to the provisions of Section 3.3, the Option will continue to vest in accordance with Section 3.1 until a Termination of Employment of
the Employee without Cause by the Company or the acquiring or successor
3
entity, at which earlier time the entire unvested portion of the Option shall vest in full and become immediately exercisable, provided that the
Employee executes a release of claims in favor of the Company and/or the acquiring or successor entity and their respective affiliates, as the case
may be.
Section 4.1 - Person Eligible to Exercise
ARTICLE 4
EXERCISE OF OPTION
During the lifetime of the Employee, only the Employee may exercise the Option or any portion thereof. After the death of the
Employee, any portion of the Option that is exercisable on the date of the Employee’s death may, prior to the time when the Option may no longer
be exercised pursuant to the provisions of Section 3.3, be exercised by the Employee’s personal representative or by any person empowered to do
so under the Employee’s will or under the then applicable laws of descent and distribution.
Section 4.2 - Partial Exercise
Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised at any time prior to the time
when the Option or portion thereof may no longer be exercised pursuant to the provisions of Article 3; provided, however, that each partial
exercise shall be for whole shares only.
Section 4.3 - Manner of Exercise
The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of the Company of all of the
following prior to the time when the Option or such portion may no longer be exercised pursuant to the provisions of Article 3:
(a) Notice in writing signed by the Employee or the other person then entitled to exercise the Option, stating that the Option or a
portion thereof is thereby exercised, such notice complying with all applicable rules established by the Committee;
(b) (i) Full payment (in cash or by check) for the shares with respect to which the Option or portion is exercised; or
(ii) If the Committee shall so permit, shares of the Company’s Common Stock owned by the Employee duly endorsed for
transfer to the Company with a fair market value on the date of delivery equal to the aggregate purchase price of the shares with respect to which
such Option or portion is exercised; or
4.3(b)(ii).
(iii) If the Committee shall so permit, a combination of the consideration provided in the foregoing Sections 4.3(b)(i) and
(c) A bona fide written representation and agreement in a form satisfactory to the Committee, signed by the Employee or other
person then entitled to exercise such Option or portion, stating that the shares of Common Stock are being acquired for the Employee’s own
4
account, for investment and without any present intention of distributing or reselling said shares or any of them except as may be permitted under
the Act and then applicable rules and regulations thereunder, and that the Employee or other person then entitled to exercise the Option or portion
will indemnify the Company against and hold it free and harmless from any loss, damage, expense or liability resulting to the Company if any sale
or distribution of the shares by such person is contrary to the representation and agreement referred to above. The Committee may, in its absolute
discretion, take whatever additional actions it deems appropriate to ensure the observance and performance of such representation and agreement
and to effect compliance with the Act and any other federal or state securities laws or regulations. Without limiting the generality of the
foregoing, the Committee may require an opinion of counsel acceptable to it to the effect that any subsequent transfer of the shares acquired upon
the exercise of the Option does not violate the Act and may issue stop-transfer orders covering such shares. Share certificates evidencing
Common Stock issued upon the exercise of the Option shall bear an appropriate legend referring to the provisions of this Section 4.3(c) and the
agreements herein and therein. The written representation and agreement referred to in the first sentence of this Section 4.3(c) shall, however, not
be required if the shares to be issued pursuant to such exercise have been registered under the Act and such registration is then effective in respect
of such shares.
(d) In the event the Option or portion shall be exercised pursuant to Section 4.1 by any person or persons other than the Director,
appropriate proof of the right of such person or persons to exercise the Option.
Section 4.4 - Conditions to Issuance of Shares
The shares of Common Stock deliverable upon the exercise of the Option, or any portion thereof, may be either previously authorized but
unissued shares or treasury shares. Such shares shall be fully paid and nonassessable. The Company shall not be required to issue any shares of
Common Stock purchased upon the exercise of the Option or portion thereof prior to fulfillment of all of the following conditions:
(a) The admission of such shares to listing on all stock exchanges on which such class of stock shall then be listed;
(b) The completion of any registration or other qualification of such shares under any state or federal law or under rulings or
regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Committee shall, in its absolute
discretion, deem necessary or advisable;
(c) The obtaining of any approval or other clearance from any state or federal governmental agency which the Committee shall, in
its absolute discretion, determine to be necessary or advisable; and
(d) The lapse of such reasonable period of time following the exercise of the Option as the Committee may from time to time
establish for reasons of administrative convenience.
5
Section 4.5 - Rights as Stockholder
The holder of the Option shall not be, and shall not have any of the rights or privileges of, a stockholder of the Company in respect of any
shares purchasable upon the exercise of any part of the Option unless and until such part of the Option is exercised in accordance with its terms.
Section 5.1 - Options Not Transferable
ARTICLE 5
MISCELLANEOUS
Neither the Option nor any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of the Employee
or the Employee’s successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or
any other means whether such disposition shall be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or
any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect;
provided, however, that this Section 5.1 shall not prevent transfers by will or by the applicable laws of descent and distribution in accordance with
the Plan.
Section 5.2 - Administration
The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration,
interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules. All actions taken and all
interpretations and determinations made by the Committee in good faith shall be final and binding upon the Employee, the Company and all other
interested persons. No member of the Committee shall be personally liable for any action, determination or interpretation made in good faith with
respect to the Plan or the Option.
Section 5.3 - Withholding
All amounts that, under federal, state or local law, are required to be withheld from the amount payable with respect to any Option shall
be withheld by the Company. Whenever the Company proposes or is required to issue or transfer shares of Common Stock, the Company shall
have the right to require the recipient to remit to the Company an amount sufficient to satisfy any federal, state or local withholding tax
requirements prior to the delivery of any certificate or certificates for such shares.
Section 5.4 - No Right of Continued Employment
Nothing contained in this Agreement or in the Plan shall confer upon the Employee any right to continue in the employ of the Company
or any Subsidiary or shall interfere with or restrict in any way the rights of the Company and any Subsidiary, which are hereby expressly reserved,
to discharge the Employee at any time for any reason whatsoever, with or without Cause.
6
Section 5.5 - Notices
Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of its Secretary, and
any notice to be given to the Employee shall be addressed to the Employee at the address given beneath the Employee’s signature hereto. By a
notice given pursuant to this Section 5.5, either party may hereafter designate a different address for notices to be given to such party. Any notice
that is required to be given to the Employee shall, if the Employee is then deceased, be given to the Employee’s personal representative if such
representative has previously informed the Company of his or her status and address by written notice under this Section 5.5. Any notice shall
have been deemed duly given when addressed as aforesaid and deposited (with postage prepaid) in the United States mail or sent by overnight
courier (with charges prepaid).
Section 5.6 - Entire Agreement
This Agreement and the Plan set forth the entire understanding of the parties with respect to the subject matter hereof and supersedes all
prior agreements and understandings between the parties regarding the Option.
Section 5.7 - Successors and Assigns
This Agreement shall inure to the successors and assigns of the parties; provided, however, that neither this Agreement nor any rights
hereunder may be assigned by the Employee.
Section 5.8 - Survival
Each provision of this Agreement that, by its terms, is intended to survive beyond the exercise of the Option shall continue in effect
thereafter until such time as such term shall no longer apply.
Section 5.9 - Titles
Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.
Section 5.10 - Counterparts; Electronic Transmission
This Agreement may be executed by the parties on separate counterparts, each of which shall be an original and both of which together
shall constitute one and the same agreement. A facsimile or electronic transmission of a scanned copy of a signed counterpart signature
page hereto shall be deemed to be an originally executed copy for purposes of this Agreement.
(Signature page follows.)
7
IN WITNESS WHEREOF, and intending to be legally bound hereby, this Agreement has been executed and delivered by the parties
hereto.
MARINUS PHARMACEUTICALS, INC.
By:
Title:
«Name»
Address of Employee:
Employee’s Taxpayer
Identification Number:
8
NONQUALIFIED STOCK OPTION AGREEMENT
Exhibit 10.18
THIS AGREEMENT, effective as of , 201 , is made by and between Marinus Pharmaceuticals, Inc. (the “Company”), a
Delaware corporation, and «Name» (the “Director”), a director of the Company.
Recitals :
WHEREAS, the Company has established the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan (the “Plan”), the terms of which
are hereby incorporated by this reference and made a part of this Agreement; and
WHEREAS, the Committee (as hereinafter defined) has determined that it would be in the best interest of the Company to grant a stock
option under the Plan, as provided for herein, to the Director as an incentive for increased efforts during the Director’s services the Company,
subject to the execution and delivery by the Director of this Agreement;
NOW, THEREFORE, in consideration of the mutual covenants herein contained and other good and valuable consideration, receipt of
which is hereby acknowledged, the parties hereto do hereby agree as follows:
ARTICLE 1
DEFINITIONS
Section 1.1 - Definitions
Whenever the following terms are used in this Agreement, they shall have the meanings specified below unless the context clearly
indicates to the contrary.
“Act” shall mean the Federal Securities Act of 1933, as amended.
“Cause” shall have the meaning set forth in Section 5(f)(v)(D) of the Plan.
“Code” shall mean the Internal Revenue Code of 1986, as amended.
“Committee” shall mean the Committee established in accordance with Section 1(a) of the Plan, if one has been appointed, or the Board
of Directors of the Company if no Committee has been appointed.
“Common Stock” shall mean the $.001 par value Common Stock of the Company.
“Option” shall mean the nonqualified stock option to purchase Common Stock granted under this Agreement.
“Plan” shall mean the Marinus Pharmaceuticals, Inc. 2014 Equity Incentive Plan.
“Subsidiary” shall mean any corporation in an unbroken chain of corporations beginning with the Company if each of the corporations
other than the last corporation in the unbroken chain then owns stock possessing 50% or more of the total combined voting power of all classes of
stock in one of the other corporations in such chain.
“Termination of Service” shall mean such time as the Director shall cease to serve as a director of the Company (or in the case of
Section 3.4, an acquiring or successor company, if applicable) for any reason. The Committee, in its absolute discretion, shall determine all
matters and questions relating to Termination of Service, including, but not limited to, whether a Termination of Service resulted from a
termination for Cause.
ARTICLE 2
GRANT OF OPTION
Section 2.1 - Grant of Option
On the date hereof the Company grants to the Director the Option to purchase any part or all of a total of shares of the
Company’s Common Stock upon the terms and conditions set forth in this Agreement. The Option shall be subject in all respects to the
provisions of this Agreement and of the Plan. The Option is not intended to be an incentive stock option under Section 422 of the Code.
Section 2.2 - Purchase Price
The purchase price of the shares of Common Stock covered by the Option shall be US$ [ ] per share.
Section 2.3 - Adjustments in Option
The number of shares subject to issuance upon exercise of the Option and the purchase price thereof are subject to adjustment in
accordance with Section 3(d) of the Plan.
ARTICLE 3
EXERCISABILITY OF OPTIONS
Section 3.1 - Vesting and Exercisability
(a) Subject to the provisions of this Article 3, the Option shall vest and become exercisable as follows: (i) «First_Installment»
shares shall vest and become exercisable on , 201 and (ii) the remaining «Balance» shares shall vest and become exercisable in ten
consecutive monthly installments of «Installment_Shares» shares each on the last day of each month succeeding the grant date.
(b) No portion of the Option that is not exercisable at the time of the Director’s Termination of Service shall thereafter become
exercisable.
2
Section 3.2 - Duration of Exercisability
Upon vesting, the installments provided for in Section 3.1 shall be cumulative. Each such installment that vests and becomes exercisable
pursuant to Section 3.1 shall remain exercisable until it becomes unexercisable under Section 3.3.
Section 3.3 - Expiration of Option
The Option may not be exercised to any extent after the first to occur of the following:
(a) the expiration of ten years from the date of grant;
(b) the expiration of 90 days after the date of the Director’s Termination of Service unless such Termination of Service results from
the Director’s (i) death, (ii) disability (within the meaning of Section 22(e)(3) of the Code), or (iii) Cause;
(c) the expiration of one year from the date the Director’s Termination of Service by reason of the Director’s death or disability
(within the meaning of Section 22(e)(3) of the Code); or
(d) the date of the Director’s Termination of Service if the Termination of Service is for Cause.
Section 3.4 - Acceleration of Exercisability
If a Change of Control shall occur prior to the termination of the Option pursuant to Section 3.3 and the Option is not then vested in full,
the Option will continue to vest in accordance with Section 3.1 until the earlier to occur of (a) twelve months after the closing of the Change of
Control and (ii) a Termination of Service without Cause by the Company or the acquiring or successor entity, at which earlier time the entire
unvested portion of the Option shall vest in full and become immediately exercisable, provided that the Director executes a release of claims in
favor of the Company and/or the acquiring or successor entity and their respective affiliates, as the case may be.
Section 4.1 - Person Eligible to Exercise
ARTICLE 4
EXERCISE OF OPTION
During the lifetime of the Director, only the Director may exercise the Option or any portion thereof. After the death of the Director, any
exercisable portion of the Option may, prior to the time when the Option becomes unexercisable under Section 3.3, be exercised by the Director’s
personal representative or by any person empowered to do so under the Director’s will or under the then applicable laws of descent and
distribution.
3
Section 4.2 - Partial Exercise
Any exercisable portion of the Option or the entire Option, if then wholly exercisable, may be exercised in whole or in part at any time
prior to the time when the Option or portion thereof becomes unexercisable under Section 3.3; provided, however, that each partial exercise shall
be for whole shares only.
Section 4.3 - Manner of Exercise
The Option, or any exercisable portion thereof, may be exercised solely by delivery to the Secretary of the Company of all of the
following prior to the time when the Option or such portion becomes unexercisable under Section 3.3:
(a) Notice in writing signed by the Director or the other person then entitled to exercise the Option or any portion, stating that the
Option or portion is thereby exercised, such notice complying with all applicable rules established by the Committee;
(b) Full payment (in cash or by check) for the shares with respect to which the Option or portion is exercised;
(c) A bona fide written representation and agreement in a form satisfactory to the Board, signed by the Director or other person
then entitled to exercise the Option or portion, stating that the shares of stock are being acquired for the Director’s own account, for investment
and without any present intention of distributing or reselling said shares or any of them except as may be permitted under the Act, and then
applicable rules and regulations thereunder, and that the Director or other person then entitled to exercise the Option or portion will indemnify the
Company against and hold it free and harmless from any loss, damage, expense or liability resulting to the Company if any sale or distribution of
the shares by such person is contrary to the representation and agreement referred to above. The Committee may, in its absolute discretion, take
whatever additional action it deems appropriate to ensure the observance and performance of such representation and agreement and to effect
compliance with the Act and any other federal or state securities laws or regulations. Without limiting the generality of the foregoing, the
Committee may require an opinion of counsel acceptable to it to the effect that any subsequent transfer of shares acquired on an Option exercise
does not violate the Act, and may issue stop-transfer orders covering such shares. Share certificates evidencing stock issued on exercise of the
Option shall bear an appropriate legend referring to the provisions of this Section 4.3(c) and the agreements contained in this Agreement. The
written representation and agreement referred to in the first sentence of this Section 4.3(c) shall, however, not be required if the shares to be issued
pursuant to such exercise have been registered under the Act, and such registration is then effective in respect of such shares;
(d) In the event the Option or portion shall be exercised pursuant to Section 4.1 by any person or persons other than the Director,
appropriate proof of the right of such person or persons to exercise the Option.
4
Section 4.4 - Conditions to Issuance of Stock Certificates
The shares of Common Stock deliverable upon the exercise of the Option, or any portion thereof, may be either previously authorized but
unissued shares or issued shares that have then been reacquired by the Company. Such shares shall be fully paid and nonassessable. The
Company shall not be required to issue or deliver any certificate or certificates for shares of Common Stock purchased upon the exercise of the
Option or portion thereof prior to fulfillment of all of the following conditions:
(a) The admission of such shares to listing on all stock exchanges or stock markets on which such class of stock is then listed;
(b) The completion of any registration or other qualification of such shares under any state or federal law or under rulings or
regulations of the Securities and Exchange Commission or of any other governmental regulatory body, which the Committee shall, in its absolute
discretion, deem necessary or advisable;
(c) The obtaining of any approval or other clearance from any state or federal government agency which the Committee shall, in its
absolute discretion, determine to be necessary or advisable; and
(d) The lapse of such reasonable period of time following the exercise of the Option as the Committee may from time to time
establish for reasons of administrative convenience.
Section 4.5 - Rights as Stockholder
The holder of the Option shall not be, nor have any of the rights or privileges of, a stockholder of the Company in respect of any shares
purchasable upon the exercise of any part of the Option unless and until such part of the Option is exercised in accordance with its terms.
Section 5.1 - Options Not Transferable
ARTICLE 5
MISCELLANEOUS
Neither the Option nor any interest or right therein or part thereof shall be liable for the debts, contracts or engagements of the Director or
any of the Director’s successors in interest or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment
or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or
any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect;
provided, however, that this Section 5.1 shall not prevent transfers by will or by the applicable laws of descent and distribution.
Section 5.2- Administration
The Committee shall have the power to interpret the Plan and this Agreement and to adopt such rules for the administration,
interpretation and application of the Plan as are
5
consistent therewith and to interpret or revoke any such rules. All actions taken and all interpretations and determinations made by the Committee
in good faith shall be final and binding upon the Director, the Company and all other interested persons. No member of the Committee shall be
personally liable for any action, determination or interpretation made in good faith with respect to the Plan or the Option.
Section 5.3 - Withholding
All amounts that, under federal, state or local law, are required to be withheld from the amount payable with respect to the Option shall
be withheld by the Company.
Section 5.4 - No Right of Continued Service
Nothing in this Agreement or in the Plan shall confer upon the Director any right to continue as a director of the Company or shall
interfere with or restrict in any way the rights of the Company, which are hereby expressly reserved, to terminate the service of the Director at any
time for any reason whatsoever, with or without cause.
Section 5.5 - Notices
Any notice to be given under the terms of this Agreement to the Company shall be addressed to the Company in care of its Secretary, and
any notice to be given to the Director shall be addressed to the Director at the address given beneath the Director’s signature hereto. By a notice
given pursuant to this Section 5.5, either party may hereafter designate a different address for notices to be given to such party. Any notice that is
required to be given to the Director shall, if the Director is then deceased, be given to the Director’s personal representative if such representative
has previously informed the Company of such representative’s status and address by written notice under this Section 5.5. Any notice shall have
been deemed duly given when sent by regular U.S. mail (with postage prepaid) or by overnight courier (with charges prepaid).
Section 5.6 - Survival
Each provision of this Agreement that, by its terms, is intended to survive beyond the exercise of the Option shall continue in effect
thereafter until such time as such term shall no longer apply.
Section 5.7 - Entire Agreement
This Agreement and the Plan set forth the entire understanding of the parties with respect to the subject matter hereof and supersedes all
prior agreements and understandings between the parties regarding the Option.
Section 5.8 - Successors and Assigns
This Agreement shall inure to the successors and assigns of the parties; provided, however, that neither this Agreement nor any rights
hereunder may be assigned by the Director, except to the extent expressly permitted herein.
6
Section 5.9 - Titles
Titles are provided herein for convenience only and are not to serve as a basis for interpretation or construction of this Agreement.
Section 5.10 - Counterparts; Electronic Transmission
This Agreement may be executed by the parties on separate counterparts, each of which shall be deemed an original and all of which
shall together constitute one and the same agreement. A facsimile or electronic transmission of a scanned copy of a signed counterpart signature
page hereto shall be deemed to be an originally executed copy for purposes of this Agreement.
(Signature page follows.)
7
IN WITNESS WHEREOF, this Agreement has been executed and delivered by the parties hereto.
MARINUS PHARMACEUTICALS, INC.
By:
Title:
«Name»
Director’s Address:
Social Security Number:
8
Consent of Independent Registered Public Accounting Firm
Exhibit 23.1
The Board of Directors
Marinus Pharmaceuticals, Inc.:
We consent to the incorporation by reference in the registration statement on Form S-8 (No. 333-200701) of Marinus Pharmaceuticals, Inc. our
report dated March 12, 2015, with respect to the balance sheets of Marinus Pharmaceuticals, Inc. as of December 31, 2014 and 2013, and the
related statements of operations, convertible preferred stock and stockholders’ equity (deficit) and cash flows for the years then ended, which
report appears in the December 31, 2014 annual report on Form 10-K of Marinus Pharmaceuticals, Inc.
/s/ KPMG LLP
Philadelphia, Pennsylvania
March 12, 2015
Exhibit 31.1
Certification of Chief Executive Officer Pursuant to
Exchange Act Rules 13a-14(a) or 15d-14(a)
I, Christopher M. Cashman, certify that:
1. I have reviewed this annual report on Form 10-K of Marinus Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.
Date: March 12, 2015
/s/ Christopher M. Cashman
Christopher M. Cashman,
President and Chief Executive Officer
Exhibit 31.2
Certification of Chief Financial Officer Pursuant to
Exchange Act Rules 13a-14(a) or 15d-14(a)
I, Edward F. Smith, certify that:
1. I have reviewed this annual report on Form 10-K of Marinus Pharmaceuticals, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact
necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others
within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the
registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent
functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.
Date: March 12, 2015
/s/ Edward F. Smith
Edward F. Smith,
Chief Financial Officer and Treasurer
Certification Pursuant to 18 U.S.C. Section 1350
Exhibit 32.1
In connection with the annual report of Marinus Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31,
2014 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on
the date indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002, that to his knowledge:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.
Date: March 12, 2015
Date: March 12, 2015
/s/ Christopher M. Cashman
President and Chief Executive Officer
(Principal executive officer)
/s/ Edward F. Smith
Chief Financial Officer and Treasurer
(Principal financial and accounting officer)